<!DOCTYPE drug_guide PUBLIC "-//ES//DTD drug_guide DTD version 3.1//EN//XML" "Y:\WWW1\tools\Drugs\3_1_drug.dtd">
<drug_guide isbn="9780323448260">
	<alpha letter="l">
		<monograph id="1" status="active" ha="yes">
			<mono_name> labetalol (Rx)</mono_name>
			<info>
				<pronunciation>(la-bet′a-lole)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x240">Trandate</tradename>
				</tradenames>
				<class type="func"> Antihypertensive, antianginal</class>
				<class type="chem"> α-1/β-Blocker</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x34">
				<para>
					<confusion>
						<tradename id="tnidelem4x340">Trandate</tradename>
						<drug type="generic" refid="idelem4x340">Tridrate</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x38">
				<sec_title>Action:</sec_title>
				<para>Produces decreases in B/P without reflex tachycardia or significant reduction in heart rate through mixture of α-blocking, β-blocking effects; elevated plasma renins are reduced</para>
			</section>
			<section type="uses" id="sidelem4x43">
				<sec_title>Uses:</sec_title>
				<para>Mild to moderate hypertension; treatment of severe hypertension (IV)</para>
				<section type="none" id="sidelem4x48">
					<section type="none" id="sidelem4x49">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Hypertension in patients with pheochromocytoma, hypertension during cloNIDine withdrawal, pediatric hypertension</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x54">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to β-blockers, cardiogenic shock, heart block (2nd or 3rd degree), sinus bradycardia, CHF, bronchial asthma</para>
				<section type="none" id="sidelem4x59">
					<section type="none" id="sidelem4x60">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, geriatric patients, major surgery, diabetes mellitus, thyroid/renal/hepatic disease, COPD, well-compensated heart failure, nonallergic bronchospasm, peripheral vascular disease</para>
						<para>
							<bbw>Abrupt discontinuation</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x75">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x78">
					<section type="none" id="sidelem4x79">
						<sec_title>Hypertension</sec_title>
						<section type="none" id="sidelem4x87">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x87">
									<item>
										<label>•</label>
										<para> 100 mg bid; may be given with diuretic; may increase to 200 mg bid after 2 days; may continue to increase q1-3days; max 2400 mg/day in divided doses</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x94">
							<label>•</label>
							<sec_title>Child/adolescent (unlabeled)<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x94">
									<item>
										<label>•</label>
										<para> 1-3 mg/kg/day, titrate to max 10-12 mg/kg/day based on B/P;  0.2-1 mg/kg over 2 min, max 40 mg/dose;  0.25-3 mg/kg/hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x104">
						<sec_title>Hypertensive crisis</sec_title>
						<section type="none" id="sidelem4x112">
							<label>•</label>
							<sec_title>Adult<route> IV Intermittent</route></sec_title>
							<para>
								<list id="lidelem4x112">
									<item>
										<label>•</label>
										<para> 20 mg over 2 min; may repeat 20-80 mg over 2 min q10min, 200 mg;  after loading dose give 1-2 mg/min until desired response or max 300 mg</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x119">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 100, 200, 300 mg; inj 5 mg/ml, 20-, 40-ml vials</para>
					</section>
					<section type="none" id="sidelem4x124">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x129">
								<item>
									<label>•</label>
									<para>PO before meals, at bedtime; tab may be crushed or swallowed whole; give with meals to increase absorption</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x137">
							<label>•</label>
							<sec_title>
								<route>Do not discontinue before surgery</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x140">
								<item>
									<label>•</label>
									<para>Store in dry area at room temperature; do not freeze</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x145">
							<sec_title>Direct IV route</sec_title>
							<para>
								<list id="lidelem4x149">
									<item>
										<label>•</label>
										<para>Give undiluted (5 mg/ml) over 2 min</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x155">
							<sec_title>Continuous IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x159">
									<item>
										<label>•</label>
										<para>Diluted in LR, D<emphasis style="inf">5</emphasis>W, D<emphasis style="inf">5</emphasis> in 0.2%, 0.9%, 0.33% NaCl, Ringer’s inj; infusion is titrated to patient response; 200 mg of product/160 ml sol = 1 mg/ml; 300 mg of product/240 ml sol = 1 mg/ml; 200 mg of product/250 ml sol = 2 mg/3 ml; use infusion pump</para>
									</item>
									<item>
										<label>•</label>
										<para>Keep patient recumbent during and for 3 hr after administration; monitor VS q5-15min</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Alemtuzumab, alfentanil, amikacin, aminocaproic acid, aminophylline, amiodarone, anidulafungin, argatroban, arsenic trioxide, ascorbic acid injection, atracurium, atropine, azithromycin, aztreonam, benztropine, bivalirudin, bleomycin, bretylium, bumetanide, buprenorphine, butorphanol, calcium chloride/gluconate, CARBOplatin, carmustine, caspofungin, ceFAZolin, cefotaxime, cefoTEtan, cefOXitin, ceftaroline, cefTAZidime, ceftizoxime, chlorproMAZINE, cimetidine, CISplatin, cloNIDine, cyanocobalamin, cyclophosphamide, cycloSPORINE, cytarabine, DACTINomycin, DAPTOmycin, DAUNOrubicin liposome, dexmedetomidine, dexrazoxane, digoxin, diltiazem, diphenhydrAMINE, DOBUTamine, DOCEtaxel, dolasetron, DOPamine, doripenem, doxacurium, DOXOrubicin, DOXOrubicin liposomal, doxycycline, enalaprilat, ePHEDrine, EPINEPHrine, epirubicin, epoetin alfa, eptifibatide, ertapenem, erythromycin lactobionate, esmolol, etoposide, etoposide phosphate, famotidine, fenoldopam, fentaNYL, fluconazole, fludarabine, fluorouracil, folic acid, gallium, ganciclovir, gatifloxacin, gemcitabine, gentamicin, glycopyrrolate, granisetron, HYDROmorphone, hydroxyzine, IDArubicin, ifosfamide, imipenem-cilastatin, inamrinone, irinotecan, isoproterenol, lactated Ringer’s injection, lepirudin, leucovorin, levofloxacin, lidocaine, linezolid injection, LORazepam, magnesium sulfate, mannitol, mechlorethamine, meperidine, metaraminol, methyldopate, methylPREDNISolone, metoclopramide, metoprolol, metroNIDAZOLE, midazolam, milrinone, minocycline, mitoXANtrone, morphine, moxifloxacin, multiple vitamins injection, mycophenolate, nalbuphine, naloxone, netilmicin, niCARdipine, nitroglycerin, nitroprusside, norepinephrine, octreotide, ondansetron, oxacillin, oxaliplatin, oxytocin, palonosetron, pamidronate, pancuronium, papaverine, PEMEtrexed, pentamidine, pentazocine, PENTobarbital, PHENobarbital, phentolamine, phenylephrine, phytonadione, polymyxin B, potassium acetate/chloride/phosphates, procainamide, prochlorperazine, promethazine, propofol, propranolol, protamine, pyridoxine, quiNIDine, quinupristin-dalfopristin, ranitidine, Ringer’s injection, rocuronium, sodium acetate/bicarbonate, succinylcholine, SUFentanil, tacrolimus, telavancin, teniposide, theophylline, thiamine, thiotepa, ticarcillin-clavulanate, tigecycline, tirofiban, tobramycin, tolazoline, urokinase, vancomycin, vasopressin, vecuronium, verapamil, vinBLAStine, VinCRIStine, vinorelbine, voriconazole, zoledronic acid</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x182">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x185">
					<section type="none" id="sidelem4x186">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Dizziness,</emphasis> mental changes, drowsiness, <emphasis style="italic">fatigue,</emphasis> headache, catatonia, depression, anxiety, nightmares, paresthesias, lethargy</para>
					</section>
					<section type="none" id="sidelem4x198">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="italic">Orthostatic hypotension, bradycardia,</emphasis><emphasis style="bold">CHF,</emphasis> chest pain, <emphasis style="bold">ventricular dysrhythmias,</emphasis> AV block, scalp tingling</para>
					</section>
					<section type="none" id="sidelem4x211">
						<sec_title>EENT:</sec_title>
						<para> <emphasis style="italic">Tinnitus,</emphasis> visual changes; sore throat; double vision; dry, burning eyes, floppy iris syndrome; nasal congestion</para>
					</section>
					<section type="none" id="sidelem4x219">
						<sec_title>ENDO:</sec_title>
						<para> Hyperkalemia</para>
					</section>
					<section type="none" id="sidelem4x224">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, diarrhea,</emphasis> dyspepsia, taste distortion, <emphasis style="bold">hepatotoxicity</emphasis></para>
					</section>
					<section type="none" id="sidelem4x234">
						<sec_title>GU:</sec_title>
						<para> Impotence, dysuria, ejaculatory failure</para>
					</section>
					<section type="none" id="sidelem4x239">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Agranulocytosis, thrombocytopenia, purpura</emphasis> (rare)</para>
					</section>
					<section type="none" id="sidelem4x247">
						<sec_title>INTEG:</sec_title>
						<para> Rash, alopecia, urticaria, pruritus, fever, <emphasis style="bold">exfoliative dermatitis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x254">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="bold">Bronchospasm,</emphasis> dyspnea, wheezing</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x262">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Half-life 2.5-8 hr, metabolized by liver (metabolites inactive), excreted in urine, crosses placenta, excreted in breast milk, protein binding 50%</para>
				<section type="none" id="sidelem4x267">
					<section type="none" id="sidelem4x268">
						<sec_title>PO:</sec_title>
						<para> Onset 30 min, peak 1-4 hr, duration 8-24 hr</para>
					</section>
					<section type="none" id="sidelem4x273">
						<sec_title>IV:</sec_title>
						<para> Onset 2-5 min, peak 5-15 min, duration 2-4 hr</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x278">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x286">
					<label>•</label>
					<sec_title>
						<route>Do not use within 2 wk of MAOIs</route>
					</sec_title>
				</section>
				<para>
					<emphasis alert="lifethreat">Increase: myocardial depression—hydantoins, general anesthetics, verapamil, class I antidysrhythmics</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> tremor—tricyclic antidepressants</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypotension—diuretics, other antihypertensives, cimetidine, nitroglycerin, alcohol, nitrates</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effects of—sympathomimetics, lidocaine, theophylline, β-blockers, bronchodilators, xanthines</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> antihypertensive effect—NSAIDs, salicylates</para>
				<para>
					<emphasis style="bold">Increase or decrease:</emphasis> effects of—antidiabetics</para>
				<section type="none" id="sidelem4x312">
					<section type="none" id="sidelem4x313">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> antihypertensive effect—hawthorn</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> antihypertensive effect—ephedra</para>
					</section>
					<section type="none" id="sidelem4x324">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> ANA titer, blood glucose, alk phos, LDH, AST, ALT, BUN, potassium, triglyceride, uric acid, serum lipoprotein</para>
						<para>
							<emphasis style="bold">False increase:</emphasis> urinary catecholamines</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x335">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x338">
					<section type="none" id="sidelem4x339">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x347">
							<label>•</label>
							<sec_title>Hypertension</sec_title>
							<para>
								<list id="lidelem4x347">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hypertension:</emphasis> B/P during beginning treatment, periodically thereafter; note pulse, rate, rhythm, quality; apical/radial pulse before administration; notify prescriber of any significant changes</para>
									</item>
								<item>
									<para>
										<emphasis alert="nurse">CHF: I&amp;O, weight daily; fluid overload: weight gain, jugular venous distention, edema, crackles in lungs</emphasis>
									</para>
								</item>
								<item>
									<para><bbw>
												<emphasis alert="lifethreat">Abrupt discontinuation:</emphasis> product should be tapered to prevent adverse reactions</bbw></para>
								</item>
								<item>
									<label>•</label>
									<para>Baselines of renal/hepatic studies before therapy begins</para>
								</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x374">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x378">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased B/P after 1-2 wk</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x384">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<bbw>Not to discontinue product abruptly; to taper over 2 wk; may cause precipitate angina</bbw>
						</para>
						<para>
							<list id="lidelem4x399">
								<item>
									<label>•</label>
									<para>Not to use OTC products containing α-adrenergic stimulants (nasal decongestants, OTC cold preparations) unless directed by prescriber</para>
								</item>
								<item>
									<label>•</label>
									<para><emphasis alert="lifethreat">To report bradycardia, dizziness, confusion, depression, fever</emphasis></para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x410">
								<item>
									<label>•</label>
									<para>To take pulse at home; advise when to notify prescriber</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x415">
								<item>
									<label>•</label>
									<para>May mask symptoms of hypoglycemia; monitor blood glucose closely</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x420">
								<item>
									<label>•</label>
									<para>To avoid alcohol, smoking, increased sodium intake</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x425">
								<item>
									<label>•</label>
									<para>To comply with weight control, dietary adjustments, modified exercise program</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x430">
								<item>
									<label>•</label>
									<para>To carry emergency ID to identify product, allergies</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x435">
								<item>
									<label>•</label>
									<para>To avoid hazardous activities if dizziness is present</para>
								</item>
								<item>
									<label>•</label>
									<para>To report symptoms of CHF <emphasis alert="lifethreat">difficulty breathing, especially on exertion or when lying down; night cough; swelling of extremities</emphasis></para>
								</item>
								<item>
									<label>•</label>
									<para>To take medication at bedtime for 1 dose to prevent effect of orthostatic hypotension; to rise slowly</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x451">
								<item>
									<label>•</label>
									<para>To avoid driving or other hazardous activities until response is known; dizziness, drowsiness, may occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x456">
								<item>
									<label>•</label>
									<para>To wear support hose</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="none" id="sidelem4x461">
				<sec_title>Treatment of overdose:</sec_title>
				<para>Lavage, IV glucagon or atropine for bradycardia, IV theophylline for bronchospasm; digoxin, O<emphasis style="inf">2</emphasis>, diuretic for cardiac failure; hemodialysis useful for removal/hypotension; administer vasopressor</para>
			</section>
		</monograph>
<monograph id="2" status="active">
			<mono_name>lacosamide (Rx)</mono_name>
			<info>
				<pronunciation>(la-koe′sa-mide)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x4740">Vimpat</tradename>
				</tradenames>
				<class type="func"> Anticonvulsant</class>
				<class type="chem"> Functionalized amino acid</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
				<class type="schedule">Controlled Substance Schedule <schedule num="5">V</schedule></class>
			</info>
			<section type="actions" id="sidelem4x486">
				<sec_title>Action:</sec_title>
				<para>May act through action at sodium channels; exact action is unknown</para>
			</section>
			<section type="uses" id="sidelem4x491">
				<sec_title>Uses:</sec_title>
				<para>Partial seizures</para>
			</section>
			<section type="contra" id="sidelem4x496">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<section type="none" id="sidelem4x501">
					<section type="none" id="sidelem4x502">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children &lt;17 yr, geriatric patients, allergies, cardiac/renal/hepatic disease, acute MI, atrial fibrillation/flutter, AV block, bradycardia, CHD, dehydration, depression, dialysis, hazardous activity, electrolyte imbalance, heart failure, labor, PR prolongation, sick sinus syndrome, substance abuse, suicidal ideation, syncope, torsades de pointes</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x507">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x515">
					<label>•</label>
					<sec_title>Adult and adolescent ≥17 yr<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x515">
							<item>
								<label>•</label>
								<para> 50 mg bid, may increase weekly by 100 mg bid to 200-400 mg/day;  50 mg bid, infuse over 30-60 min, may be increased by 100 mg/day weekly up to 200-400 mg/day maintenance</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x524">
					<section type="none" id="sidelem4x525">
						<sec_title>Renal/hepatic dose</sec_title>
						<section type="none" id="sidelem4x533">
							<label>•</label>
							<sec_title>Adult<route> PO/IV max 300 mg/day for mild to moderate hepatic disease or CCr ≤30 ml/min</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x536">
						<sec_title>Available forms:</sec_title>
						<para> Film-coated tabs 50, 100, 150, 200 mg; IV 20 ml single-use vials (200 mg/20 ml); oral sol 10 mg/ml</para>
					</section>
					<section type="none" id="sidelem4x541">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x545">
								<item>
									<label>•</label>
									<para>Store PO products/IV vials at room temperature; sol is stable for 24 hr when mixed with compatible diluents in glass or PVC bags at room temperature</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x551">
							<sec_title>PO route</sec_title>
							<section type="none" id="sidelem4x559">
								<label>•</label>
								<sec_title>Tablet</sec_title>
								<para>
									<list id="lidelem4x559">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Tablet:</emphasis> give without regard to meals</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x566">
								<label>•</label>
								<sec_title>Oral sol</sec_title>
								<para>
									<list id="lidelem4x566">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Oral sol:</emphasis> measure with calibrated measuring device</para>
										</item>
									</list>
								</para>
							</section>
						</section>
						<section type="none" id="sidelem4x570">
							<sec_title>IV route</sec_title>
							<para>
								<list id="lidelem4x574">
									<item>
										<label>•</label>
										<para>May give undiluted or mixed in 0.9% NaCl, D<emphasis style="inf">5</emphasis>W, or LR</para>
									</item>
									<item>
										<label>•</label>
										<para>Infuse over 30-60 min, stable for 24 hr at room temperature</para>
									</item>
									<item>
										<label>•</label>
										<para>Do not use if discolored or if particulates are present; discard unused portions</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x593">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x596">
					<section type="none" id="sidelem4x597">
						<sec_title>CNS:</sec_title>
						<para> Dizziness, syncope, tremor, vertigo, ataxia, drowsiness, fever, hypoesthesia, paresthesias, depression, fatigue, headache, confusion, irritability, psychologic dependence, <emphasis style="bold">suicidal ideation,</emphasis> euphoria</para>
					</section>
					<section type="none" id="sidelem4x605">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">Atrial fibrillation/flutter, AV block, bradycardia, myocarditis, orthostatic hypotension, palpitations, PR prolongation</emphasis></para>
					</section>
					<section type="none" id="sidelem4x612">
						<sec_title>EENT:</sec_title>
						<para> Diplopia, blurred vision, nystagmus, tinnitus</para>
					</section>
					<section type="none" id="sidelem4x617">
						<sec_title>GI:</sec_title>
						<para> Nausea, constipation, vomiting, <emphasis style="bold">hepatitis,</emphasis> diarrhea, dyspepsia</para>
					</section>
					<section type="none" id="sidelem4x625">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Anemia, neutropenia, agranulocytosis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x632">
						<sec_title>INTEG:</sec_title>
						<para> Rash, erythema, inj-site reaction, pruritus, xerostomia</para>
					</section>
					<section type="none" id="sidelem4x637">
						<sec_title>MS:</sec_title>
						<para> Asthenia, dysarthria, muscle cramps</para>
					</section>
					<section type="none" id="sidelem4x642">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Drug reaction with eosinophilia, systemic symptoms (DRESS)</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x649">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Metabolized by liver; excreted by kidneys, 95%; protein binding &lt;15%</para>
				<section type="none" id="sidelem4x654">
					<section type="none" id="sidelem4x655">
						<sec_title>PO:</sec_title>
						<para> Peak 1-4 hr</para>
					</section>
					<section type="none" id="sidelem4x660">
						<sec_title>IV:</sec_title>
						<para> Peak 30-60 min; half-life 13 hr; elimination half-life 15-23 hr</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x665">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="nurse">Increase: PR prolongation—β-blockers, calcium channel blockers, atazanavir, dronedarone, digoxin, lopinavir, ritonavir</emphasis>
				</para>
				<para>
					<emphasis alert="nurse">Increase: lacosamide effect—CYP2C19 inhibitors (fluconazole, isoniazid, miconazole)</emphasis>
				</para>
				<section type="none" id="sidelem4x678">
					<section type="none" id="sidelem4x679">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> LFTs</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x686">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x689">
					<section type="none" id="sidelem4x690">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x698">
							<label>•</label>
							<sec_title>Seizures<route> duration, type, intensity precipitating factors</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x701">
								<item>
									<label>•</label>
									<para>Renal function: albumin concentration</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x706">
								<item>
									<label>•</label>
									<para>CV status: orthostatic hypotension, PR prolongation; monitor cardiac status throughout treatment</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x714">
							<label>•</label>
							<sec_title>Mental status<route> mood, sensorium, affect, memory (long, short term), depression, suicidal ideation, psychologic dependence</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x717">
								<item>
									<label>•</label>
									<para>Rash, hypersensitivity reactions</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x725">
							<label>•</label>
							<sec_title>Pregnancy</sec_title>
							<para>
								<list id="lidelem4x725">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Pregnancy:</emphasis> Enroll in UCB Antiepileptic Drugs Registry 1-888-537-7734</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x729">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x733">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in severity of seizures</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x739">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x747">
							<label>•</label>
							<sec_title>
								<route>Not to discontinue product abruptly; to taper over 1 week because seizures may occur</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x750">
								<item>
									<label>•</label>
									<para>To avoid hazardous activities until stabilized on product</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x755">
								<item>
									<label>•</label>
									<para>To carry emergency ID stating product use</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x763">
							<label>•</label>
							<sec_title>
								<route>To notify prescriber of suicidal thoughts/behaviors, syncope, cardiac changes</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x766">
								<item>
									<label>•</label>
									<para>To notify prescriber if pregnancy is planned or suspected</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x771">
								<item>
									<label>•</label>
									<para>That interactions with other medications may occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x776">
								<item>
									<label>•</label>
									<para>To consult MedGuide for proper use, risks</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="3" status="active">
			<mono_name>lactulose (Rx)</mono_name>
			<info>
				<pronunciation>(lak′tyoo-lose)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x7873">Constulose</tradename>
					<tradename id="tnidelem4x7872">Enulose</tradename>
					<tradename id="tnidelem4x7871">Generlac</tradename>
					<tradename id="tnidelem4x7870">Kristalose</tradename>
				</tradenames>
				<class type="func"> Laxative; ammonia detoxicant (hyperosmotic)</class>
				<class type="chem"> Lactose synthetic derivative</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="confusion" id="sidelem4x797">
				<para>
					<confusion>
						<tradename id="tnidelem4x7970">lactulose</tradename>
						<drug type="generic" refid="idelem4x7970">lactose</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x801">
				<sec_title>Action:</sec_title>
				<para>Prevents absorption of ammonia in colon by acidifying stool; increases water, softens stool</para>
			</section>
			<section type="uses" id="sidelem4x806">
				<sec_title>Uses:</sec_title>
				<para>Chronic constipation, portal-systemic encephalopathy in patients with hepatic disease</para>
			</section>
			<section type="contra" id="sidelem4x811">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, low-galactose diet</para>
				<section type="none" id="sidelem4x816">
					<section type="none" id="sidelem4x817">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, geriatric patients, debilitated patients, diabetes mellitus</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x822">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x825">
					<section type="none" id="sidelem4x826">
						<sec_title>Constipation</sec_title>
						<section type="none" id="sidelem4x834">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x834">
									<item>
										<label>•</label>
										<para> 15-30 ml/day (10-20 g), may increase to 60 ml/day prn</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x841">
							<label>•</label>
							<sec_title>Child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x841">
									<item>
										<label>•</label>
										<para> 7.5 ml/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x845">
						<sec_title>Hepatic encephalopathy</sec_title>
						<section type="none" id="sidelem4x853">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x853">
									<item>
										<label>•</label>
										<para> 30-45 ml (20-30 g) tid or qid until stools soft;  300 ml (200 g) diluted</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x863">
							<label>•</label>
							<sec_title>Child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x863">
									<item>
										<label>•</label>
										<para> 40-90 ml/day in 3-4 divided doses</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x870">
							<label>•</label>
							<sec_title>Infant<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x870">
									<item>
										<label>•</label>
										<para> 2.5-10 ml/day in divided doses</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x874">
						<sec_title>Available forms:</sec_title>
						<para> Oral sol 10 g/15 ml; packets 10, 20 g; rectal sol 10 g/15 ml</para>
					</section>
					<section type="none" id="sidelem4x879">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x882">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x887">
									<item>
										<label>•</label>
										<para>With 8 oz fruit juice, water, milk to increase palatability of oral form; for rapid effect, give on empty stomach</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x892">
									<item>
										<label>•</label>
										<para>Increased fluids to 2 L/day; do not give with other laxatives; if diarrhea occurs, reduce dosage</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x900">
								<label>•</label>
								<sec_title>Kristalose</sec_title>
								<para>
									<list id="lidelem4x900">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Kristalose:</emphasis> dissolve contents of packet/4 oz water</para>
										</item>
									</list>
								</para>
							</section>
						</section>
						<section type="none" id="sidelem4x904">
							<sec_title>Rectal route</sec_title>
							<section type="none" id="sidelem4x912">
								<label>•</label>
								<sec_title>
									<route>Retention enema</route>
								</sec_title>
								<para>
									<list id="lidelem4x912">
										<item>
											<label>•</label>
											<para> by diluting 300 ml lactose/700 ml of water; administer by rectal balloon catheter</para>
										</item>
									</list>
								</para>
							</section>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x916">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x919">
					<section type="none" id="sidelem4x920">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, anorexia, abdominal cramps,</emphasis> diarrhea, flatulence, distention, belching</para>
					</section>
					<section type="none" id="sidelem4x928">
						<sec_title>META:</sec_title>
						<para> Hypernatremia</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x933">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Metabolized in colon, onset 1-2 days, peak unknown, duration unknown</para>
			</section>
			<section type="interactions" id="sidelem4x938">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x946">
					<label>•</label>
					<sec_title>
						<route>Do not use with other laxatives (hepatic encephalopathy)</route>
					</sec_title>
				</section>
				<para>
					<emphasis alert="lifethreat">Increase: GI obstruction—NIFEdipine ext-rel tabs</emphasis>
				</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> lactulose effects—neomycin, other oral antiinfectives, antacids</para>
				<section type="none" id="sidelem4x956">
					<section type="none" id="sidelem4x957">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> laxative action—flax, senna</para>
					</section>
					<section type="none" id="sidelem4x964">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> blood glucose (diabetic patients)</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> blood ammonia</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x975">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x978">
					<section type="none" id="sidelem4x979">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x987">
							<label>•</label>
							<sec_title>Stool</sec_title>
							<para>
								<list id="lidelem4x987">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Stool:</emphasis> amount, color, consistency</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x994">
							<label>•</label>
							<sec_title>
								<route>Cause of constipation;</route>
							</sec_title>
							<para>
								<list id="lidelem4x994">
									<item>
										<label>•</label>
										<para> determine whether fluids, bulk, or exercise is missing from lifestyle; use of constipating products</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1001">
							<label>•</label>
							<sec_title>Hepatic encephalopathy<route> blood ammonia level (30-70 mg/100 ml); may decrease ammonia level by 25%-50%; clearing of confusion, lethargy, restlessness, irritability if portal-systemic encephalopathy, monitor sodium in higher doses</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x1004">
								<item>
									<label>•</label>
									<para>Blood, urine electrolytes if product used often; may cause diarrhea, hypokalemia, hyponatremia</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1010">
								<item>
									<label>•</label>
									<para>I&amp;O ratio to identify fluid loss, replace any loss</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x1018">
							<label>•</label>
							<sec_title>
								<route>Cramping, rectal bleeding, nausea, vomiting; if these symptoms occur, product should be discontinued</route>
							</sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x1021">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x1025">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased constipation, decreased blood ammonia level, clearing of mental state</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x1031">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x1035">
								<item>
									<label>•</label>
									<para>Not to use laxatives long term</para>
								</item>
								<item>
									<label>•</label>
									<para>To dilute with water or fruit juice to counteract sweet taste</para>
								</item>
								<item>
									<label>•</label>
									<para>To store in cool environment; not to freeze</para>
								</item>
								<item>
									<label>•</label>
									<para>To take on an empty stomach for rapid action</para>
								</item>
								<item>
									<label>•</label>
									<para>To report diarrhea; may indicate overdose</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="4" status="active">
			<mono_name>lamiVUDine 3TC (Rx)</mono_name>
			<info>
				<pronunciation>(lam-i-voo′deen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x10661">Epivir</tradename>
					<tradename id="tnidelem4x10660">Epivir HBV</tradename>
				</tradenames>
				<class type="func"> Antiretroviral</class>
				<class type="chem"> Nucleoside reverse transcriptase inhibitor (NRTI)</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x1076">
				<para>
					<confusion>
						<tradename id="tnidelem4x10760">lamiVUDine</tradename>
						<drug type="generic" refid="idelem4x10760">lamoTRIgine</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x1080">
				<sec_title>Action:</sec_title>
				<para>Inhibits replication of HIV virus by incorporating into cellular DNA by viral reverse transcriptase, thereby terminating cellular DNA chain</para>
			</section>
			<section type="uses" id="sidelem4x1085">
				<sec_title>Uses:</sec_title>
				<para>HIV-1 infection in combination with at least 2 other antiretrovirals; chronic hepatitis B (Epivir-HBV)</para>
				<section type="none" id="sidelem4x1090">
					<section type="none" id="sidelem4x1091">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Prophylaxis of HIV: postexposure with indinavir and zidovudine</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x1096">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<section type="none" id="sidelem4x1101">
					<section type="none" id="sidelem4x1102">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, geriatric patients, granulocyte count &lt;1000/mm<emphasis style="sup">3</emphasis> or Hgb &lt;9.5 g/dl, renal disease, pancreatitis, peripheral neuropathy</para>
						<para>
							<bbw>Severe hepatic dysfunction, lactic acidosis</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x1120">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x1123">
					<section type="none" id="sidelem4x1124">
						<sec_title>HIV</sec_title>
						<section type="none" id="sidelem4x1132">
							<label>•</label>
							<sec_title>Adult and adolescent &gt;16 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x1132">
									<item>
										<label>•</label>
										<para> 150 mg bid or 300 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1139">
							<label>•</label>
							<sec_title>Child 3 mo-16 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x1139">
									<item>
										<label>•</label>
										<para> 4 mg/kg bid, max 150 mg bid</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1143">
						<sec_title>Chronic hepatitis B</sec_title>
						<section type="none" id="sidelem4x1151">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x1151">
									<item>
										<label>•</label>
										<para> 100 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1158">
							<label>•</label>
							<sec_title>Child and adolescent 2-17 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x1158">
									<item>
										<label>•</label>
										<para> 3 mg/kg/day, max 100 mg</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1162">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x1170">
							<label>•</label>
							<sec_title>Adult<route> PO CCr 30-49 ml/min</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x1173">
						<sec_title>Available forms:</sec_title>
						<para> <emphasis style="bold">(Epivir)</emphasis> oral sol 10 mg/ml; tabs 150, 300 mg; (<emphasis style="bold">Epivir HBV</emphasis>) oral sol 5 mg/ml; tabs 100 mg</para>
					</section>
					<section type="none" id="sidelem4x1184">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x1189">
								<item>
									<label>•</label>
									<para>PO daily or bid, without regard to meals</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x1197">
							<label>•</label>
							<sec_title>
								<route>Epivir and Epivir HBV are not interchangeable</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x1203">
							<label>•</label>
							<sec_title>
								<route>With other antiretrovirals only</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x1206">
								<item>
									<label>•</label>
									<para>Store in cool environment; protect from light</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x1211">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x1214">
					<section type="none" id="sidelem4x1215">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Fever, headache, malaise, dizziness, insomnia, depression, fatigue, chills,</emphasis><emphasis style="bold">seizures,</emphasis> peripheral neuropathy, paresthesias</para>
					</section>
					<section type="none" id="sidelem4x1225">
						<sec_title>EENT:</sec_title>
						<para> Taste change, hearing loss, photophobia</para>
					</section>
					<section type="none" id="sidelem4x1230">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="bold">Nausea, vomiting, diarrhea,</emphasis> anorexia, cramps, dyspepsia, <emphasis style="bold">hepatomegaly with steatosis, pancreatitis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x1241">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Neutropenia, anemia, thrombocytopenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x1248">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash</emphasis></para>
					</section>
					<section type="none" id="sidelem4x1255">
						<sec_title>MS:</sec_title>
						<para> <emphasis style="bold">Myalgia, arthralgia, pain</emphasis></para>
					</section>
					<section type="none" id="sidelem4x1262">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="italic">Cough</emphasis></para>
					</section>
					<section type="none" id="sidelem4x1269">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Lactic acidosis, anaphylaxis, Stevens-Johnson syndrome</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x1276">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Rapidly absorbed, distributed to extravascular space, excreted unchanged in urine, protein binding &lt;36%, terminal half-life 5-7 hr</para>
			</section>
			<section type="interactions" id="sidelem4x1281">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Decrease:</emphasis> both products—zalcitabine; avoid concurrent use</para>
				<section type="none" id="sidelem4x1296">
					<label>•</label>
					<sec_title>
						<route>Do not use with emtricitabine, duplication</route>
					</sec_title>
				</section>
				<para>
					<emphasis style="bold">Decrease:</emphasis> lamiVUDine effect—interferons</para>
				<section type="none" id="sidelem4x1303">
					<section type="none" id="sidelem4x1304">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> ALT, bilirubin</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> Hgb, neutrophil, platelet count</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x1315">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x1318">
					<section type="none" id="sidelem4x1319">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x1327">
							<label>•</label>
							<sec_title>HIV</sec_title>
							<para>
								<list id="lidelem4x1327">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">HIV:</emphasis> Test for HIV before starting treatment, blood counts q2wk; watch for neutropenia, thrombocytopenia, Hgb, CD4, viral load; if low, therapy may have to be discontinued and restarted after hematologic recovery; blood transfusions may be required; assess for lessening of symptoms; if HBV is present, a higher dose of Epivir-HBV is needed</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1334">
							<label>•</label>
							<sec_title>Hepatitis B<route> fatigue, anorexia, pruritus, jaundice during and for several months after discontinuation; AST, ALT, bilirubin; amylase, lipase, triglycerides, periodically during treatment</route></sec_title>
						</section>
						<section type="none" id="sidelem4x1340">
							<label>•</label>
							<sec_title>Children for pancreatitis<route> abdominal pain, nausea, vomiting, neuropathy</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x1352">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x1356">
								<item>
									<label>•</label>
									<para>Decreasing symptoms of HIV, CD4, viral load</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x1362">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x1367">
								<item>
									<label>•</label>
									<para>That GI complaints, insomnia resolve after 3-4 wk of treatment</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1372">
								<item>
									<label>•</label>
									<para>That product is not a cure for HIV but will control symptoms; that compliance is necessary; to take as directed; to complete full course of treatment even if feeling better</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x1380">
							<label>•</label>
							<sec_title>
								<route>To notify prescriber of sore throat, swollen lymph nodes, malaise, fever, peripheral neuropathy; other infections may occur</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x1383">
								<item>
									<label>•</label>
									<para>That patient is still infective, may pass HIV virus on to others</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x1391">
							<label>•</label>
							<sec_title>
								<route>That follow-up visits must be continued since serious toxicity may occur; that blood counts must be done</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x1394">
								<item>
									<label>•</label>
									<para>That other products may be necessary to prevent other infections</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1399">
								<item>
									<label>•</label>
									<para>That product may cause fainting or dizziness</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x1407">
							<label>•</label>
							<sec_title>
								<route>Not to breastfeed, excreted in breast milk</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="5" status="active">
			<mono_name>lamoTRIgine (Rx)</mono_name>
			<info>
				<pronunciation>(la-moe′tri-geen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x14153">LaMICtal</tradename>
					<tradename id="tnidelem4x14152">LaMICtal CD</tradename>
					<tradename id="tnidelem4x14151">LaMICtal ODT</tradename>
					<tradename id="tnidelem4x14150">LaMICtal XR</tradename>
				</tradenames>
				<class type="func"> Anticonvulsant—miscellaneous</class>
				<class type="chem"> Phenyltriazine</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x1425">
				<para>
					<confusion>
						<tradename id="tnidelem4x14250">lamoTRIgine</tradename>
						<drug type="generic" refid="idelem4x14250">lamiVUDine</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x1432">
				<sec_title>Action:</sec_title>
				<para>Inhibits voltage-sensitive sodium channels, thus decreasing seizures</para>
			</section>
			<section type="uses" id="sidelem4x1437">
				<sec_title>Uses:</sec_title>
				<para>Adjunct for the treatment of partial, tonic-clonic seizures; children with Lennox-Gastaut syndrome, bipolar disorder</para>
				<section type="none" id="sidelem4x1442">
					<section type="none" id="sidelem4x1443">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Absence seizures</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x1449">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<section type="none" id="sidelem4x1454">
					<section type="none" id="sidelem4x1455">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>) (cleft lip/palate during 1st trimester), breastfeeding, geriatric patients, cardiac/renal/hepatic disease, severe depression, suicidal, blood dyscrasias, children &lt;16 yr, serious rash</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x1460">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x1463">
					<section type="none" id="sidelem4x1464">
						<sec_title>Seizures: monotherapy</sec_title>
						<section type="none" id="sidelem4x1472">
							<label>•</label>
							<sec_title>Adult and adolescent ≥16 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x1472">
									<item>
										<label>•</label>
										<para> 50 mg/day while receiving 1 enzyme-inducing AED (carBAMazepine, PHENobarbital, phenytoin, primidone but not valproic acid) wk 1-2, then increase to 100 mg divided bid wk 3-4; maintenance 300-500 mg/day; EXT REL 50 mg/day × 1-2 wk, then 100 mg/day wk 3-4, then 200 mg/day wk 5, then 300 mg/day wk 6, then 400 mg/day wk 7; after wk 7, range is 400-600 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1479">
							<label>•</label>
							<sec_title>Adolescent &lt;16 yr and child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x1479">
									<item>
										<label>•</label>
										<para> 0.3 mg/kg/day wk 1-2, then 0.6 mg/kg/day wk 3-4; depends on use of AED; usual dose 4.5-7.5 mg/kg/day, max 300 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1483">
						<sec_title>Monotherapy for patients taking valproate</sec_title>
						<section type="none" id="sidelem4x1491">
							<label>•</label>
							<sec_title>Adult and adolescent ≥16 yr receiving lamoTRIgine and valproate without enzyme-inducing drug<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x1491">
									<item>
										<label>•</label>
										<para> (immediate release) stabilize on valproate, target dose of 200 mg/day lamoTRIgine; if patient is not taking lamoTRIgine 200 mg/day, increase dose by 25-50 mg/day q1-2wk to reach 200 mg/day; while maintaining lamoTRIgine 200 mg/day, decrease valproate to 500 mg/day by ≤500 mg/day/wk, maintain valproate at 500 mg/day × 1 wk, then increase lamoTRIgine to 300 mg/day while decreasing valproate 250 mg/day × 1 wk, then discontinue valproate and increase lamoTRIgine by 100 mg/day/wk to maintenance of 500 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1495">
						<sec_title>Seizures: multiple therapy with valproate</sec_title>
						<section type="none" id="sidelem4x1503">
							<label>•</label>
							<sec_title>Adult and adolescent ≥16 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x1503">
									<item>
										<label>•</label>
										<para> 25 mg every other day, then 25 mg/day wk 3-4, increase by 25-50 mg q1-2wk, maintenance 100-500 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1510">
							<label>•</label>
							<sec_title>Adolescent &lt;16 yr and child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x1510">
									<item>
										<label>•</label>
										<para> 0.1-0.2 mg/kg/day initially, then increase q2wk as needed to 1-5 mg/kg/day or 200 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1514">
						<sec_title>Bipolar disorder (escalation regimen for those not taking carBAMazepine, other enzyme-inducing drugs, or valproate)</sec_title>
						<section type="none" id="sidelem4x1522">
							<label>•</label>
							<sec_title>Adult and adolescent ≥16 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x1522">
									<item>
										<label>•</label>
										<para> wk 1-2, 25 mg/day; wk 3-4, 50 mg/day; wk 5, 100 mg/day; wk 6-7, 200 mg/day; for patients taking valproic acid: wk 1-2, 25 mg every other day; wk 3-4, 25 mg/day; wk 5, 50 mg/day; wk 6, 100 mg/day; wk 7, 100 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1526">
						<sec_title>Hepatic dose</sec_title>
						<section type="none" id="sidelem4x1534">
							<label>•</label>
							<sec_title>Adult<route> PO moderate hepatic impairment or severe without ascites</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x1537">
						<sec_title>Absence seizures (unlabeled)</sec_title>
						<section type="none" id="sidelem4x1545">
							<label>•</label>
							<sec_title>Adolescent and child 3-13 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x1545">
									<item>
										<label>•</label>
										<para> 0.5 mg/kg/day in 2 divided doses × 2 wk, then 1 mg/kg/day in 2 divided doses × 2 wk, adjusted q5days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1549">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 25, 100, 150, 200 mg; PO ext rel 25-50-100, 50-100-200 mg titration kit; PO 25-100 mg starter kit; ext rel 25, 50, 100, 250, 300 mg; chew dispersible tabs 5, 25 mg; oral disintegrating tab 25, 50, 100, 200 mg; oral disintegrating tab 25-50, 50-100 mg, 25-50-100 mg titration kit</para>
					</section>
					<section type="none" id="sidelem4x1554">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x1562">
							<label>•</label>
							<sec_title>
								<route>severe side effects here occurred from incorrect starter kit</route>
							</sec_title>
							<para>
								<list id="lidelem4x1562">
									<item>
										<label>•</label>
										<para>Correct starter kit; </para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1569">
							<label>•</label>
							<sec_title>Orange starter kit</sec_title>
							<para>
								<list id="lidelem4x1569">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Orange starter kit:</emphasis> for those  taking carBAMazepine, phenytoin, PHENobarbital, primidone, rifampin, valproate</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1579">
							<label>•</label>
							<sec_title>Green starter kit</sec_title>
							<para>
								<list id="lidelem4x1579">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Green starter kit:</emphasis> for those taking carBAMazepine, phenytoin, PHENobarbital, primidone, rifampin but  valproate</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1589">
							<label>•</label>
							<sec_title>Blue starter kit</sec_title>
							<para>
								<list id="lidelem4x1589">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Blue starter kit:</emphasis> for those taking </para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x1595">
								<item>
									<label>•</label>
									<para>Discontinue all products gradually over ≥2 wk; abrupt discontinuation can increase seizures</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1600">
								<item>
									<label>•</label>
									<para>All forms may be given without regard to meals</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x1609">
							<label>•</label>
							<sec_title>Chewable dispersible tab</sec_title>
							<para>
								<list id="lidelem4x1609">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Chewable dispersible tab:</emphasis> may be swallowed whole, chewed, mixed in water or fruit juice; to mix, add to small amount of liquid in glass or spoon; tabs will dissolve in 1 min, then mix in more liquid and swirl and swallow immediately; do not cut tabs in half</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1616">
							<label>•</label>
							<sec_title>Orally disintegrating tabs</sec_title>
							<para>
								<list id="lidelem4x1616">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Orally disintegrating tabs:</emphasis> place on tongue, move around in mouth, when disintegrated, swallow; examine blister pack before use, do not use if blisters are torn or missing</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1623">
							<label>•</label>
							<sec_title>Extended-release tabs</sec_title>
							<para>
								<list id="lidelem4x1623">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Extended-release tabs:</emphasis> swallow whole, do not cut, break, chew; without regard to food</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x1627">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x1630">
					<section type="none" id="sidelem4x1631">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Dizziness,</emphasis> ataxia, <emphasis style="italic">headache,</emphasis> fever, insomnia, tremor, depression, anxiety, <emphasis style="bold">suicidal ideation, seizures, poor concentration</emphasis></para>
					</section>
					<section type="none" id="sidelem4x1644">
						<sec_title>EENT:</sec_title>
						<para> Nystagmus, <emphasis style="bold">diplopia, blurred vision</emphasis></para>
					</section>
					<section type="none" id="sidelem4x1651">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="bold">Nausea, vomiting, anorexia, abdominal pain</emphasis>, <emphasis style="bold">hepatotoxicity</emphasis></para>
					</section>
					<section type="none" id="sidelem4x1661">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="italic">Dysmenorrhea</emphasis></para>
					</section>
					<section type="none" id="sidelem4x1668">
						<sec_title>HEMA:</sec_title>
						<para> Anemia, <emphasis style="bold">DIC, leukopenia, thrombocytopenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x1675">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="bold">Rash (potentially life-threatening),</emphasis> alopecia, photosensitivity</para>
					</section>
					<section type="none" id="sidelem4x1683">
						<sec_title>CV:</sec_title>
						<para> Chest pain, palpitations</para>
					</section>
					<section type="none" id="sidelem4x1688">
						<sec_title>MS:</sec_title>
						<para> Neck pain, myalgias</para>
					</section>
					<section type="none" id="sidelem4x1693">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Stevens-Johnson syndrome, angioedema, toxic epidermal necrolysis, DRESS</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x1700">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Half-life varies depending on dose; terminal half-life 24 hr, 15 hr with enzyme inducers; rapidly, completely absorbed; metabolized by glucuronic acid conjunction; protein binding 55%; peak 1.4-2.3 hr; crosses placenta; excreted in breast milk</para>
			</section>
			<section type="interactions" id="sidelem4x1705">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Decrease:</emphasis> metabolic clearance of lamoTRIgine—valproic acid, CYP3A4 inhibitors</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> lamoTRIgine concentration—carBAMazepine, rifamycins, oral contraceptives, acetaminophen, phenytoin, primodone, PHENobarbital, OXcarbazepine, succinimides, estrogen</para>
				<section type="none" id="sidelem4x1716">
					<section type="none" id="sidelem4x1717">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> anticonvulsant effect—ginkgo</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> anticonvulsant effect—ginseng</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x1728">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x1731">
					<section type="none" id="sidelem4x1732">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x1740">
							<label>•</label>
							<sec_title>Seizure</sec_title>
							<para>
								<list id="lidelem4x1740">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Seizure:</emphasis> duration, type, intensity, halo before seizure</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x1745">
								<item>
									<para>
										<emphasis alert="nurse">Rash (Stevens-Johnson syndrome, toxic epidermal necrolysis) in pediatric patients; product should be discontinued at first sign of rash</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1751">
								<item>
									<para>
										<emphasis alert="nurse">Bipolar disorder: suicidal thoughts/behaviors</emphasis>
									</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x1756">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x1760">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in severity of seizures or of bipolar symptoms</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x1766">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x1771">
								<item>
									<label>•</label>
									<para>To take PO doses divided, with or after meals to decrease adverse effects; not to discontinue product abruptly because seizures may occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1776">
								<item>
									<label>•</label>
									<para>To avoid hazardous activities until stabilized on product</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1781">
								<item>
									<label>•</label>
									<para>To carry emergency ID; to notify prescriber of skin rash, increased seizure activity; to use sunscreen, protective clothing if photosensitivity occurs</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x1789">
							<label>•</label>
							<sec_title>
								<route>To notify prescriber if pregnant, intending to become pregnant</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x1795">
							<label>•</label>
							<sec_title>
								<route>To notify prescriber immediately of suicidal thoughts/behaviors</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x1801">
							<label>•</label>
							<sec_title>
								<route>To notify prescriber if pregnancy is planned or suspected, pregnancy (C), product decreases folate, avoid breastfeeding</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="6" status="active">
			<mono_name>lansoprazole (Rx, <emphasis style="smallcaps">otc</emphasis>)</mono_name>
			<info>
				<pronunciation>(lan-so-prey′zole)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x18121">Prevacid</tradename>
					<tradename id="tnidelem4x18120">Prevacid SoluTab</tradename>
				</tradenames>
				<class type="func"> Antiulcer, proton pump inhibitor</class>
				<class type="chem"> Benzimidazole</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="confusion" id="sidelem4x1823">
				<para>
					<confusion>
						<tradename id="tnidelem4x18230">Prevacid</tradename>
						<drug type="generic" refid="idelem4x18230">Pravachol/Prinivil</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x1827">
				<sec_title>Action:</sec_title>
				<para>Suppresses gastric secretion by inhibiting hydrogen/potassium ATPase enzyme system in gastric parietal cell; characterized as gastric acid pump inhibitor because it blocks the final step of acid production</para>
			</section>
			<section type="uses" id="sidelem4x1832">
				<sec_title>Uses:</sec_title>
				<para>Gastroesophageal reflux disease (GERD), severe erosive esophagitis, poorly responsive systemic GERD, pathologic hypersecretory conditions (Zollinger-Ellison syndrome, systemic mastocytosis, multiple endocrine adenomas); possibly effective for treatment of duodenal, gastric ulcers, maintenance of healed duodenal ulcers</para>
				<section type="none" id="sidelem4x1837">
					<section type="none" id="sidelem4x1838">
						<sec_title>Unlabeled uses:</sec_title>
						<para> GERD (infants/neonates)</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x1843">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<section type="none" id="sidelem4x1848">
					<section type="none" id="sidelem4x1849">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, children, hypomagnesemia, osteoporosis</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x1854">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x1857">
					<section type="none" id="sidelem4x1858">
						<sec_title>Frequent heartburn</sec_title>
						<section type="none" id="sidelem4x1866">
							<label>•</label>
							<sec_title>Adult<route> PO (OTC)</route></sec_title>
							<para>
								<list id="lidelem4x1866">
									<item>
										<label>•</label>
										<para> 15 mg daily up to 14 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1870">
						<sec_title>Duodenal ulcer</sec_title>
						<section type="none" id="sidelem4x1878">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x1878">
									<item>
										<label>•</label>
										<para> 15 mg/day before eating for 4 wk, then 15 mg/day to maintain healing of ulcers; associated with <emphasis style="italic">Helicobacter pylori:</emphasis> 30 mg lansoprazole, 500 mg clarithromycin, 1 g amoxicillin bid × 14 days or 30 mg lansoprazole, 1 g amoxicillin tid × 14 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1885">
						<sec_title>Pathologic hypersecretory conditions</sec_title>
						<section type="none" id="sidelem4x1893">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x1893">
									<item>
										<label>•</label>
										<para> 60 mg/day, may give up to 90 mg bid, administer doses of &gt;120 mg/day in divided doses</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1897">
						<sec_title>GERD/esophagitis</sec_title>
						<section type="none" id="sidelem4x1905">
							<label>•</label>
							<sec_title>Adult and adolescent<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x1905">
									<item>
										<label>•</label>
										<para> 15-30 mg/day × 8 wk</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1912">
							<label>•</label>
							<sec_title>Child 1-11 yr (&gt;30 kg)<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x1912">
									<item>
										<label>•</label>
										<para> 30 mg/day ≤12 wk</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1919">
							<label>•</label>
							<sec_title>Child 1-11 yr (≤30 kg)<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x1919">
									<item>
										<label>•</label>
										<para> 15 mg/day ≤12 wk</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1926">
							<label>•</label>
							<sec_title>Infant (unlabeled)<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x1926">
									<item>
										<label>•</label>
										<para> 1-1.74 mg/kg/day; limited data available</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1933">
							<label>•</label>
							<sec_title>Neonate (unlabeled)<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x1933">
									<item>
										<label>•</label>
										<para> 0.5-1 mg/kg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1937">
						<sec_title>Stress gastric prophylaxis</sec_title>
						<section type="none" id="sidelem4x1945">
							<label>•</label>
							<sec_title>Adult<route> NG</route></sec_title>
							<para>
								<list id="lidelem4x1945">
									<item>
										<label>•</label>
										<para> Use 30 mg oral cap or 30 mg disintegrating tab</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1949">
						<sec_title>Available forms:</sec_title>
						<para> Del rel caps 15, 30 mg; oral powder; orally disintegrating tabs 15, 30 mg</para>
					</section>
					<section type="none" id="sidelem4x1954">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x1957">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x1961">
									<item>
										<label>•</label>
										<para>Swallow caps whole 30 min before eating; do not crush or chew caps; caps may be opened and contents sprinkled on food</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1967">
							<sec_title>NG route</sec_title>
							<section type="none" id="sidelem4x1975">
								<label>•</label>
								<sec_title>Oral cap</sec_title>
								<para>
									<list id="lidelem4x1975">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Oral cap:</emphasis> open cap and pour <emphasis style="sup">1</emphasis>/<emphasis style="inf">4</emphasis> of granules into NG feeding syringe with plunger removed, slowly add water and depress plunger, repeat until all granules used; flush tube with 15 ml water</para>
										</item>
									</list>
								</para>
							</section>
							<para>
								<list id="lidelem4x1985">
									<item>
										<label>•</label>
										<para>Place on tongue, allow to dissolve, use without regard to water</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x1993">
								<label>•</label>
								<sec_title>Oral syringe</sec_title>
								<para>
									<list id="lidelem4x1993">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Oral syringe:</emphasis> dissolve 15 mg/4 ml or 30 mg/10 ml water, use extra water in syringe to remove all of the product</para>
										</item>
									</list>
								</para>
							</section>
						</section>
						<section type="none" id="sidelem4x1997">
							<sec_title>NG tube</sec_title>
							<section type="none" id="sidelem4x2005">
								<label>•</label>
								<sec_title>Oral disintegrating tab</sec_title>
								<para>
									<list id="lidelem4x2005">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Oral disintegrating tab:</emphasis> mix 30 mg tab in 10 ml water, give via NG tube, flush tube with 10 ml sterile water, clamp for 60 min</para>
										</item>
									</list>
								</para>
							</section>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x2009">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x2012">
					<section type="none" id="sidelem4x2013">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache</emphasis></para>
					</section>
					<section type="none" id="sidelem4x2020">
						<sec_title>GI:</sec_title>
						<para> Diarrhea, abdominal pain, vomiting, nausea, <emphasis style="italic">constipation,</emphasis> flatulence, acid regurgitation, anorexia, irritable colon, microscopic colitis</para>
					</section>
					<section type="none" id="sidelem4x2028">
						<sec_title>GU:</sec_title>
						<para> Hematuria, glycosuria, impotence, kidney calculus, breast enlargement</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x2033">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Absorption after granules leave stomach 80%; plasma half-life 1<emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis>-2 hr; protein binding 97%; extensively metabolized in liver; excreted in urine, feces; clearance decreased in geriatric patients, renal/hepatic impairment</para>
			</section>
			<section type="interactions" id="sidelem4x2044">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Decrease:</emphasis> antiplatelets, effect of—clopidogrel</para>
				<para>
					<emphasis alert="lifethreat">Increase: lansoprazole, toxicity—fluvoxaMINE, voriconazole</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> bleeding risk—warfarin</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> lansoprazole absorption—sucralfate</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> absorption of ketoconazole, itraconazole, iron salts, calcium carbonate, atazanavir, ampicillin</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypomagnesemia—loop/thiazide diuretics</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> lansoprazole effect—antimuscarinics, octreotide, H<emphasis style="inf">2</emphasis>-blockers, misoprostol</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> release of ext rel amphetamine/dextroamphetamine<list id="lidelem4x2082">
						<item>
							<label>•</label>
							<para>Avoid use with dasatinib, delavirdine</para>
						</item>
					</list></para>
				<section type="none" id="sidelem4x2088">
					<section type="none" id="sidelem4x2089">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<list id="lidelem4x2093">
								<item>
									<label>•</label>
									<para>Avoid use with red yeast rice, St. John’s wort</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x2099">
						<sec_title>Drug/Food</sec_title>
						<para>
							<list id="lidelem4x2103">
								<item>
									<label>•</label>
									<para>Food decreases rate of absorption, use before food</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x2109">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x2112">
					<section type="none" id="sidelem4x2113">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x2121">
							<label>•</label>
							<sec_title>GI system</sec_title>
							<para>
								<list id="lidelem4x2121">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">GI system:</emphasis> bowel sounds q8hr, abdomen for pain, swelling, anorexia, blood in stool, emesis</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x2128">
							<label>•</label>
							<sec_title>Hepatic studies</sec_title>
							<para>
								<list id="lidelem4x2128">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hepatic studies:</emphasis> AST, ALT, alk phos during treatment</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x2132">
								<item>
									<label>•</label>
									<para>INR and prothrombin time when taking warfarin</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2137">
								<item>
									<label>•</label>
									<para>Magnesium: low magnesium may occur</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x2142">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x2146">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of epigastric pain, swelling, fullness</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x2152">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x2160">
							<label>•</label>
							<sec_title>
								<route>To report severe diarrhea; product may have to be discontinued</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x2163">
								<item>
									<label>•</label>
									<para>That hypoglycemia may occur if diabetic</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2168">
								<item>
									<label>•</label>
									<para>To avoid hazardous activities; that dizziness may occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2173">
								<item>
									<label>•</label>
									<para>To avoid alcohol, salicylates, ibuprofen; may cause GI irritation</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2178">
								<item>
									<label>•</label>
									<para>That if using OTC for heartburn, it may take 1-4 days to see full benefit</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="7" status="active" ru="yes">
			<mono_name> lanthanum (Rx)</mono_name>
			<info>
				<pronunciation>(lan′-tha-num)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x21900">Fosrenol</tradename>
				</tradenames>
				<class type="func"> Phosphate binder</class>
			</info>
			<section type="uses" id="sidelem4x2196">
				<sec_title>Uses:</sec_title>
				<para>End-stage renal disease</para>
			</section>
			<section type="contra" id="sidelem4x2201">
				<sec_title>Contraindications:</sec_title>
				<para>Hypophosphatemia, hypersensitivity</para>
			</section>
			<section type="doses" id="sidelem4x2206">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x2214">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x2214">
							<item>
								<label>•</label>
								<para> 750-1500 mg/day in divided doses with meals; titrate dose q2-3wk until an acceptable phosphate level is reached; tabs should be chewed completely before swallowing; intact tabs should not be swallowed; maintenance dose 1500-3000 mg/day divided with meals; max 3750 mg/day</para>
							</item>
						</list>
					</para>
				</section>
			</section>
		</monograph>
<monograph id="8" status="active" ru="yes">
			<mono_name> lapatinib (Rx)</mono_name>
			<info>
				<pronunciation>(la-pa′tin-ib)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x22250">Tykerb</tradename>
				</tradenames>
				<class type="func"> Antineoplastic—miscellaneous</class>
				<class type="chem"> Biologic response modifier, signal transduction inhibitor (STIs)</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="uses" id="sidelem4x2235">
				<sec_title>Uses:</sec_title>
				<para>Advanced metastatic breast cancer patients with tumor that overexpresses HER2 protein and who have received previous chemotherapy</para>
			</section>
			<section type="contra" id="sidelem4x2240">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>), breastfeeding, hypersensitivity</para>
			</section>
			<section type="doses" id="sidelem4x2246">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x2249">
					<section type="none" id="sidelem4x2250">
						<sec_title>Advanced/metastatic breast cancer with HER2 overexpression who have received previous therapy</sec_title>
						<section type="none" id="sidelem4x2258">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x2258">
									<item>
										<label>•</label>
										<para> 1250 mg (5 tabs)/day 1 hr before or after food on days 1-21 plus capecitabine 2000 mg/m<emphasis style="sup">2</emphasis>/day in 2 divided doses on days 1-14 in a repeating 21-day cycle; continue until therapeutic response or toxicity occurs</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2265">
						<sec_title>Metastatic breast cancer with HER2 overexpression for whom hormonal therapy is indicated</sec_title>
						<section type="none" id="sidelem4x2273">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x2273">
									<item>
										<label>•</label>
										<para> 1500 mg (6 tabs) 1 hr before food with letrozole 2.5 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2277">
						<sec_title>Hepatic dose</sec_title>
						<section type="none" id="sidelem4x2285">
							<label>•</label>
							<sec_title>Adult<route> PO (Child-Pugh C) 750 mg/day (with capecitabine); 1000 mg/day (with letrozole)</route></sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="9" status="active">
			<mono_name>latanoprost (ophthalmic)</mono_name>
			<info>
				<pronunciation>(lah-tan′oh-prost)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x22930">Xalatan</tradename>
				</tradenames>
				<class type="func"> Antiglaucoma agent</class>
				<class type="chem"> Prostaglandin agonist</class>
			</info>
			<section type="confusion" id="sidelem4x2303">
				<para>
					<confusion>
						<tradename id="tnidelem4x23030">latanoprost</tradename>
						<drug type="generic" refid="idelem4x23030">bimatoprost</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x2307">
				<sec_title>Action:</sec_title>
				<para>Increases aqueous humor outflow</para>
			</section>
			<section type="uses" id="sidelem4x2312">
				<sec_title>Uses:</sec_title>
				<para>Increased intraocular pressure in those who have open-angle glaucoma/ocular hypertension and who do not respond to other IOP-lowering products</para>
			</section>
			<section type="contra" id="sidelem4x2317">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product, benzalkonium chloride</para>
				<section type="none" id="sidelem4x2322">
					<section type="none" id="sidelem4x2323">
						<sec_title>Precautions:</sec_title>
						<para> Eye infections, angle-closure glaucoma, renal/hepatic function impairment, children, contact lens</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x2328">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x2336">
					<label>•</label>
					<sec_title>Adult<route> OPHTH</route></sec_title>
					<para>
						<list id="lidelem4x2336">
							<item>
								<label>•</label>
								<para> Instill 1 drop in each affected eye (conjunctival sac) every night</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x2340">
					<section type="none" id="sidelem4x2341">
						<sec_title>Available forms:</sec_title>
						<para> Ophthalmic solution 0.005%</para>
					</section>
					<section type="none" id="sidelem4x2346">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x2349">
							<sec_title>Ophthalmic route</sec_title>
							<para>
								<list id="lidelem4x2353">
									<item>
										<label>•</label>
										<para>Wash hands before and after use; contact lenses should be removed before using the product, reinsert 15 min after use; contains benzalkonium chloride, which may be absorbed by soft contact lenses</para>
									</item>
									<item>
										<label>•</label>
										<para>Tilt the head back slightly and pull the lower eyelid down with the index finger to form a pouch; squeeze the prescribed number of drops into the pouch and gently close the eyes for 1-2 min; do not blink; to avoid contamination, do not touch the tip of the dropper to the eye, fingertips, or other surface</para>
									</item>
									<item>
										<label>•</label>
										<para>The solution may be used concomitantly with other topical ophthalmic drug products to lower IOP; if more than one topical ophthalmic drug is being used, the drugs should be administered at least 5 min apart</para>
									</item>
									<item>
										<label>•</label>
										<para>Store unopened bottle refrigerated; once opened, it may be stored at room temperature, protected from light, for up to 6 wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x2374">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x2377">
					<section type="none" id="sidelem4x2378">
						<sec_title>EENT:</sec_title>
						<para> <emphasis style="italic">Conjunctival hyperemia, iris color change, ocular pruritus</emphasis>, xerophthalmia, visual disturbance, ocular irritation burning, foreign body sensation, ocular pain, blepharitis, cataracts, and superficial punctate keratitis</para>
					</section>
					<section type="none" id="sidelem4x2386">
						<sec_title>INTEG:</sec_title>
						<para> Rash, allergic reactions</para>
					</section>
					<section type="none" id="sidelem4x2391">
						<sec_title>MISC:</sec_title>
						<para> Flulike symptoms</para>
					</section>
					<section type="none" id="sidelem4x2396">
						<sec_title>CV: </sec_title>
						<para>Angina</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x2401">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Ophthalmic: Onset 3-4 hr, peak 8-12 hr; half-life 3 hr</para>
			</section>
			<section type="considerations" id="sidelem4x2406">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x2409">
					<section type="none" id="sidelem4x2410">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x2418">
							<label>•</label>
							<sec_title>Intraocular pressure</sec_title>
							<para>
								<list id="lidelem4x2418">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Intraocular pressure:</emphasis> in those with ongoing increased IOP</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2422">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x2426">
								<item>
									<label>•</label>
									<para>Decreasing IOP</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x2433">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x2436">
							<sec_title>Ophthalmic route</sec_title>
							<para>
								<list id="lidelem4x2440">
									<item>
										<label>•</label>
										<para>To wash hands before and after use; that contact lenses should be removed, reinsert 15 min after use; contains benzalkonium chloride, which may be absorbed by soft contact lenses</para>
									</item>
									<item>
										<label>•</label>
										<para>Tilt the head back slightly and pull lower eyelid down to form a pouch; squeeze drops into the pouch and close the eyes for 1-2 min; not to blink; to avoid contamination, do not touch the tip of the dropper to the eye, fingertips, or other surface</para>
									</item>
									<item>
										<label>•</label>
										<para>May be used concomitantly with other topical ophthalmic products to lower IOP; if more than one is used, the drugs should be administered at least 5 min apart, do not exceed dose</para>
									</item>
									<item>
										<label>•</label>
										<para>To store unopened bottle refrigerated; once opened, it may be stored at room temperature, protected from light, for up to 6 wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="10" status="active" ha="yes">
			<mono_name> ledipasvir/sofosbuvir</mono_name>
			<info>
				<pronunciation>(le-dip′as-vir/soe-fos′bue-veer)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x24680">Harvoni</tradename>
				</tradenames>
				<class type="func"> Antiviral antihepatitis agent</class>
			</info>
			<section type="actions" id="sidelem4x2474">
				<sec_title>Action:</sec_title>
				<para> A combination product with a HCV NS5A inhibitor (ledipasvir) and a nucleotide analog HCV NS5B polymerase inhibitor (sofosbuvir)</para>
			</section>
			<section type="uses" id="sidelem4x2479">
				<sec_title>Uses:</sec_title>
				<para> Chronic hepatitis C virus (HCV) genotype 1 infection in patients with compensated liver disease</para>
			</section>
			<section type="contra" id="sidelem4x2484">
				<sec_title>Contraindications:</sec_title>
				<para> Hypersensitivity</para>
				<section type="none" id="sidelem4x2489">
					<section type="none" id="sidelem4x2490">
						<sec_title>Precautions:</sec_title>
						<para> Decompensated hepatic disease, decompensated cirrhosis, severe renal impairment (eGFR &lt;30 ml/min/1.73 m<emphasis style="sup">2</emphasis>), end-stage renal failure requiring dialysis, pregnancy (B), breastfeeding</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x2498">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x2506">
					<label>•</label>
					<sec_title>Adults with or without cirrhosis who are treatment-naive<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x2506">
							<item>
								<label>•</label>
								<para> One tab (90 mg ledipasvir; 400 mg sofosbuvir) every day with or without food for 12 wk; 8 wk can be considered for those patients with a baseline HCV RNA &lt;6 million IU/ml</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x2514">
					<label>•</label>
					<sec_title>Adults without cirrhosis who are treatment-experienced<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x2514">
							<item>
								<label>
									<emphasis alert="lifethreat">•</emphasis>
								</label>
								<para> One tablet (90 mg ledipasvir; 400 mg sofosbuvir) every day with or without food for 12 wk</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x2521">
					<label>•</label>
					<sec_title>Adults with cirrhosis who are treatment-experienced<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x2521">
							<item>
								<label>•</label>
								<para> One tablet (90 mg ledipasvir; 400 mg sofosbuvir) every day with or without food for 24 wk</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x2525">
					<sec_title>Available forms:</sec_title>
					<para> Tab 90/400 mg</para>
				</section>
				<section type="none" id="sidelem4x2530">
					<sec_title>Administer:</sec_title>
					<para>
						<list id="lidelem4x2534">
							<item>
								<label>•</label>
								<para>Without regard to food</para>
							</item>
						</list>
					</para>
				</section>
			</section>
			<section type="effects" id="sidelem4x2540">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x2543">
					<section type="none" id="sidelem4x2544">
						<sec_title>CNS:</sec_title>
						<para> Fatigue, headache, insomnia</para>
					</section>
					<section type="none" id="sidelem4x2549">
						<sec_title>GI:</sec_title>
						<para> Nausea, vomiting, diarrhea</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x2554">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x2557">
					<section type="none" id="sidelem4x2558">
						<sec_title>Ledipasvir:</sec_title>
						<para> &gt;99.8% protein binding, elimination biliary excretion, terminal half-life 47 hr, peak 4-5 hr</para>
					</section>
					<section type="none" id="sidelem4x2563">
						<sec_title>Sofosbuvir:</sec_title>
						<para> 61%-65% protein binding, elimination kidneys 80% recovered in the urine peak 0.8-1 hr</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x2568">
				<sec_title>Interactions</sec_title>
				<para>Avoid use with products that increase P-glycoprotein</para>
				<section type="none" id="sidelem4x2573">
					<section type="none" id="sidelem4x2574">
						<sec_title>Drug/lab test:</sec_title>
						<para/>
					</section>
					<section type="none" id="sidelem4x2578">
						<sec_title>Increase:</sec_title>
						<para> bilirubin</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x2583">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x2586">
					<section type="none" id="sidelem4x2587">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x2595">
							<label>•</label>
							<sec_title>Hepatitis C</sec_title>
							<para>
								<list id="lidelem4x2595">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hepatitis C:</emphasis> monitor hepatitis C RNA, serum bilirubin, creatinine</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2599">
						<sec_title>Evaluate:</sec_title>
						<section type="none" id="sidelem4x2607">
							<label>•</label>
							<sec_title>Therapeutic response</sec_title>
							<para>
								<list id="lidelem4x2607">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Therapeutic response:</emphasis> hepatitis C RNA reduction</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2611">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x2615">
								<item>
									<label>•</label>
									<para>To report effects to the prescriber</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="11" status="active">
			<mono_name>leflunomide (Rx)</mono_name>
			<info>
				<pronunciation>(leh-floo′noh-mide)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x26270">Arava</tradename>
				</tradenames>
				<class type="func"> Antirheumatic (DMARDs)</class>
				<class type="chem"> Immune modulator, pyrimidine synthesis inhibitor</class>
				<class type="preg">Pregnancy category <preg cat="X">X</preg></class>
			</info>
			<section type="actions" id="sidelem4x2637">
				<sec_title>Action:</sec_title>
				<para>Inhibits an enzyme involved in pyrimidine synthesis; has antiproliferative, antiinflammatory effect</para>
			</section>
			<section type="uses" id="sidelem4x2642">
				<sec_title>Uses:</sec_title>
				<para>RA: to reduce disease process and symptoms</para>
				<section type="none" id="sidelem4x2647">
					<section type="none" id="sidelem4x2648">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Juvenile RA</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x2653">
				<sec_title>Contraindications:</sec_title>
				<para>Breastfeeding, hypersensitivity</para>
				<para>
					<bbw>Pregnancy (X)</bbw>
				</para>
				<section type="none" id="sidelem4x2668">
					<section type="none" id="sidelem4x2669">
						<sec_title>Precautions:</sec_title>
						<para> Children, renal disorders, vaccinations, infection, alcoholism, immunosuppression, jaundice, lactase deficiency, hepatic disease</para>
						<para>
							<bbw>Hepatic disease (ALT &gt;2 × ULN)</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x2684">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x2687">
					<section type="none" id="sidelem4x2688">
						<sec_title>Rheumatoid arthritis</sec_title>
						<section type="none" id="sidelem4x2696">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x2696">
									<item>
										<label>•</label>
										<para> Loading dose 100 mg/day × 3 days, maintenance 20 mg/day; may be decreased to 10 mg/day if not well tolerated</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2700">
						<sec_title>Juvenile rheumatoid arthritis (unlabeled)</sec_title>
						<section type="none" id="sidelem4x2708">
							<label>•</label>
							<sec_title>Adolescent and child &gt;40 kg<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x2708">
									<item>
										<label>•</label>
										<para> 20 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x2715">
							<label>•</label>
							<sec_title>Adolescent and child 20-40 kg<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x2715">
									<item>
										<label>•</label>
										<para> 15 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x2722">
							<label>•</label>
							<sec_title>Adolescent and child 10-19.9 kg<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x2722">
									<item>
										<label>•</label>
										<para> 10 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2726">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 10, 20 mg</para>
					</section>
					<section type="none" id="sidelem4x2731">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x2736">
								<item>
									<label>•</label>
									<para>With food for GI upset, give same time each day, loading dose is recommended</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x2744">
							<label>•</label>
							<sec_title>Drug elimination</sec_title>
							<para>
								<list id="lidelem4x2744">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Drug elimination:</emphasis> give cholestyramine 8 g tid × 11 days, check levels</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x2748">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x2751">
					<section type="none" id="sidelem4x2752">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache,</emphasis> dizziness, insomnia, depression, paresthesia, anxiety, migraine, neuralgia</para>
					</section>
					<section type="none" id="sidelem4x2760">
						<sec_title>CV:</sec_title>
						<para> Palpitations, hypertension, chest pain, angina pectoris, peripheral edema</para>
					</section>
					<section type="none" id="sidelem4x2765">
						<sec_title>EENT:</sec_title>
						<para> Pharyngitis, oral candidiasis, stomatitis, dry mouth, blurred vision</para>
					</section>
					<section type="none" id="sidelem4x2770">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, anorexia, vomiting, constipation, flatulence, diarrhea, elevated LFTs,</emphasis><emphasis style="bold">hepatotoxicity,</emphasis> weight loss</para>
					</section>
					<section type="none" id="sidelem4x2780">
						<sec_title>HEMA:</sec_title>
						<para> Anemia, ecchymosis, hyperlipidemia</para>
					</section>
					<section type="none" id="sidelem4x2785">
						<sec_title>INTEG:</sec_title>
						<para> Rash, pruritus, alopecia, acne, hematoma, herpes infections</para>
					</section>
					<section type="none" id="sidelem4x2790">
						<sec_title>RESP:</sec_title>
						<para> Pharyngitis, rhinitis, bronchitis, cough, respiratory infection, pneumonia, sinusitis, <emphasis style="bold">interstitial lung disease</emphasis></para>
					</section>
					<section type="none" id="sidelem4x2797">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Opportunistic/fatal infections, Stevens-Johnson syndrome</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x2804">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Metabolized in liver to active metabolite, half-life of metabolite 2 wk, excreted in urine</para>
			</section>
			<section type="interactions" id="sidelem4x2809">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> NSAID effect—NSAIDs</para>
				<para>
					<emphasis alert="lifethreat">Increase: hepatotoxicity—hepatotoxic agents, methotrexate</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> leflunomide levels—rifampin</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> antibody response—live virus vaccines</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> leflunomide effect—activated charcoal, cholestyramine, use for overdose</para>
			</section>
			<section type="considerations" id="sidelem4x2831">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x2834">
					<section type="none" id="sidelem4x2835">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x2840">
								<item>
									<label>•</label>
									<para>Screen for latent TB before starting treatment; if TB is present, pretreat before using product</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x2849">
							<label>•</label>
							<sec_title>Interstitial lung disease<route> increased or worsening cough, SOB, fever; product may need to be discontinued</route></sec_title>
						</section>
						<section type="none" id="sidelem4x2855">
							<label>•</label>
							<sec_title>Arthritic symptoms</sec_title>
							<para>
								<list id="lidelem4x2855">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Arthritic symptoms:</emphasis> ROM, mobility, swelling of joints at baseline and during treatment
<bbw>Hepatic studies: if ALT elevations are &gt;2× ULN, reduce dose to 10 mg/day, monitor monthly or more frequently</bbw>
</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x2869">
								<item>
									<label>•</label>
									<para>CBC with differential monthly × 6 mo, then q6-8 wk thereafter; pregnancy test; serum electrolytes</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2875">
								<item>
									<para>
										<emphasis alert="nurse">Infections: fatal infections can occur</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x2883">
							<para>
								<list id="lidelem4x2883">
									<item>
										<label>•</label>
										<para>B/P, weight; edema can occur
<bbw>
												<emphasis alert="lifethreat">Pregnancy (X):</emphasis> determine that patient is not pregnant before treatment; not to be given to women of childbearing potential who are not using reliable contraception</bbw>
</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2896">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x2900">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased inflammation, pain in joints</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x2906">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x2910">
								<item>
									<label>•</label>
									<para>That product must be continued for prescribed time to be effective, that up to a month may be required for improvement</para>
								</item>
								<item>
									<label>•</label>
									<para>To take with food, milk, or antacids to avoid GI upset; to take at same time of day</para>
								</item>
								<item>
									<label>•</label>
									<para>To use caution when driving because drowsiness, dizziness may occur</para>
								</item>
								<item>
									<label>•</label>
									<para>To take with a full glass of water to enhance absorption, may continue with correct prescribed treatment with other antiinflammatories
<bbw>Not to become pregnant (X) while taking this product; not to breastfeed while taking this product; men should also discontinue product and begin leflunomide removal protocol if pregnancy is planned</bbw>
</para>
								</item>
								<item>
									<label>•</label>
									<para>That hair may be lost; review alternatives</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid live virus vaccinations during treatment</para>
								</item>
								<item>
									<label>•</label>
									<para>To notify prescriber of weight loss</para>
								</item>
								<item>
									<label>•</label>
									<para>Overdose treatment: give cholestyramine 8 g tid × 11 days</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="12" status="active" ha="yes">
			<mono_name> letrozole (Rx)</mono_name>
			<info>
				<pronunciation>(let′tro-zohl)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x29670">Femara</tradename>
				</tradenames>
				<class type="func"> Antineoplastic, nonsteroidal aromatase inhibitor</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="actions" id="sidelem4x2973">
				<sec_title>Action:</sec_title>
				<para>Binds to the heme group of aromatase; inhibits conversion of androgens to estrogens to reduce plasma estrogen levels</para>
			</section>
			<section type="uses" id="sidelem4x2978">
				<sec_title>Uses:</sec_title>
				<para>Early, advanced, or metastatic breast cancer in postmenopausal women who are hormone receptor positive</para>
				<section type="none" id="sidelem4x2983">
					<section type="none" id="sidelem4x2984">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Infertility, idiopathic short stature, constitutional delayed puberty</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x2989">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>), premenopausal females, hypersensitivity</para>
				<section type="none" id="sidelem4x2994">
					<section type="none" id="sidelem4x2995">
						<sec_title>Precautions:</sec_title>
						<para> Respiratory/hepatic disease, osteoporosis</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x3000">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x3008">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x3008">
							<item>
								<label>•</label>
								<para> 2.5 mg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x3012">
					<section type="none" id="sidelem4x3013">
						<sec_title>Infertility (unlabeled)</sec_title>
						<section type="none" id="sidelem4x3021">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3021">
									<item>
										<label>•</label>
										<para> 2.5, 5, 7.5 mg/day × 5 days, usually days 3-7 of menstrual cycle</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3025">
						<sec_title>Idiopathic short stature, constitutional delayed puberty (unlabeled)</sec_title>
						<section type="none" id="sidelem4x3033">
							<label>•</label>
							<sec_title>Adolescent and child ≥9 (male)<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3033">
									<item>
										<label>•</label>
										<para> 2.5 mg/day; use with testosterone for delayed puberty</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3037">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 2.5 mg</para>
					</section>
					<section type="none" id="sidelem4x3042">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x3046">
								<item>
									<label>•</label>
									<para>Without regard to meals; with small glass of water</para>
								</item>
								<item>
									<label>•</label>
									<para>May administer biphosphates to increase bone density</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x3057">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x3060">
					<section type="none" id="sidelem4x3061">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache, lethargy,</emphasis> somnolence, dizziness, depression, anxiety</para>
					</section>
					<section type="none" id="sidelem4x3070">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">Angina, MI, CVA, thromboembolic events,</emphasis> hypertension, peripheral edema</para>
					</section>
					<section type="none" id="sidelem4x3078">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, anorexia,</emphasis> constipation, heartburn, diarrhea</para>
					</section>
					<section type="none" id="sidelem4x3086">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="bold">Endometrial cancer, vaginal bleeding, endometrial proliferation disorders</emphasis></para>
					</section>
					<section type="none" id="sidelem4x3093">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash, pruritus,</emphasis> alopecia, sweating</para>
					</section>
					<section type="none" id="sidelem4x3101">
						<sec_title>MISC:</sec_title>
						<para> Hot flashes, night sweats, <emphasis style="bold">second malignancies, anaphylaxis, angioedema</emphasis></para>
					</section>
					<section type="none" id="sidelem4x3108">
						<sec_title>MS:</sec_title>
						<para> Arthralgia, arthritis, bone fracture, myalgia, osteoporosis</para>
					</section>
					<section type="none" id="sidelem4x3113">
						<sec_title>RESP:</sec_title>
						<para> Dyspnea, cough</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x3118">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Metabolized in liver, excreted in urine, peak 2 days, terminal half-life 48 hr, steady state 2-6 wk</para>
			</section>
			<section type="interactions" id="sidelem4x3123">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Decrease:</emphasis> letrozole effect—estrogens, oral contraceptives</para>
			</section>
			<section type="considerations" id="sidelem4x3130">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x3133">
					<section type="none" id="sidelem4x3134">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x3138">
								<item>
									<label>•</label>
									<para>Hepatic studies before, during therapy (bilirubin, AST, ALT, LDH) as needed or monthly</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x3144">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x3148">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in size of tumor</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x3154">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x3163">
							<label>•</label>
							<sec_title>
								<route>To report allergic reactions (rash; hives; difficulty breathing; tightness in chest; swelling of mouth, face, lips, tongue)</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x3169">
							<label>•</label>
							<sec_title>
								<route>To report vaginal bleeding, diarrhea, chest/bone pain</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x3175">
							<label>•</label>
							<sec_title>
								<route>To use adequate contraception in perimenopausal, recently postmenopausal women; pregnancy (D)</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="13" status="active" ru="yes">
			<mono_name> leucovorin (Rx)</mono_name>
			<info>
				<pronunciation>(loo-koe-vor′in)</pronunciation>
				<class type="func"> Vitamin, folic acid/methotrexate antagonist antidote</class>
				<class type="chem"> Tetrahydrofolic acid derivative</class>
			</info>
			<section type="uses" id="sidelem4x3193">
				<sec_title>Uses:</sec_title>
				<para>Megaloblastic or macrocytic anemia caused by folic acid deficiency, overdose of folic acid antagonist, methotrexate/pyrimethamine/trimetrexate/trimethoprim toxicity, pneumocystosis, toxoplasmosis</para>
			</section>
			<section type="contra" id="sidelem4x3198">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product or folic acid, benzyl alcohol; anemias other than megaloblastic not associated with vit B<emphasis style="inf">12</emphasis> deficiency</para>
			</section>
			<section type="doses" id="sidelem4x3206">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x3209">
					<section type="none" id="sidelem4x3210">
						<sec_title>Megaloblastic anemia caused by enzyme deficiency</sec_title>
						<section type="none" id="sidelem4x3218">
							<label>•</label>
							<sec_title>Adult and child<route> PO/IV/IM</route></sec_title>
							<para>
								<list id="lidelem4x3218">
									<item>
										<label>•</label>
										<para> up to 6 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3222">
						<sec_title>Megaloblastic anemia caused by deficiency of folate</sec_title>
						<section type="none" id="sidelem4x3230">
							<label>•</label>
							<sec_title>Adult and child<route> IM</route></sec_title>
							<para>
								<list id="lidelem4x3230">
									<item>
										<label>•</label>
										<para> ≤1 mg/day until adequate response</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3234">
						<sec_title>Methotrexate toxicity/leucovorin rescue</sec_title>
						<section type="none" id="sidelem4x3242">
							<label>•</label>
							<sec_title>Adult and child<route> PO/IM/IV Normal elimination</route></sec_title>
							<para>
								<list id="lidelem4x3242">
									<item>
										<label>•</label>
										<para> given 6 hr after dose of methotrexate (10 mg/m<emphasis style="sup">2</emphasis>) until methotrexate &lt;5 × 10<emphasis style="sup">−8</emphasis> m, CCr &gt;50% above prior level, or methotrexate level 5 × 10<emphasis style="sup">−8</emphasis> m at 24 hr or &gt;9 × 10<emphasis style="sup">−8</emphasis> m at 48 hr; give leucovorin 100 mg/m<emphasis style="sup">2</emphasis> q3hr until level drops to &lt;10<emphasis style="sup">−8</emphasis> m</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3264">
						<sec_title>Pyrimethamine/trimethoprim toxicity</sec_title>
						<section type="none" id="sidelem4x3272">
							<label>•</label>
							<sec_title>Adult and child<route> PO/IM</route></sec_title>
							<para>
								<list id="lidelem4x3272">
									<item>
										<label>•</label>
										<para> 5-15 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3276">
						<sec_title>Advanced colorectal cancer</sec_title>
						<section type="none" id="sidelem4x3284">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x3284">
									<item>
										<label>•</label>
										<para> 200 mg/m<emphasis style="sup">2</emphasis>, then 5-FU 370 mg/m<emphasis style="sup">2</emphasis> or leucovorin 20 mg/m<emphasis style="sup">2</emphasis>, then 5-FU 425 mg/m<emphasis style="sup">2</emphasis>; give daily × 5 days q4-5wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="14" status="active" ha="yes">
			<mono_name> leuprolide (Rx)</mono_name>
			<info>
				<pronunciation>(loo-proe′lide)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x33082">Eligard</tradename>
					<tradename id="tnidelem4x33081">Lupron Depot</tradename>
					<tradename id="tnidelem4x33080">Lupron Depot-Ped</tradename>
				</tradenames>
				<class type="func"> Antineoplastic hormone</class>
				<class type="chem"> Gonadotropin-releasing hormone</class>
				<class type="preg">Pregnancy category <preg cat="X">X</preg></class>
			</info>
			<section type="confusion" id="sidelem4x3318">
				<para>
					<confusion>
						<tradename id="tnidelem4x33180">Lupron</tradename>
						<drug type="generic" refid="idelem4x33180">Nuprin/Lopurin</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x3322">
				<sec_title>Action:</sec_title>
				<para>Causes initial increase in circulating levels of LH, FSH; continuous administration results in decreased LH, FSH; in men, testosterone is reduced to castrate levels; in premenopausal women, estrogen is reduced to menopausal levels</para>
			</section>
			<section type="uses" id="sidelem4x3327">
				<sec_title>Uses:</sec_title>
				<para>Metastatic prostate cancer (inj implant), management of endometriosis, central precocious puberty, uterine leiomyomata (fibroids)</para>
				<section type="none" id="sidelem4x3332">
					<section type="none" id="sidelem4x3333">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Breast cancer, recurrent priapism, benign prostatic hyperplasia</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x3338">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="X">X</preg>), breastfeeding, hypersensitivity to GnRH or analogs, thromboembolic disorders, undiagnosed vaginal bleeding; Viadur implant or Eligard should not be used in women, children</para>
				<section type="none" id="sidelem4x3343">
					<section type="none" id="sidelem4x3344">
						<sec_title>Precautions:</sec_title>
						<para> Edema, hepatic disease, CVA, MI, seizures, hypertension, diabetes mellitus, CHF, depression, osteoporosis, spinal cord compression, urinary tract obstruction</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x3349">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x3352">
					<section type="none" id="sidelem4x3353">
						<sec_title>Prostate cancer</sec_title>
						<section type="none" id="sidelem4x3361">
							<label>•</label>
							<sec_title>Adult<route> SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x3361">
									<item>
										<label>•</label>
										<para> 1 mg/day;  7.5 mg/dose monthly; Viadur implant (72 mg) yearly; or  22.5 mg q3mo; or  30 mg q4mo; or IM 45 mg q6mo</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3374">
						<sec_title>Endometriosis/fibroids</sec_title>
						<section type="none" id="sidelem4x3382">
							<label>•</label>
							<sec_title>Adult<route> IM</route></sec_title>
							<para>
								<list id="lidelem4x3382">
									<item>
										<label>•</label>
										<para> 3.75 mg monthly for 6 mo or 11.25 mg q3mo for 6 mo or 30 mg q4mo</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3386">
						<sec_title>Central precocious puberty</sec_title>
						<section type="none" id="sidelem4x3394">
							<label>•</label>
							<sec_title>Child<route> SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x3394">
									<item>
										<label>•</label>
										<para> 50 mcg/kg/day; may increase by 10 mcg/kg/day as needed</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3401">
							<label>•</label>
							<sec_title>Child &gt;37.5 kg<route> IM</route></sec_title>
							<para>
								<list id="lidelem4x3401">
									<item>
										<label>•</label>
										<para> 15 mg q4wk</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3408">
							<label>•</label>
							<sec_title>Child 25-37.5 kg<route> IM</route></sec_title>
							<para>
								<list id="lidelem4x3408">
									<item>
										<label>•</label>
										<para> 11.25 mg q4wk</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3415">
							<label>•</label>
							<sec_title>Child ≤25 kg</sec_title>
							<para>
								<list id="lidelem4x3415">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Child ≤25 kg:</emphasis> 7.5 mg q4wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3419">
						<sec_title>Benign prostatic hyperplasia (BPH) (unlabeled)</sec_title>
						<section type="none" id="sidelem4x3427">
							<label>•</label>
							<sec_title>Adult<route> SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x3427">
									<item>
										<label>•</label>
										<para> (sol for inj) 1 mg/day, IM (injection susp) 3.75 mg q28day × 24 wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3431">
						<sec_title>Available forms:</sec_title>
						<para> Depot inj: 3.75, 7.5, 11.25, 15, 22.5, 30, 45 mg; Inj: 5 mg/ml (2.8-ml multidose vials)</para>
					</section>
					<section type="none" id="sidelem4x3436">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x3441">
								<item>
									<label>•</label>
									<para>Store in tight container at room temperature</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x3449">
							<label>•</label>
							<sec_title>SUBCUT</sec_title>
							<para>
								<list id="lidelem4x3449">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">SUBCUT:</emphasis> No dilution needed if patient self-administering; make sure patient using syringes provided by manufacturer</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3456">
							<label>•</label>
							<sec_title>Viadur DUROS Implant</sec_title>
							<para>
								<list id="lidelem4x3456">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Viadur DUROS Implant:</emphasis> Insert in inner aspect of arm, remove after 12 mo</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3463">
							<label>•</label>
							<sec_title>SUBCUT<route> Eligard</route></sec_title>
							<para>
								<list id="lidelem4x3463">
									<item>
										<label>•</label>
										<para> bring to room temperature, once mixed, give within 30 min, prepare the 2 syringes for mixing, join the 2 syringes together by pushing in and twisting until secure; mix the product by pushing the contents of both syringes back and forth between syringes until uniform; should be light tan to tan, hold syringes vertically with syringe B on the bottom, draw entire mixed product into syringe B (short, wide syringe) by depressing the syringe A plunger and slightly withdrawing syringe B plunger, uncouple syringe A, while pushing down on syringe A plunger, small air bubbles will remain, hold syringe B upright, remove pink cap, attach needle cartridge to the end of syringe B, remove needle cover, give by subcut</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3467">
							<sec_title>IM route</sec_title>
							<section type="none" id="sidelem4x3475">
								<label>•</label>
								<sec_title>Monthly</sec_title>
								<para>
									<list id="lidelem4x3475">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Monthly:</emphasis> reconstitute single-use vial with 1 ml of diluent; if multiple vials used, withdraw 0.5 ml, inject into each vial (1 ml); withdraw all, inject at 90-degree angle (3.75 mg)</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x3482">
								<label>•</label>
								<sec_title>3-mo</sec_title>
								<para>
									<list id="lidelem4x3482">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">3-mo:</emphasis> reconstitute microspheres using 1.5 ml of diluent, inject into vial; shake, withdraw, inject</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x3489">
								<label>•</label>
								<sec_title>12-mo</sec_title>
								<para>
									<list id="lidelem4x3489">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">12-mo:</emphasis> insert into upper arm; at the end of 12 mo, implant must be removed</para>
										</item>
									</list>
								</para>
							</section>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x3494">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x3497">
					<section type="none" id="sidelem4x3498">
						<sec_title>CNS:</sec_title>
						<para> Memory impairment, depression, <emphasis style="bold">seizures</emphasis></para>
					</section>
					<section type="none" id="sidelem4x3505">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">MI, PE, dysrhythmias,</emphasis> peripheral edema</para>
					</section>
					<section type="none" id="sidelem4x3513">
						<sec_title>GI:</sec_title>
						<para> Nausea, vomiting, anorexia, diarrhea, <emphasis style="bold">GI bleeding</emphasis></para>
					</section>
					<section type="none" id="sidelem4x3520">
						<sec_title>GU:</sec_title>
						<para> Edema, hot flashes, impotence, decreased libido, amenorrhea, vaginal dryness, gynecomastia, <emphasis style="bold">profuse vaginal bleeding</emphasis></para>
					</section>
					<section type="none" id="sidelem4x3527">
						<sec_title>INTEG:</sec_title>
						<para> Alopecia</para>
					</section>
					<section type="none" id="sidelem4x3532">
						<sec_title>MS:</sec_title>
						<para> Bone pain</para>
					</section>
					<section type="none" id="sidelem4x3537">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="bold">Dyspnea, pulmonary fibrosis, interstitial lung disease</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x3544">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x3547">
					<section type="none" id="sidelem4x3548">
						<sec_title>IM/SUBCUT:</sec_title>
						<para> Peak 1-2 mo, duration 1-3 mo; <emphasis style="bold">Implant:</emphasis> peak 4 hr, duration 12 mo; absorbed rapidly (SUBCUT), slowly (IM depot); half-life 3 hr</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x3556">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> antineoplastic action—flutamide, megestrol</para>
				<section type="none" id="sidelem4x3563">
					<section type="none" id="sidelem4x3564">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<list id="lidelem4x3568">
								<item>
									<label>•</label>
									<para>Do not use with black cohosh or chaste tree fruit, may interfere with treatment</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x3574">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x3577">
					<section type="none" id="sidelem4x3578">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x3586">
							<label>•</label>
							<sec_title>Prostate cancer</sec_title>
							<para>
								<list id="lidelem4x3586">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Prostate cancer:</emphasis> increased bone pain for first 4 wk of treatment; those with metastases in spinal column may exhibit severe back pain</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3593">
							<label>•</label>
							<sec_title>
								<route>Symptoms of endometriosis</route>
							</sec_title>
							<para>
								<list id="lidelem4x3593">
									<item>
										<label>•</label>
										<para> (lower abdominal pain)/ (pelvic pain, excessive vaginal bleeding, bloating) before, during, after treatment</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3603">
							<label>•</label>
							<sec_title>
								<route>Central precocious puberty (CPP)</route>
							</sec_title>
							<para>
								<list id="lidelem4x3603">
									<item>
										<label>•</label>
										<para> diagnosis should have been confirmed by secondary S<emphasis style="inf">4</emphasis> characteristics in children &lt;9 yr, estradiol/testosterone levels, GnRH test, tomography of head, adrenal steroids, chorionic gonadotropin, wrist x-ray, height, weight</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x3610">
								<item>
									<label>•</label>
									<para>Hepatic studies before, during therapy (bilirubin, AST, ALT, LDH) monthly, as needed; PSA, calcium, testosterone with prostate cancer; bone mineral density; blood glucose, HbA1c</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3615">
								<item>
									<label>•</label>
									<para>Pituitary gonadotropic and gonadal function during therapy and 4-8 wk after therapy decreased</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x3623">
							<label>•</label>
							<sec_title>Tumor flare<route> worsening of signs and symptoms; normal during beginning therapy</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x3626">
								<item>
									<label>•</label>
									<para>Fatigue, increased pulse, pallor, lethargy; edema in feet, joints; stomach pain</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3632">
								<item>
									<para>
										<emphasis alert="nurse">Severe allergic reaction: rash, pruritus, urticaria, purpuric skin lesions, itching, flushing</emphasis>
									</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x3637">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x3641">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased tumor size and spread of malignancy; decrease in lesions, pain with endometriosis, fibroids, correction of CPP; increased follicle maturation</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x3647">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x3652">
								<item>
									<label>•</label>
									<para>To notify prescriber if menstruation continues; menstruation should stop</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x3660">
							<label>•</label>
							<sec_title>
								<route>To notify prescriber if pregnancy is planned or suspected (X), avoid breastfeeding</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x3663">
								<item>
									<label>•</label>
									<para>That bone pain will disappear after 1 wk</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3668">
								<item>
									<label>•</label>
									<para>To report any complaints, side effects to nurse, prescriber; hot flashes may occur; record weight, report gain of &gt;2 lb/day</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3673">
								<item>
									<label>•</label>
									<para>How to prepare, give; to rotate sites for SUBCUT/IM inj</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3678">
								<item>
									<label>•</label>
									<para>To keep accurate records of dose</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x3686">
							<label>•</label>
							<sec_title>That tumor flare may occur<route> increase in size of tumor, increased bone pain, will subside rapidly; may take analgesics for pain</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x3689">
								<item>
									<label>•</label>
									<para>That voiding problems may increase during beginning of therapy but will decrease in several weeks</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="15" status="active">
			<mono_name>levalbuterol (Rx)</mono_name>
			<info>
				<pronunciation>(lev-al-byoo′ter-ole)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x36991">Xopenex</tradename>
					<tradename id="tnidelem4x36990">Xopenex HFA</tradename>
				</tradenames>
				<class type="func"> Bronchodilator, adrenergic β-agonist</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x3708">
				<sec_title>Action:</sec_title>
				<para>Causes bronchodilation by action on β<emphasis style="inf">2</emphasis> (pulmonary) receptors by increasing levels of cAMP, which relaxes smooth muscle; produces bronchodilation, CNS, cardiac stimulation as well as increased diuresis and gastric acid secretion</para>
			</section>
			<section type="uses" id="sidelem4x3718">
				<sec_title>Uses:</sec_title>
				<para>Treatment or prevention of bronchospasm (reversible obstructive airway disease), asthma</para>
			</section>
			<section type="contra" id="sidelem4x3723">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to sympathomimetics, this product, albuterol</para>
				<section type="none" id="sidelem4x3728">
					<section type="none" id="sidelem4x3729">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, hyperthyroidism, diabetes mellitus, hypertension, prostatic hypertrophy, angle-closure glaucoma, seizures, renal disease, QT prolongation, tachydysrhythmias, severe cardiac disease, hypokalemia, children</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x3734">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x3737">
					<section type="none" id="sidelem4x3738">
						<sec_title>Bronchospasm</sec_title>
						<section type="none" id="sidelem4x3746">
							<label>•</label>
							<sec_title>Adult/child ≥12 yr<route> INH</route></sec_title>
							<para>
								<list id="lidelem4x3746">
									<item>
										<label>•</label>
										<para> 0.63 mg tid q6-8hr by nebulization, may increase 1.25 mg q8hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3753">
							<label>•</label>
							<sec_title>Adult/adolescent/child &gt;4 yr</sec_title>
							<para>
								<list id="lidelem4x3753">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Adult/adolescent/child &gt;4 yr:</emphasis> (HFA, metered dose) 90 mcg (2 ) q4-6hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3763">
							<label>•</label>
							<sec_title>Child 6-11 yr<route> INH</route></sec_title>
							<para>
								<list id="lidelem4x3763">
									<item>
										<label>•</label>
										<para> 0.31 mg tid by nebulization, max 0.63 mg tid</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3767">
						<sec_title>Asthma, relief</sec_title>
						<section type="none" id="sidelem4x3775">
							<label>•</label>
							<sec_title>Child &lt;4 yr</sec_title>
							<para>
								<list id="lidelem4x3775">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Child &lt;4 yr:</emphasis> (unlabeled) 0.075 mg/kg in Neb Sol q20min × 3 doses, then 0.075-0.15 mg/kg up to 5 mg q1-4hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3779">
						<sec_title>Available forms:</sec_title>
						<para> Sol, inh pediatric 0.31 mg/3 ml; 0.63 mg/3 ml; 1.25 mg/3 ml; 1.25 mg/0.5 ml; 45 mcg per actuation (HFA)</para>
					</section>
					<section type="none" id="sidelem4x3784">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x3788">
								<item>
									<label>•</label>
									<para>Every 6-8hr; wait ≥1 min between inhalation of aerosols</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x3794">
							<sec_title>Inhalation route</sec_title>
							<para>
								<list id="lidelem4x3798">
									<item>
										<label>•</label>
										<para>Shake well before use, use a spacer device, prime with 4 test sprays in new canister or when not used for &gt;3 days</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3804">
							<sec_title>Nebulizer route</sec_title>
							<para>
								<list id="lidelem4x3808">
									<item>
										<label>•</label>
										<para>Dilute concentrated (1.25 mg/0.5 ml) with normal sterile saline before use</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x3814">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x3817">
					<section type="none" id="sidelem4x3818">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Tremors, anxiety,</emphasis> insomnia, <emphasis style="italic">headache,</emphasis> dizziness, stimulation, <emphasis style="italic">restlessness,</emphasis> irritability, weakness</para>
					</section>
					<section type="none" id="sidelem4x3832">
						<sec_title>CV:</sec_title>
						<para> Palpitations, tachycardia, hypertension, angina, hypotension, dysrhythmias, <emphasis style="bold">QT prolongation</emphasis></para>
					</section>
					<section type="none" id="sidelem4x3839">
						<sec_title>EENT:</sec_title>
						<para> Dry nose, irritation of nose and throat, rhinitis</para>
					</section>
					<section type="none" id="sidelem4x3844">
						<sec_title>GI:</sec_title>
						<para> Heartburn, nausea, vomiting, diarrhea</para>
					</section>
					<section type="none" id="sidelem4x3849">
						<sec_title>INTEG:</sec_title>
						<para> Rash</para>
					</section>
					<section type="none" id="sidelem4x3854">
						<sec_title>META:</sec_title>
						<para> <emphasis style="italic">Hypokalemia, hyperglycemia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x3861">
						<sec_title>MS:</sec_title>
						<para> Muscle cramps</para>
					</section>
					<section type="none" id="sidelem4x3866">
						<sec_title>RESP:</sec_title>
						<para> Cough, dyspnea</para>
					</section>
					<section type="none" id="sidelem4x3871">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Anaphylaxis, angioedema</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x3878">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Metabolized in the liver and tissues; crosses placenta, breast milk, blood-brain barrier; half-life 3.3-4 hr</para>
				<section type="none" id="sidelem4x3883">
					<section type="none" id="sidelem4x3884">
						<sec_title>INH sol:</sec_title>
						<para> Onset 10-17 min, peak 1<emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> hr, duration 5-6 hr; <emphasis style="bold">INH aerosol:</emphasis> onset 4.5-10.2 min, peak 76-78 min, duration ≤6 hr</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x3898">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="lifethreat">Increase: QT prolongation—Class IA, III antidysrhythmics, usually at high doses or hypokalemia</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypokalemia—loop/thiazide diuretics</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> action of aerosol bronchodilators</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> levalbuterol action—tricyclics, MAOIs, other adrenergics</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> levalbuterol action—other β-blockers, severe bronchospasm may occur</para>
				<section type="none" id="sidelem4x3920">
					<section type="none" id="sidelem4x3921">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> stimulation—black/green tea, coffee, cola nut, guarana, yerba mat(c)</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x3928">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x3931">
					<section type="none" id="sidelem4x3932">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x3940">
							<label>•</label>
							<sec_title>Respiratory function</sec_title>
							<para>
								<list id="lidelem4x3940">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Respiratory function:</emphasis> vital capacity, forced expiratory volume, ABGs, lung sounds, heart rate and rhythm (baseline); character of sputum: color, consistency, amount</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x3944">
								<item>
									<label>•</label>
									<para>Cardiac status: palpitations, increase/decrease in B/P, dysrhythmias</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3951">
								<item>
									<para>
										<emphasis alert="nurse">For evidence of allergic reactions, paradoxic bronchospasm, anaphylaxis, angioedema</emphasis>
									</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x3956">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x3960">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of dyspnea, wheezing after 1 hr; improved airway exchange, ABGs</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x3966">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x3971">
								<item>
									<label>•</label>
									<para>Not to use OTC medications because excess stimulation may occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3976">
								<item>
									<label>•</label>
									<para>To avoid getting aerosol in eyes because blurring may result</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3981">
								<item>
									<label>•</label>
									<para>To avoid smoking, smoke-filled rooms, persons with respiratory infections</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3987">
								<item>
									<para>
										<emphasis alert="nurse">That paradoxic bronchospasm may occur; to stop product immediately, contact prescriber</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3992">
								<item>
									<label>•</label>
									<para>To limit caffeine products such as chocolate, coffee, tea, colas, and herbs such as cola nut, guarana, yerba mat(c)</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3997">
								<item>
									<label>•</label>
									<para>To use this product first if using other inhalers; to wait 5 min or more between products; to rinse mouth with water after each dose to prevent dry mouth</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="none" id="sidelem4x4002">
				<sec_title>Treatment of overdose:</sec_title>
				<para>Administer a β<emphasis style="inf">1</emphasis>-adrenergic blocker</para>
			</section>
		</monograph>
<monograph id="16" status="active">
			<mono_name>levETIRAcetam (Rx)</mono_name>
			<info>
				<pronunciation>(lev-eh-teer-ass′eh-tam)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x40151">Keppra</tradename>
					<tradename id="tnidelem4x40150">Keppra XR</tradename>
				</tradenames>
				<class type="func"> Anticonvulsant</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x4021">
				<para>
					<confusion>
						<tradename id="tnidelem4x40210">Keppra</tradename>
						<drug type="generic" refid="idelem4x40210">Kaletra</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x4025">
				<sec_title>Action:</sec_title>
				<para>Unknown; may inhibit nerve impulses by limiting influx of sodium ions across cell membrane in motor cortex</para>
			</section>
			<section type="uses" id="sidelem4x4030">
				<sec_title>Uses:</sec_title>
				<para>Adjunctive therapy for partial-onset seizures, primary generalized tonic-clonic seizures, myoclonic seizures in juvenile patients</para>
			</section>
			<section type="contra" id="sidelem4x4035">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, breastfeeding</para>
				<section type="none" id="sidelem4x4040">
					<section type="none" id="sidelem4x4041">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), children, geriatric patients, renal/cardiac disease, psychosis</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x4046">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x4049">
					<section type="none" id="sidelem4x4050">
						<sec_title>Adjunctive treatment of partial seizures</sec_title>
						<section type="none" id="sidelem4x4058">
							<label>•</label>
							<sec_title>Adult/adolescent ≥16 yr<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x4058">
									<item>
										<label>•</label>
										<para> 500 mg bid, may be titrated by 1000 mg/day q2wk, max 3000 mg/day in divided doses;  1000 mg/day, may increase q2wk, max 3000 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x4068">
							<label>•</label>
							<sec_title>Adolescent &lt;16 yr/child/infant<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x4068">
									<item>
										<label>•</label>
										<para> 10 mg/kg bid, increase daily dose q2wk by 20 mg/kg to dose of 30 mg/kg bid; if patient unable to tolerate, may reduce dose</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4072">
						<sec_title>Myoclonic seizures/tonic-clonic seizures/partial seizures</sec_title>
						<section type="none" id="sidelem4x4080">
							<label>•</label>
							<sec_title>Adult/adolescent ≥16 yr<route> PO/IV</route></sec_title>
							<para>
								<list id="lidelem4x4080">
									<item>
										<label>•</label>
										<para> 500 mg bid, may increase by 1000 mg/day q2wk, max 3000 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4084">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x4092">
							<label>•</label>
							<sec_title>Adult<route> PO CCr 50-80 ml/min, 500-1000 mg q12hr or EXT REL 1000-2000 mg q24hr, max 2000 mg/day; CCr 30-49 ml/min, 250-750 mg q12hr or EXT REL 500-1500 mg q24hr, max 1500 mg/day; CCr &lt;30 ml/min, 250-500 mg q12hr or EXT REL 500-1000 mg q24hr, max 1000 mg/day</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x4095">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 250, 500, 750, 1000 mg; oral sol 100 mg/ml; sol for inj 100 mg/ml; ext rel tab 500, 750 mg; 1000 mg/100 ml 0.75% NaCl, 1500 mg/100 ml 0.54% NaCl, 500 mg/100 ml 0.82% NaCl</para>
					</section>
					<section type="none" id="sidelem4x4100">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x4103">
							<sec_title>PO route</sec_title>
							<section type="none" id="sidelem4x4111">
								<label>•</label>
								<sec_title>
									<route>Extended release product should not be used in dialysis patients</route>
								</sec_title>
							</section>
							<para>
								<list id="lidelem4x4114">
									<item>
										<label>•</label>
										<para>Swallow tab whole; do not break, crush, or chew</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x4119">
									<item>
										<label>•</label>
										<para>With food, milk to decrease GI symptoms (rare)</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x4124">
									<item>
										<label>•</label>
										<para>Store at room temperature (PO)</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x4132">
								<label>•</label>
								<sec_title>Child</sec_title>
								<para>
									<list id="lidelem4x4132">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Child:</emphasis>&lt;20 kg should be given oral solution; use calibrated device</para>
										</item>
									</list>
								</para>
							</section>
						</section>
						<section type="none" id="sidelem4x4136">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x4140">
									<item>
										<label>•</label>
										<para>Single-use vials: dilute in 100 ml of 0.9% NaCl, D<emphasis style="inf">5</emphasis>W, LR; give over 15 min, discard unused vial contents, do not use product with particulates or discoloration</para>
									</item>
									<item>
										<label>•</label>
										<para>Diluted preparation stable for 24 hr at room temperature in polyvinyl bags</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Additive compatibilities:</emphasis> diazepam, LORazepam, valproate</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x4159">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x4162">
					<section type="none" id="sidelem4x4163">
						<sec_title>CNS:</sec_title>
						<para> Dizziness, somnolence, asthenia, psychosis, <emphasis style="bold">suicidal ideation,</emphasis> nonpsychotic behavioral symptoms, headache, ataxia</para>
					</section>
					<section type="none" id="sidelem4x4171">
						<sec_title>EENT:</sec_title>
						<para> Diplopia, conjunctivitis</para>
					</section>
					<section type="none" id="sidelem4x4176">
						<sec_title>GI:</sec_title>
						<para> Nausea, vomiting, anorexia, diarrhea, constipation, <emphasis style="bold">hepatitis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x4183">
						<sec_title>HEMA:</sec_title>
						<para> Infection, leukopenia</para>
					</section>
					<section type="none" id="sidelem4x4188">
						<sec_title>INTEG:</sec_title>
						<para> Pruritus, rash</para>
					</section>
					<section type="none" id="sidelem4x4193">
						<sec_title>MISC:</sec_title>
						<para> Infection, abdominal pain, pharyngitis</para>
					</section>
					<section type="none" id="sidelem4x4198">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Stevens-Johnson syndrome, toxic epidermal necrolysis;</emphasis> dehydration (child &lt;4 yr)</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x4206">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Rapidly absorbed; not protein bound; excreted via kidneys 66% unchanged; half-life 6-8 hr, longer in geriatric patients or with renal disease</para>
			</section>
			<section type="interactions" id="sidelem4x4211">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> sedation—TCAs, antihistamines, benzodiazepines, other CNS depressants, alcohol<list id="lidelem4x4218">
						<item>
							<label>•</label>
							<para>Possible increased carBAMazepine toxicity: carBAMazepine</para>
						</item>
					</list></para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> levETIRAcetam absorption—sevelamer; separate by 1 hr before, 3 hr after sevelamer</para>
				<section type="none" id="sidelem4x4228">
					<section type="none" id="sidelem4x4229">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> Hct/Hgb, WBC, RBC</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x4236">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x4239">
					<section type="none" id="sidelem4x4240">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x4248">
							<label>•</label>
							<sec_title>Seizures</sec_title>
							<para>
								<list id="lidelem4x4248">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Seizures:</emphasis> type, location, duration, character; provide seizure precautions</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x4252">
								<item>
									<label>•</label>
									<para>Renal studies: urinalysis, BUN, urine creatinine q3mo</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4257">
								<item>
									<label>•</label>
									<para>Blood studies: CBC, LFTs</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4263">
								<item>
									<para>
										<emphasis alert="nurse">Mental status: mood, sensorium, affect, behavioral changes, suicidal thoughts/behaviors; if mental status changes, notify prescriber</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4268">
								<item>
									<label>•</label>
									<para>Assistance with ambulation during early part of treatment; dizziness occurs</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x4273">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x4277">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased seizure activity; document on patient’s chart</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x4283">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x4288">
								<item>
									<label>•</label>
									<para>To carry emergency ID stating patient’s name, products taken, condition, prescriber’s name, phone number</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4293">
								<item>
									<label>•</label>
									<para>How to use oral sol; if trouble swallowing, measure oral sol in medicine cup or dropper, do not use teaspoon</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4298">
								<item>
									<label>•</label>
									<para>To notify prescriber if pregnant, intending to become pregnant</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4303">
								<item>
									<label>•</label>
									<para>To avoid driving, other activities that require alertness, until response is known, drowsiness occurs during first month</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4308">
								<item>
									<label>•</label>
									<para>Not to discontinue medication quickly after long-term use because withdrawal seizure may occur</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x4316">
							<label>•</label>
							<sec_title>
								<route>Not to breastfeed, excreted in breast milk</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x4322">
							<label>•</label>
							<sec_title>
								<route>To report suicidal thoughts</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="17" status="active">
			<mono_name>levobetaxolol ophthalmic</mono_name>
			<section type="none" id="sidelem4x4328">
				<para>
					<see refid="tra">See Appendix B</see>
				</para>
			</section>
		</monograph>
<monograph id="18" status="active">
			<mono_name>levobunolol (ophthalmic)</mono_name>
			<info>
				<pronunciation>(lee′voe-byoo′no-lahl)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x43360">Betagan</tradename>
				</tradenames>
				<class type="func"> Antiglaucoma</class>
				<class type="chem"> β-Blocker</class>
			</info>
			<section type="actions" id="sidelem4x4346">
				<sec_title>Action:</sec_title>
				<para>Can decrease aqueous humor and increase outflows</para>
			</section>
			<section type="uses" id="sidelem4x4351">
				<sec_title>Uses:</sec_title>
				<para>Treatment of chronic open-angle glaucoma and ocular hypertension</para>
			</section>
			<section type="contra" id="sidelem4x4356">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, AV block, heart failure, bradycardia, sick sinus syndrome, asthma</para>
				<section type="none" id="sidelem4x4361">
					<section type="none" id="sidelem4x4362">
						<sec_title>Precautions:</sec_title>
						<para> Abrupt discontinuation, children, pregnancy, breastfeeding, COPD, depression, diabetes mellitus, myasthenia gravis, hyperthyroidism, pulmonary disease, sulfite sensitivity, angle-closure glaucoma</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x4369">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x4377">
					<label>•</label>
					<sec_title>Adult</sec_title>
					<para>
						<list id="lidelem4x4377">
							<item>
								<label>•</label>
								<para>
									<emphasis style="bold">Adult:</emphasis> Instill 1-2 drops in the affected eyes once a day (0.5% solution), bid (0.25% solution)</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x4381">
					<section type="none" id="sidelem4x4382">
						<sec_title>Available forms:</sec_title>
						<para> Ophthalmic solution 0.25%, 0.5%</para>
					</section>
					<section type="none" id="sidelem4x4387">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x4391">
								<item>
									<label>•</label>
									<para>For ophthalmic use only</para>
								</item>
								<item>
									<label>•</label>
									<para>Do not touch the tip of the dropper to the eye, fingertips, or other surface to prevent contamination</para>
								</item>
								<item>
									<label>•</label>
									<para>Wash hands before and after use; tilt head back slightly and pull the lower eyelid down with the index finger to form a pouch; squeeze the prescribed number of drops into the pouch; close eyes to spread drops; to avoid excessive systemic absorption, apply finger pressure on the lacrimal sac for 1-2 min after use</para>
								</item>
								<item>
									<label>•</label>
									<para>If more than one topical ophthalmic drug product is being used, the drugs should be administered at least 5 min apart</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid contamination or the spread of infection, do not use dropper for more than one person</para>
								</item>
								<item>
									<label>•</label>
									<para>Decreased intraocular pressure can take several weeks, monitor IOP after a month</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x4422">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x4425">
					<section type="none" id="sidelem4x4426">
						<sec_title>CNS:</sec_title>
						<para> Insomnia, headache, dizziness</para>
					</section>
					<section type="none" id="sidelem4x4431">
						<sec_title>CV:</sec_title>
						<para> Palpitations</para>
					</section>
					<section type="none" id="sidelem4x4436">
						<sec_title>EENT:</sec_title>
						<para> Eye stinging/burning, tearing, photophobia</para>
					</section>
					<section type="none" id="sidelem4x4441">
						<sec_title>PULM:</sec_title>
						<para> Bronchospasm</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x4446">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Onset 60 min, peak 2-6 hr, duration 24 hr</para>
			</section>
			<section type="interactions" id="sidelem4x4451">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> β-blocking effect—oral β-blockers</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> Intraocular pressure reduction—topical miotics, dipivefrin, EPINEPHrine, carbonic anhydrase inhibitors; this may be beneficial</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> Depression of AV nodal conduction, bradycardia, or hypotension—adenosine, cardiac glycosides, disopyramide, other antiarrhythmics, class 1C antiarrhythmic drugs (flecainide, propafenone, moricizine, encainide, quiNIDine, or drugs that significantly depress AV nodal conduction</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> AV block nodal conduction, induce AV block—high doses of procainamide</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> Antihypertensive effect—other antihypertensives</para>
			</section>
			<section type="considerations" id="sidelem4x4474">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x4477">
					<section type="none" id="sidelem4x4478">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x4484">
								<item>
									<para>
										<emphasis alert="nurse">Systemic absorption: When used in the eye, systemic absorption is common with the same adverse reactions and interactions</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x4492">
							<label>•</label>
							<sec_title>Glaucoma</sec_title>
							<para>
								<list id="lidelem4x4492">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Glaucoma:</emphasis> Monitor intraocular pressure</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4496">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x4500">
								<item>
									<label>•</label>
									<para>Decreasing intraocular pressure</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x4506">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x4510">
								<item>
									<label>•</label>
									<para>That product is for ophthalmic use only</para>
								</item>
								<item>
									<label>•</label>
									<para>Not to touch the tip of the dropper to the eye, fingertips, or other surface to prevent contamination</para>
								</item>
								<item>
									<label>•</label>
									<para>To wash hands before and after use; tilt the head back slightly and pull the lower eyelid down with the index finger to form a pouch; squeeze the prescribed number of drops into the pouch; close eyes to spread drops; to avoid excessive systemic absorption by applying finger pressure on the lacrimal sac for 1-2 min following use</para>
								</item>
								<item>
									<label>•</label>
									<para>That if more than one topical ophthalmic drug product is being used, the drugs should be administered at least 5 min apart</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid contamination or the spread of infection by not using dropper for more than one person</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="19" status="active">
			<mono_name>levocabastine ophthalmic</mono_name>
			<section type="none" id="sidelem4x4540">
				<para>
					<see refid="tra">See Appendix B</see>
				</para>
			</section>
		</monograph>
<monograph id="20" status="active">
			<mono_name>levocetirizine (Rx)</mono_name>
			<info>
				<pronunciation>(lee-voh-she-teer′ah-zeen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x45480">Xyzal</tradename>
				</tradenames>
				<class type="func"> Antihistamine, low sedating</class>
				<class type="chem"> H histamine blocker, low sedating</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="actions" id="sidelem4x4561">
				<sec_title>Action:</sec_title>
				<para>Acts on blood vessels, GI, respiratory system by competing with histamine for H<emphasis style="inf">1</emphasis>-receptor site; decreases allergic response by blocking pharmacologic effects of histamine; minimal anticholinergic action</para>
			</section>
			<section type="uses" id="sidelem4x4569">
				<sec_title>Uses:</sec_title>
				<para>Perennial or seasonal rhinitis, allergy symptoms, chronic idiopathic urticaria</para>
			</section>
			<section type="contra" id="sidelem4x4574">
				<sec_title>Contraindications:</sec_title>
				<para>Breastfeeding; children 6-11 yr with renal disease; end-stage renal disease; dialysis; hypersensitivity to this product, cetirizine, hydrOXYzine</para>
				<section type="none" id="sidelem4x4579">
					<section type="none" id="sidelem4x4580">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), driving, renal disease</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x4585">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x4593">
					<label>•</label>
					<sec_title>Adult and child ≥12 yr<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x4593">
							<item>
								<label>•</label>
								<para> 2.5-5 mg/day in the evening</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x4600">
					<label>•</label>
					<sec_title>Child 6-11 yr<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x4600">
							<item>
								<label>•</label>
								<para> (oral solution) 2.5 mg/day in the evening</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x4607">
					<label>•</label>
					<sec_title>Child 2-5 yr<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x4607">
							<item>
								<label>•</label>
								<para> (oral solution) 1.25 mg/day in the evening</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x4614">
					<label>•</label>
					<sec_title>Geriatric<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x4614">
							<item>
								<label>•</label>
								<para> 2.5-5 mg/day in the evening</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x4618">
					<section type="none" id="sidelem4x4619">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x4627">
							<label>•</label>
							<sec_title>Adult<route> PO CCr 50-80 ml/min, 2.5 mg/day; CCr 30-50 ml/min, 2.5 mg every other day; CCr 10-30 ml/min, 2.5 mg 2×/wk; CCr &lt;10 ml/min, do not use</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x4630">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 5 mg; oral sol 2.5 mg/5 ml</para>
					</section>
					<section type="none" id="sidelem4x4635">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x4639">
								<item>
									<label>•</label>
									<para>Without regard to meals in the evening; tabs scored, may be broken in half</para>
								</item>
								<item>
									<label>•</label>
									<para>Store in tight, light-resistant container</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x4650">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x4653">
					<section type="none" id="sidelem4x4654">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Drowsiness, fatigue</emphasis>, asthenia, dizziness</para>
					</section>
					<section type="none" id="sidelem4x4662">
						<sec_title>GI:</sec_title>
						<para> Dry mouth, increase LFTs, <emphasis style="bold">hepatitis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x4669">
						<sec_title>MISC:</sec_title>
						<para> Urinary retention</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x4674">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Rapid absorption; peak 0.9 hr; protein binding 91%-92%; half-life 8 hr; excreted in urine 85.4%, feces 12.9%</para>
			</section>
			<section type="interactions" id="sidelem4x4679">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> CNS depression—alcohol, other CNS depressants</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> anticholinergic/sedative effect—MAOIs, phenothiazines, tricyclics</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> clearance of levocetirizine—ritonavir</para>
				<section type="none" id="sidelem4x4694">
					<section type="none" id="sidelem4x4695">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">False negative:</emphasis> Skin allergy tests</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x4702">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x4705">
					<section type="none" id="sidelem4x4706">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x4714">
							<label>•</label>
							<sec_title>Allergy symptoms</sec_title>
							<para>
								<list id="lidelem4x4714">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Allergy symptoms:</emphasis> pruritus, urticaria, watering eyes at baseline, during treatment</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x4721">
							<label>•</label>
							<sec_title>Respiratory status</sec_title>
							<para>
								<list id="lidelem4x4721">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Respiratory status:</emphasis> rate, rhythm, increase in bronchial secretions, wheezing, chest tightness</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x4725">
								<item>
									<label>•</label>
									<para>Liver function tests, serum creatinine, BUN</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x4730">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x4734">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of running or congested nose or rashes</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x4740">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x4744">
								<item>
									<label>•</label>
									<para>About all aspects of product use; to notify prescriber if confusion, sedation, hypotension occur, not to exceed recommended dose</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid driving, other hazardous activities if drowsiness occurs</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid alcohol, other CNS depressants</para>
								</item>
								<item>
									<label>•</label>
									<para>That product not recommended while breastfeeding</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="none" id="sidelem4x4766">
				<sec_title>Treatment of overdose:</sec_title>
				<para>Administer diazepam, vasopressors, IV phenytoin</para>
			</section>
		</monograph>
<monograph id="21" status="active">
			<mono_name>levodopa-carbidopa (Rx)</mono_name>
			<info>
				<pronunciation>(lee-voe-doe′pa)-(kar-bi-doe′pa)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x47763">
						<country code="CAN">Apo-Levocarb</country>
					</tradename>
					<tradename id="tnidelem4x47762">
						<country code="CAN">Duodopa</country>
					</tradename>
					<tradename id="tnidelem4x47761">Sinemet</tradename>
					<tradename id="tnidelem4x47760">Sinemet CR</tradename>
				</tradenames>
				<class type="func"> Antiparkinson agent</class>
				<class type="chem"> Catecholamine</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x4792">
				<sec_title>Action:</sec_title>
				<para>Decarboxylation of levodopa in periphery is inhibited by carbidopa; more levodopa is made available for transport to the brain and for conversion to DOPamine in the brain</para>
			</section>
			<section type="uses" id="sidelem4x4797">
				<sec_title>Uses:</sec_title>
				<para>Parkinson’s disease, parkinsonism resulting from carbon monoxide, chronic manganese intoxication, cerebral arteriosclerosis</para>
				<section type="none" id="sidelem4x4802">
					<section type="none" id="sidelem4x4803">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Restless leg syndrome</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x4808">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, malignant melanoma, history of malignant melanoma or undiagnosed skin lesions resembling melanoma</para>
				<section type="none" id="sidelem4x4813">
					<section type="none" id="sidelem4x4814">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, diabetes, closed-angle glaucoma, respiratory/cardiac/renal/hepatic disease, MI with dysrhythmias, seizures, peptic ulcer, depression</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x4819">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x4822">
					<section type="none" id="sidelem4x4823">
						<sec_title>Beginning therapy for those not taking levodopa</sec_title>
						<section type="none" id="sidelem4x4831">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x4831">
									<item>
										<label>•</label>
										<para> 25 mg carbidopa/100 mg levodopa tid, may increase daily or every other day by 1 tab to desired response (8 tabs/day);  tabs (Sinemet CR) 50 mg carbidopa/200 mg levodopa bid;  caps (Rytary) 23.75 mg/95 mg tid × 3 days, then 36.25 mg/145 mg tid on day 4, may increase to 97.5 mg/390 mg tid</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4841">
						<sec_title>For those not taking levodopa ER</sec_title>
						<para>
							<list id="lidelem4x4845">
								<item>
									<label>•</label>
									<para>50 mg carbidopa/200 mg levodopa bid</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x4851">
						<sec_title>For those taking levodopa ER</sec_title>
						<para>
							<list id="lidelem4x4855">
								<item>
									<label>•</label>
									<para>Begin treatment with 10% more levodopa/day given q4-8hr, may increase or decrease dose q3days</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x4861">
						<sec_title>For those taking levodopa &lt;1.5 g/day</sec_title>
						<section type="none" id="sidelem4x4869">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x4869">
									<item>
										<label>•</label>
										<para> 25 mg carbidopa/100 mg levodopa tid-qid, may increase daily to desired response</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4873">
						<sec_title>For those taking levodopa &gt;1.5 g/day</sec_title>
						<section type="none" id="sidelem4x4881">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x4881">
									<item>
										<label>•</label>
										<para> 25 mg carbidopa/250 mg levodopa tid-qid, may increase daily to desired response</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4885">
						<sec_title>Restless leg syndrome (RLS) (unlabeled)</sec_title>
						<section type="none" id="sidelem4x4893">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x4893">
									<item>
										<label>•</label>
										<para> 25 mg carbidopa/100 mg levodopa, 1 tab at bedtime, may repeat if awakening within 2 hr or 50 mg carbidopa/200 mg levodopa sus rel tab 1-2 tabs 1 hr before bedtime</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4897">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 10 mg carbidopa/100 mg levodopa, 25 mg carbidopa/100 mg levodopa, 25 mg carbidopa/250 mg levodopa; ext rel tab 25 mg/100 mg, 50 mg carbidopa/200 mg levodopa (Sinemet CR); oral disintegrating tab (Parcopa) 10 mg carbidopa/100 mg levodopa, 25 mg carbidopa/100 mg levodopa; 25 mg carbidopa/250 mg levodopa; <emphasis style="bold">EXT REL</emphasis> caps (Rytary 23.75 mg/95 mg, 36.25 mg/145 mg, 48.75/195 mg, 61.25/245 mg</para>
					</section>
					<section type="none" id="sidelem4x4905">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x4909">
								<item>
									<label>•</label>
									<para>Pyridoxine (B<emphasis style="inf">6</emphasis>) not effective for reversing Sinemet or Sinemet CR</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x4918">
							<sec_title>PO route</sec_title>
							<section type="none" id="sidelem4x4926">
								<label>•</label>
								<sec_title>
									<route>ext rel tabs;</route>
								</sec_title>
								<para>
									<list id="lidelem4x4926">
										<item>
											<label>•</label>
											<para>Do not crush or chew  they may be broken in half; adjust dosage to response</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x4934">
								<label>•</label>
								<sec_title>
									<route>Oral disintegrating tab</route>
								</sec_title>
								<para>
									<list id="lidelem4x4934">
										<item>
											<label>•</label>
											<para> by gently removing from bottle, placing on tongue and swallowing with saliva; after tab dissolves, liquid is not necessary</para>
										</item>
									</list>
								</para>
							</section>
							<para>
								<list id="lidelem4x4938">
									<item>
										<label>•</label>
										<para>With meals if GI symptoms occur; limit protein taken with product</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x4943">
									<item>
										<label>•</label>
										<para>Only after nonselective MAOIs have been discontinued for 2 wk; if patient has been previously treated with levodopa, discontinue for at least 12 hr before change to carbidopa-levodopa</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x4949">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x4952">
					<section type="none" id="sidelem4x4953">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Involuntary choreiform movements, hand tremors, fatigue, headache, anxiety, twitching, numbness, weakness, confusion, agitation, insomnia, nightmares,</emphasis> psychosis, hallucination, hypomania, severe depression, dizziness, impulsive behaviors, <emphasis style="bold">neuroleptic malignant syndrome</emphasis></para>
					</section>
					<section type="none" id="sidelem4x4963">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="italic">Orthostatic hypotension,</emphasis> tachycardia, hypertension, palpitation</para>
					</section>
					<section type="none" id="sidelem4x4971">
						<sec_title>EENT:</sec_title>
						<para> Blurred vision, diplopia, dilated pupils</para>
					</section>
					<section type="none" id="sidelem4x4976">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, anorexia, abdominal distress, dry mouth, flatulence, dysphagia,</emphasis> bitter taste, diarrhea, constipation</para>
					</section>
					<section type="none" id="sidelem4x4984">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Hemolytic anemia, leukopenia, agranulocytosis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x4991">
						<sec_title>INTEG:</sec_title>
						<para> Rash, sweating, alopecia</para>
					</section>
					<section type="none" id="sidelem4x4996">
						<sec_title>MISC:</sec_title>
						<para> Urinary retention, incontinence, weight change, dark urine ​</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x5001">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x5004">
					<section type="none" id="sidelem4x5005">
						<sec_title>PO:</sec_title>
						<para> Onset 30 min, peak 1-3 hr, excreted in urine (metabolites)</para>
					</section>
					<section type="none" id="sidelem4x5010">
						<sec_title>EXT REL:</sec_title>
						<para> Onset 4-6 hr</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x5015">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="lifethreat">Increase: Hypertensive crisis—nonselective MAOIs</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> risk for sedation—CNS depressants</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> CV reactions—dobutamine, dopamine, epinephrine, isoproterenol, norepinephrine, TCAs</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> effects of levodopa—antacids, metoclopramide</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effects of levodopa—anticholinergics, hydantoins, papaverine, pyridoxine, benzodiazepines, antipsychotics</para>
				<section type="none" id="sidelem4x5037">
					<section type="none" id="sidelem4x5038">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> BUN, AST, ALT, bilirubin, alk phos, LDH, serum glucose</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> BUN, creatinine, uric acid</para>
						<para>
							<emphasis style="bold">False positive:</emphasis> urine ketones (dipstick), Coombs’ test</para>
						<para>
							<emphasis style="bold">False negative:</emphasis> urine glucose</para>
						<para>
							<emphasis style="bold">False increase:</emphasis> urine protein</para>
					</section>
					<section type="none" id="sidelem4x5061">
						<sec_title>Drug/Food</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> absorption of levodopa—protein</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x5068">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x5071">
					<section type="none" id="sidelem4x5072">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x5080">
							<label>•</label>
							<sec_title>Parkinson’s symptoms</sec_title>
							<para>
								<list id="lidelem4x5080">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Parkinson’s symptoms:</emphasis> tremors, pill rolling, drooling, akinesia, rigidity, shuffling gait before, during treatment</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x5084">
								<item>
									<label>•</label>
									<para>B/P, respiration; orthostatic B/P</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5089">
								<item>
									<label>•</label>
									<para>Mental status: affect, mood, behavioral changes, depression, complete suicide assessment</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x5097">
							<label>•</label>
							<sec_title>Toxicity<route> muscle twitching, blepharospasm</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x5100">
								<item>
									<label>•</label>
									<para>Renal, hepatic, hematopoietic tests; also for diabetes, acromegaly if on long-term therapy</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x5105">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x5109">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in akathisia/bradykinesis, tremor, rigidity, improved mood</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x5115">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x5120">
								<item>
									<label>•</label>
									<para>To change positions slowly to prevent orthostatic hypotension</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5125">
								<item>
									<label>•</label>
									<para>To report side effects: twitching, eye spasms because these indicate overdose</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x5133">
							<label>•</label>
							<sec_title>
								<route>To use product as prescribed; if discontinued abruptly, parkinsonian crisis, neuroleptic malignant syndrome (NMS) may occur; to gradually taper</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x5136">
								<item>
									<label>•</label>
									<para>That urine, sweat may darken</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5141">
								<item>
									<label>•</label>
									<para>To use physical activities to maintain mobility, lessen spasms</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5146">
								<item>
									<label>•</label>
									<para>Use with meals to decrease GI upset</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5151">
								<item>
									<label>•</label>
									<para>That improvement may not occur for 2-4 mo; about “on-off phenomenon”</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="22" status="active">
			<mono_name>levofloxacin (Rx)</mono_name>
			<info>
				<pronunciation>(lee-voh-floks′a-sin)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x51610">Levaquin</tradename>
				</tradenames>
				<class type="func"> Antiinfective</class>
				<class type="chem"> Fluoroquinolone</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x5171">
				<sec_title>Action:</sec_title>
				<para>Interferes with conversion of intermediate DNA fragments into high-molecular-weight DNA in bacteria; DNA gyrase inhibitor; inhibits topoisomerase IV</para>
			</section>
			<section type="uses" id="sidelem4x5177">
				<sec_title>Uses:</sec_title>
				<para>Acute sinusitis, acute chronic bronchitis, community-acquired pneumonia, uncomplicated skin infections, UTI, cellulitis, prostatitis, inhalational anthrax (postexposure); acute pyelonephritis caused by <emphasis style="italic">Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae, Haemophilis parainfluenzae, Moraxella catarrhalis, Escherichia coli, Serratia marcescens, Klebsiella pneumoniae, Chlamydia pneumoniae, Legionella pneumophilia, Mycoplasma pneumoniae, Enterococcus faecalis, Staphylococcus epidermidis, Staphylococcus pyogenes, Staphylococcus aureus, Bacillus anthracis;</emphasis> inhalation anthrax in children</para>
				<section type="none" id="sidelem4x5185">
					<section type="none" id="sidelem4x5186">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Adnexitis, Bartholin abscess, bartholinitis, cervicitis, epididymis, gastroenteritis, <emphasis style="italic">H. pylori</emphasis> eradication, mastitis, MAC, nongonococcal urethritis, obstetric infections, PID, plague, SARS, shigellosis, TB, typhoid fever, disseminated; otitis media, otitis externa, tonsillitis, pharyngitis, sialadenitis</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x5194">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to quinolones</para>
				<section type="none" id="sidelem4x5199">
					<section type="none" id="sidelem4x5200">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, photosensitivity, acute MI, atrial fibrillation, colitis, dehydration, diabetes, QT prolongation, myasthenia gravis, renal disease, seizure disorder, syphilis</para>
						<para>
							<bbw>Tendon pain/rupture, tendinitis</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x5215">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x5218">
					<section type="none" id="sidelem4x5219">
						<sec_title>Acute bacterial exacerbation of chronic bronchitis</sec_title>
						<section type="none" id="sidelem4x5227">
							<label>•</label>
							<sec_title>Adult<route> PO/IV</route></sec_title>
							<para>
								<list id="lidelem4x5227">
									<item>
										<label>•</label>
										<para> 500 mg q24hr × 7 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5231">
						<sec_title>Acute bacterial sinusitis</sec_title>
						<section type="none" id="sidelem4x5239">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x5239">
									<item>
										<label>•</label>
										<para> 500 mg q24hr × 10-14 days or 750 mg q24hr × 5 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5243">
						<sec_title>Mild-moderate UTI/acute pyelonephritis</sec_title>
						<section type="none" id="sidelem4x5251">
							<label>•</label>
							<sec_title>Adult<route> PO/IV</route></sec_title>
							<para>
								<list id="lidelem4x5251">
									<item>
										<label>•</label>
										<para> 750 mg q24hr × 5 days or 250 mg q24hr × 10 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5255">
						<sec_title>Chronic bacterial prostitis</sec_title>
						<section type="none" id="sidelem4x5263">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x5263">
									<item>
										<label>•</label>
										<para> 500 mg q24hr × 28 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5267">
						<sec_title>Postexposure inhalational anthrax</sec_title>
						<section type="none" id="sidelem4x5275">
							<label>•</label>
							<sec_title>Adult/adolescent/child &gt;50 kg<route> PO/IV</route></sec_title>
							<para>
								<list id="lidelem4x5275">
									<item>
										<label>•</label>
										<para> 500 mg q24hr × 60 days</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x5282">
							<label>•</label>
							<sec_title>Infant &gt;6 mo/child &lt;50 kg<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x5282">
									<item>
										<label>•</label>
										<para> 8 mg/kg q12hr × 60 days, max 250 mg/dose</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5286">
						<sec_title>Pneumonia, community acquired</sec_title>
						<section type="none" id="sidelem4x5294">
							<label>•</label>
							<sec_title>Adult<route> PO/IV</route></sec_title>
							<para>
								<list id="lidelem4x5294">
									<item>
										<label>•</label>
										<para> 500 mg q24hr × 7-14 days or 750 mg q24hr × 5 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5298">
						<sec_title>Pneumonia, nosocomial</sec_title>
						<section type="none" id="sidelem4x5306">
							<label>•</label>
							<sec_title>Adult<route> PO/IV</route></sec_title>
							<para>
								<list id="lidelem4x5306">
									<item>
										<label>•</label>
										<para> 750 mg q24hr × 7-14 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5310">
						<sec_title>Skin/skin-structure infections, complicated</sec_title>
						<section type="none" id="sidelem4x5318">
							<label>•</label>
							<sec_title>Adult<route> PO/IV</route></sec_title>
							<para>
								<list id="lidelem4x5318">
									<item>
										<label>•</label>
										<para> 750 mg q24hr × 7-14 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5322">
						<sec_title>Skin/skin-structure infections, uncomplicated</sec_title>
						<section type="none" id="sidelem4x5330">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x5330">
									<item>
										<label>•</label>
										<para> 500 mg q24hr × 7-10 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5334">
						<sec_title>UTI, complicated</sec_title>
						<section type="none" id="sidelem4x5342">
							<label>•</label>
							<sec_title>Adult<route> PO/IV</route></sec_title>
							<para>
								<list id="lidelem4x5342">
									<item>
										<label>•</label>
										<para> 750 mg q24hr × 5 days or 250 mg q24hr × 10 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5346">
						<sec_title>UTI, uncomplicated</sec_title>
						<section type="none" id="sidelem4x5354">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x5354">
									<item>
										<label>•</label>
										<para> 250 mg q24hr × 3 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5358">
						<sec_title>Plague <emphasis style="bold">
								<emphasis style="italic">(Y. pestis)</emphasis>
							</emphasis></sec_title>
						<section type="none" id="sidelem4x5369">
							<label>•</label>
							<sec_title>Adult<route> PO/IV</route></sec_title>
							<para>
								<list id="lidelem4x5369">
									<item>
										<label>•</label>
										<para> 500 mg q24hr × 10-14 days, with pneumonia 750 mg q24hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x5376">
							<label>•</label>
							<sec_title>Child/adolescent &lt;50 kg<route> PO/IV</route></sec_title>
							<para>
								<list id="lidelem4x5376">
									<item>
										<label>•</label>
										<para> 8 mg/kg (max 250 mg/dose) q12hr × 10-14 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5380">
						<sec_title>Otitis media (unlabeled)</sec_title>
						<section type="none" id="sidelem4x5388">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x5388">
									<item>
										<label>•</label>
										<para> 100-200 mg bid-tid × 3-14 days</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x5395">
							<label>•</label>
							<sec_title>Child 6 mo-14 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x5395">
									<item>
										<label>•</label>
										<para> 10 mg/kg bid × ≥10 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5399">
						<sec_title>Renal disease</sec_title>
						<section type="none" id="sidelem4x5407">
							<label>•</label>
							<sec_title>Adult<route> PO/IV CCr 20-49 ml/min for 750 mg doses, give 750 mg q48hr; for 500 mg doses, give 500 mg once, then 250 mg q24hr; for 250 mg doses, no adjustment; CCr 10-19 ml/min for 750 mg dose, give 750 mg once, then 500 mg q48hr; for 500 mg dose, give 500 mg once, then 250 mg q48hr; for 250 mg dose, give 250 mg q48hr, except when treating complicated UTI, then no dose adjustment</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x5410">
						<sec_title>Available forms:</sec_title>
						<para> Single-use vials 500, 750 mg; premixed flexible containers 250 mg/50 ml D<emphasis style="inf">5</emphasis>W, 500 mg/100 ml D<emphasis style="inf">5</emphasis>W, 750 mg/150 ml D<emphasis style="inf">5</emphasis>W; tabs 250, 500, 750 mg; oral sol 25 mg/ml</para>
					</section>
					<section type="none" id="sidelem4x5425">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x5430">
								<item>
									<label>•</label>
									<para>Obtain C&amp;S before treatment and periodically</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5435">
								<item>
									<label>•</label>
									<para>PO 2 hr before or after antacids, iron, calcium, zinc, give fluids</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x5443">
							<label>•</label>
							<sec_title>Oral solution</sec_title>
							<para>
								<list id="lidelem4x5443">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Oral solution:</emphasis> Give 1 hr before or 2 hr after food</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x5447">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x5451">
									<item>
										<label>•</label>
										<para>Discard any unused sol in single-dose vial</para>
									</item>
									<item>
										<label>•</label>
										<para>Visually inspect for particulate matter/discoloration before use</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x5462">
							<sec_title>IV (single-use vial)</sec_title>
							<section type="none" id="sidelem4x5470">
								<label>•</label>
								<sec_title>500 mg/20 ml vials</sec_title>
								<para>
									<list id="lidelem4x5470">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">500 mg/20 ml vials:</emphasis> To prepare a dose of 500 mg, withdraw 10 ml from a 20 ml vial and dilute with a compatible IV solution (D<emphasis style="inf">5</emphasis>W, NS) to a total volume of 50 ml; to prepare a 500 mg dosage, withdraw all 20 ml from the vial and dilute with a compatible intravenous solution to a total volume of 100 ml</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x5480">
								<label>•</label>
								<sec_title>750 mg/30 ml vials</sec_title>
								<para>
									<list id="lidelem4x5480">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">750 mg/30 ml vials:</emphasis> To prepare a dose of 750 mg, withdraw 30 ml from a 30 ml vial and dilute with a compatible intravenous solution (D<emphasis style="inf">5</emphasis>W, NS) to a total volume of 150 ml</para>
										</item>
									</list>
								</para>
							</section>
							<para>
								<list id="lidelem4x5487">
									<item>
										<label>•</label>
										<para>The concentration of the diluted solution should be 5 mg/ml before administration; solutions contain no preservatives; any unused portions must be discarded</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x5495">
								<label>•</label>
								<sec_title>Storage</sec_title>
								<para>
									<list id="lidelem4x5495">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Storage:</emphasis> The diluted solution may be stored for up to 72 hr when stored at or below 25°C (77°F) or for 14 days when stored under refrigeration at 5°C (41°F) in plastic containers; solutions may be frozen for up to 6 mo (−20°C or −4°F) in glass bottles or plastic containers; thaw frozen solutions at room temperature (25°C or 77°F) or in a refrigerator (8°C or 46°F); do not force thaw by microwave or water bath immersion; do not refreeze after initial thawing</para>
										</item>
									</list>
								</para>
							</section>
						</section>
						<section type="none" id="sidelem4x5499">
							<sec_title>Premixed IV solution</sec_title>
							<para>
								<list id="lidelem4x5503">
									<item>
										<label>•</label>
										<para>No dilution is necessary</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x5509">
							<sec_title>Intermittent IV injection</sec_title>
							<para>
								<list id="lidelem4x5513">
									<item>
										<label>•</label>
										<para>Infuse doses of ≤500 mg IV over 60 min and doses of 750 mg IV over 90 min; shorter infusions or bolus inj should be avoided because of the risk of hypotension</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Alemtuzumab, alfentanil, amifostine, amikacin, aminocaproic acid, aminophylline, ampicillin, ampicillin-sulbactam, anidulafungin, argatroban, atenolol, atracurium, aztreonam, bivalirudin, bleomycin, bumetanide, buprenorphine, busulfan, butorphanol, caffeine citrate, calcium gluconate, CARBOplatin, carmustine, caspofungin, cefepime, cefoTEtan, ceftaroline, cefTAZidime, ceftizoxime, cefTRIAXone, cefuroxime, chlorproMAZINE, cimetidine, cisatracurium, CISplatin, clindamycin, codeine, cyclophosphamide, cycloSPORINE, cytarabine, dacarbazine, DACTINomycin, DAPTOmycin, DAUNOrubicin liposomal, dexamethasone, dexrazoxane, digoxin, diltiazem, diphenhydrAMINE, DOBUTamine, DOCEtaxel, dolasetron, DOPamine, doripenem, doxacurium, doxycycline, droperidol, enalaprilat, ePHEDrine, EPINEPHrine, epirubicin, ertapenem, erythromycin, esmolol, etoposide, etoposide phosphate, famotidine, fenoldopam, fentaNYL, filgrastim, floxuridine, fluconazole, fludarabine, foscarnet, fosphenytoin, gallium, gemcitabine, gemtuzumab, gentamicin, granisetron, haloperidol, hydrocortisone, HYDROmorphone, IDArubicin, ifosfamide, imipenem-cilastatin, irinotecan, isoproterenol, labetalol, lepirudin, leucovorin, levorphanol, lidocaine, linezolid, mannitol, mechlorethamine, meperidine, mesna, methylPREDNISolone, metoclopramide, metroNIDAZOLE, midazolam, milrinone, minocycline, mitoMYcin, mitoXANtrone, mivacurium, morphine, mycophenolate mofetil, nalbuphine, naloxone, nesiritide, netilmicin, niCARdipine, octreotide, ondansetron, oxacillin, oxaliplatin, oxytocin, PACLitaxel, palonosetron, pamidronate, pancuronium, PEMEtrexed, penicillin G sodium, pentamidine, phenylephrine, plicamycin, potassium acetate/chloride, promethazine, propranolol, quinupristin-dalfopristin, ranitidine, remifentanil, rocuronium, sargramostim, sodium bicarbonate, succinylcholine, SUFentanil, sulfamethoxazole-trimethoprim, tacrolimus, teniposide, theophylline, thiotepa, ticarcillin, ticarcillin-clavulanate, tigecycline, tirofiban, tobramycin, topotecan, trimethobenzamide, vancomycin, vasopressin, vecuronium, verapamil, vinBLAStine, vinCRIStine, vinorelbine, voriconazole, zidovudine, zoledronic acid</para>
							<para>
								<emphasis style="bold">Solution compatibilities:</emphasis> 0.9% NaCl, D<emphasis style="inf">5</emphasis>W, D<emphasis style="inf">5</emphasis>/0.9% NaCl, D<emphasis style="inf">5</emphasis>LR, D<emphasis style="inf">5</emphasis>/0.45% NaCl, sodium lactate, plasma-lyte 56/D<emphasis style="inf">5</emphasis>W</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x5544">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x5547">
					<section type="none" id="sidelem4x5548">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache,</emphasis> dizziness, <emphasis style="italic">insomnia,</emphasis> anxiety, <emphasis style="bold">seizures,</emphasis><emphasis style="italic">encephalopathy,</emphasis> paresthesia, <emphasis style="bold">pseudotumor cerebri</emphasis></para>
					</section>
					<section type="none" id="sidelem4x5566">
						<sec_title>CV:</sec_title>
						<para> Chest pain, palpitations, vasodilation, <emphasis style="bold">QT prolongation,</emphasis> hypotension (rapid infusion)</para>
					</section>
					<section type="none" id="sidelem4x5574">
						<sec_title>EENT:</sec_title>
						<para> Dry mouth, visual impairment, tinnitus</para>
					</section>
					<section type="none" id="sidelem4x5579">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea,</emphasis> flatulence, <emphasis style="italic">vomiting,</emphasis> diarrhea, abdominal pain, <emphasis style="bold">pseudomembranous colitis, hepatotoxicity, esophagitis, pancreatitis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x5592">
						<sec_title>GU:</sec_title>
						<para> Vaginitis, crystalluria</para>
					</section>
					<section type="none" id="sidelem4x5597">
						<sec_title>HEMA:</sec_title>
						<para> Eosinophilia, <emphasis style="bold">hemolytic anemia,</emphasis> lymphopenia</para>
					</section>
					<section type="none" id="sidelem4x5605">
						<sec_title>INTEG:</sec_title>
						<para> Rash, pruritus, <emphasis style="italic">photosensitivity,</emphasis><emphasis style="bold">epidermal necrolysis,</emphasis> injection-site reaction, edema</para>
					</section>
					<section type="none" id="sidelem4x5615">
						<sec_title>MISC:</sec_title>
						<para> Hypoglycemia, hypersensitivity, tendinitis, <emphasis style="bold">tendon rupture, rhabdomyolysis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x5622">
						<sec_title>RESP:</sec_title>
						<para> Pneumonitis</para>
					</section>
					<section type="none" id="sidelem4x5627">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Anaphylaxis, multisystem organ failure, Stevens-Johnson syndrome, angioedema, toxic epidermal necrolysis</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x5634">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Excreted in urine unchanged, half-life 6-8 hr, peak 1-2 hr</para>
			</section>
			<section type="interactions" id="sidelem4x5639">
				<sec_title>Interactions</sec_title>
				<para>
					<bbw>
						<emphasis alert="lifethreat">Increase:</emphasis> tendon rupture—corticosteroids</bbw>
				</para>
				<section type="none" id="sidelem4x5658">
					<label>•</label>
					<sec_title>
						<route>Do not use with magnesium in same IV line</route>
					</sec_title>
				</section>
				<para>
					<emphasis alert="lifethreat">Increase: QT prolongation products causing a QT prolongation</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> levofloxacin levels—probenecid</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> CNS stimulation, seizures—NSAIDs, foscarnet, cycloSPORINE</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> bleeding risk—warfarin</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> levofloxacin absorption—antacids containing aluminum, magnesium; sucralfate, zinc, iron, calcium</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> clearance of theophylline; toxicity may result</para>
				<section type="none" id="sidelem4x5684">
					<section type="none" id="sidelem4x5685">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> PT, INR</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> glucose, lymphocytes</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x5696">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x5699">
					<section type="none" id="sidelem4x5700">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x5705">
								<item>
									<label>•</label>
									<para>Previous sensitivity reaction to quinolones</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x5713">
							<label>•</label>
							<sec_title>Signs, symptoms of infection</sec_title>
							<para>
								<list id="lidelem4x5713">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Signs, symptoms of infection:</emphasis> characteristics of sputum, WBC &gt;10,000/mm<emphasis style="sup">3</emphasis>, fever; obtain baseline information before, during treatment</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x5720">
								<item>
									<label>•</label>
									<para>C&amp;S before beginning product therapy to identify if correct treatment initiated</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5726">
								<item>
									<para>
										<emphasis alert="nurse">Allergic reactions, anaphylaxis: rash, urticaria, pruritus, chills, fever, joint pain; may occur a few days after therapy begins; EPINEPHrine and resuscitation equipment should be available for anaphylactic reaction</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x5734">
							<label>•</label>
							<sec_title>Pseudomembranous colitis<route> bowel pattern daily; if severe diarrhea, fever occurs, product should be discontinued</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x5738">
								<item>
									<para>
										<emphasis alert="nurse">Overgrowth of infection: perineal itching, fever, malaise, redness, pain, swelling, drainage, rash, diarrhea, change in cough, sputum</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x5746">
							<para>
								<list id="lidelem4x5746">
									<item>
										<label>•</label>
										<para>Renal function (BUN/creatinine)
<bbw>
												<emphasis alert="lifethreat">Tendon rupture:</emphasis> discontinue product at first sign of tendon pain or inflammation, usually the Achilles tendon is affected; can occur up to few months after treatment and may require surgical repair; steroids may increase risk</bbw>
</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x5759">
								<item>
									<label>•</label>
									<para>Increased fluid intake to 2 L/day to prevent crystalluria</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x5764">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x5768">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of signs, symptoms of infection (WBC &lt;10,000/mm<emphasis style="sup">3</emphasis>, temperature WNL)</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x5778">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x5783">
								<item>
									<label>•</label>
									<para>To contact prescriber if vaginal itching; loose, foul-smelling stools; furry tongue occur (may indicate superinfection); to report itching, rash, pruritus, urticaria</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x5791">
							<label>•</label>
							<sec_title>
								<route>To notify prescriber of diarrhea with blood or pus</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x5794">
								<item>
									<label>•</label>
									<para>To take product 2 hr before or after antacids, iron, calcium, zinc products</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5799">
								<item>
									<label>•</label>
									<para>To complete full course of therapy</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5804">
								<item>
									<label>•</label>
									<para>To avoid hazardous activities until response is known</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5809">
								<item>
									<label>•</label>
									<para>To use frequent rinsing of mouth, sugarless candy or gum for dry mouth</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5814">
								<item>
									<label>•</label>
									<para>To avoid other medication unless approved by prescriber</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5819">
								<item>
									<label>•</label>
									<para>To prevent sun exposure or to use sunscreen to prevent phototoxicity</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5824">
								<item>
									<label>•</label>
									<para>To monitor glucose (diabetes)
<bbw>To notify prescriber of tendon pain, inflammation; avoid corticosteroids with this product</bbw>
</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="23" status="active">
			<mono_name>levofloxacin ophthalmic</mono_name>
			<section type="none" id="sidelem4x5841">
				<para>
					<see refid="tra">See Appendix B</see>
				</para>
			</section>
		</monograph>
<monograph id="24" status="active">
			<mono_name>levomilnacipran</mono_name>
			<info>
				<pronunciation>(lee′voe-mil-na′si-pran)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x58490">Fetzima</tradename>
				</tradenames>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x5859">
				<sec_title>Action:</sec_title>
				<para>May potentiate serotonergic, adrenergic activity in the CNS; is a potent inhibitor of adrenal serotonin and norepinephrine reuptake</para>
			</section>
			<section type="uses" id="sidelem4x5864">
				<sec_title>Uses:</sec_title>
				<para>Major depressive disorder in adults</para>
			</section>
			<section type="contra" id="sidelem4x5869">
				<sec_title>Contraindications:</sec_title>
				<para>Alcohol intoxication, alcoholism, closed angle glaucoma, hepatic disease, hepatitis, jaundice, hypersensitivity</para>
				<section type="none" id="sidelem4x5874">
					<section type="none" id="sidelem4x5875">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, geriatric patients, mania, hypertension, renal/cardiac disease, seizures, increased intraocular pressure, anorexia, bleeding, dehydration, diabetes, hypotension, hypovolemia, orthostatic hypotension, abrupt product withdrawal</para>
						<para>
							<bbw>Children, suicidal ideation</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x5890">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x5898">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x5898">
							<item>
								<label>•</label>
								<para> 20 mg/day ×2 days, then 40 mg/day; may increase in increments of 40 mg at intervals of at least 2 days, max 120 mg/day; max 80 mg/day (strong CYP3A4 inhibitors therapy)</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x5902">
					<section type="none" id="sidelem4x5903">
						<sec_title>Renal Dose</sec_title>
						<section type="none" id="sidelem4x5911">
							<label>•</label>
							<sec_title>Adult<route> PO CCr 30-59 ml/min max 80 mg/day; 15-29 ml/min, max 40 mg/day; &lt;15 ml/min; avoid use</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x5914">
						<sec_title>Available forms:</sec_title>
						<para> Ext rel caps 20, 40, 80, 120 mg</para>
					</section>
					<section type="none" id="sidelem4x5919">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x5923">
								<item>
									<label>•</label>
									<para>Swallow cap whole; do not break, crush, or chew; do not sprinkle on food or mix with liquid</para>
								</item>
								<item>
									<label>•</label>
									<para>Without regard to food</para>
								</item>
								<item>
									<label>•</label>
									<para>Give at the same time each day</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x5939">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x5942">
					<section type="none" id="sidelem4x5943">
						<sec_title>CNS:</sec_title>
						<para> Dizziness, agitation, hallucinations, seizures, drowsiness, mania, migraine, paresthesias, serotonin syndrome, suicidal ideation, syncope</para>
					</section>
					<section type="none" id="sidelem4x5948">
						<sec_title>CV:</sec_title>
						<para> Hypertension, palpitations, dysrhythmia, sinus tachycardia</para>
					</section>
					<section type="none" id="sidelem4x5953">
						<sec_title>EENT:</sec_title>
						<para> Teeth grinding, blurred vision</para>
					</section>
					<section type="none" id="sidelem4x5958">
						<sec_title>GI:</sec_title>
						<para> Constipation, diarrhea, nausea, vomiting, anorexia, dry mouth, abdominal pain</para>
					</section>
					<section type="none" id="sidelem4x5963">
						<sec_title>GU:</sec_title>
						<para> Urinary retention</para>
					</section>
					<section type="none" id="sidelem4x5968">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Serotonin syndrome, Stevens-Johnson syndrome</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x5975">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Peak 6-8 hr metabolized (CYP2D6) in the liver; 22% protein binding, half-life 12 hr</para>
			</section>
			<section type="interactions" id="sidelem4x5981">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x5989">
					<label>•</label>
					<sec_title>
						<route>Do not use with linezolid or methylene blue IV, or within 14 days of MAOIs</route>
					</sec_title>
				</section>
				<para>
					<list id="lidelem4x5992">
						<item>
							<label>•</label>
							<para>Increase levomilnacipran effect—CYP34A inhibitors</para>
						</item>
					</list>
				</para>
				<para>
					<emphasis alert="lifethreat">Increase: Serotonin syndrome, SSRIs, serotonin receptor agonists, SNRIs</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> bleeding risk—anticoagulants, antiplatelets, salicylates, NSAIDs</para>
				<section type="none" id="sidelem4x6004">
					<section type="none" id="sidelem4x6005">
						<section type="none" id="sidelem4x6006">
							<sec_title>Drug/Herb</sec_title>
							<section type="none" id="sidelem4x6014">
								<label>•</label>
								<sec_title>Serotonin syndrome<route> St. John’s wort</route></sec_title>
							</section>
							<para>
								<emphasis style="bold">Increase:</emphasis> CNS depression—kava, valerian</para>
						</section>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x6021">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x6024">
					<section type="none" id="sidelem4x6025">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>Hyperthermia, rigidity, rapid fluctuations of vital signs, mental status changes, neuroleptic malignant syndrome-MAOIs coadministration contraindicated within 14 days of MAOI</bbw>
						</para>
						<para>
							<bbw>Depression: mood, sensorium, affect, suicidal tendencies, increase in psychiatric symptoms; depression, panic, monitor children weekly face to face during first 4 wk, or dosage change, then every other week for the next 4 wk, then at 12 wk</bbw>
						</para>
						<para>
							<list id="lidelem4x6048">
								<item>
									<label>•</label>
									<para>B/P lying, standing; pulse q4hr; if systolic B/P drops 20 mm Hg, hold product, notify prescriber; take VS q4hr in patients with CV disease</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x6056">
							<label>•</label>
							<sec_title>Hepatic studies</sec_title>
							<para>
								<list id="lidelem4x6056">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hepatic studies:</emphasis> AST ALT, bilirubin</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6063">
							<label>•</label>
							<sec_title>Withdrawal symptoms</sec_title>
							<para>
								<list id="lidelem4x6063">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Withdrawal symptoms:</emphasis> headache, nausea, vomiting, muscle pain, weakness; not common unless product is discontinued abruptly</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<bbw>Serotonin syndrome: nausea/vomiting, dizziness, facial flush, shivering, sweating</bbw>
						</para>
					</section>
					<section type="none" id="sidelem4x6077">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x6081">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased depression</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x6087">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x6091">
								<item>
									<label>•</label>
									<para>About signs and symptoms of bleeding (GI bleeding, nosebleed, ecchymosis, bruising)</para>
								</item>
								<item>
									<label>•</label>
									<para>To use with caution when driving and performing other activities requiring alertness because of drowsiness and blurred vision</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid alcohol ingestion, MAOIs, other CNS depressants</para>
								</item>
								<item>
									<label>•</label>
									<para>Not to discontinue medication quickly after long term use; may cause headache, malaise; taper</para>
								</item>
							</list>
						</para>
						<para>
							<bbw>That clinical worsening and suicidal risk may occur</bbw>
						</para>
						<para>
							<list id="lidelem4x6122">
								<item>
									<label>•</label>
									<para>To notify prescriber if pregnancy is planned or suspected or if breastfeeding</para>
								</item>
								<item>
									<label>•</label>
									<para>Improvement may occur in 4-8 wk or up to 12 wk (geriatric patients)</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="25" status="active">
			<mono_name>levothyroxine (T4) (Rx)</mono_name>
			<info>
				<pronunciation>(lee-voe-thye-rox′een)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x61415">
						<country code="CAN">Eltroxin </country>
					</tradename>
					<tradename id="tnidelem4x61414">Levothroid</tradename>
					<tradename id="tnidelem4x61413">Levoxyl</tradename>
					<tradename id="tnidelem4x61412">Synthroid</tradename>
					<tradename id="tnidelem4x61411">Tirosint</tradename>
					<tradename id="tnidelem4x61410">Unithroid</tradename>
				</tradenames>
				<class type="func"> Thyroid hormone</class>
				<class type="chem"> Levoisomer of thyroxine</class>
				<class type="preg">Pregnancy category <preg cat="A">A</preg></class>
			</info>
			<section type="confusion" id="sidelem4x6154">
				<para>
					<confusion>
						<tradename id="tnidelem4x61540">Synthroid</tradename>
						<drug type="generic" refid="idelem4x61540">Symmetrel</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x6158">
				<sec_title>Action:</sec_title>
				<para>Increases metabolic rate; controls protein synthesis; increases cardiac output, renal blood flow, O<emphasis style="inf">2</emphasis> consumption, body temperature, blood volume, growth, development at cellular level via action on thyroid hormone receptors</para>
			</section>
			<section type="uses" id="sidelem4x6166">
				<sec_title>Uses:</sec_title>
				<para>Hypothyroidism, myxedema coma, thyroid hormone replacement, thyrotoxicosis, congenital hypothyroidism, some types of thyroid cancer, pituitary TSH suppression</para>
			</section>
			<section type="contra" id="sidelem4x6171">
				<sec_title>Contraindications:</sec_title>
				<para>Adrenal insufficiency, recent MI, thyrotoxicosis, hypersensitivity to beef, alcohol intolerance (inj only)</para>
				<para>
					<bbw>Obesity treatment</bbw>
				</para>
				<section type="none" id="sidelem4x6187">
					<section type="none" id="sidelem4x6188">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="A">A</preg>), breastfeeding, geriatric patients, angina pectoris, hypertension, ischemia, cardiac disease, diabetes</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x6193">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x6196">
					<section type="none" id="sidelem4x6197">
						<sec_title>Hypothyroidism</sec_title>
						<section type="none" id="sidelem4x6205">
							<label>•</label>
							<sec_title>Adult ≤50 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x6205">
									<item>
										<label>•</label>
										<para> 1.7 mcg/kg/day, 6-8 wk, average dose 100-200 mcg/day; IM/IV 50-100 mcg/day as single dose or 50% of usual oral dosage</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6212">
							<label>•</label>
							<sec_title>Adult &gt;50 yr without heart disease or &lt;50 yr with heart disease<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x6212">
									<item>
										<label>•</label>
										<para> 25-50 mcg/day, titrate q6-8wk</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6219">
							<label>•</label>
							<sec_title>Adult &gt;50 yr with heart disease<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x6219">
									<item>
										<label>•</label>
										<para> 12.5-25 mcg/day, titrate by 12.5-25 mcg q6-8wk</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6226">
							<label>•</label>
							<sec_title>Child &gt;12 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x6226">
									<item>
										<label>•</label>
										<para> 2-3 mcg/kg/day as single dose in <emphasis style="smallcaps">am</emphasis></para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6235">
							<label>•</label>
							<sec_title>Child 6-12 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x6235">
									<item>
										<label>•</label>
										<para> 4-5 mcg/kg/day as single dose in <emphasis style="smallcaps">am</emphasis></para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6244">
							<label>•</label>
							<sec_title>Child 1-5 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x6244">
									<item>
										<label>•</label>
										<para> 5-6 mcg/kg/day as single dose in <emphasis style="smallcaps">am</emphasis></para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6253">
							<label>•</label>
							<sec_title>Child 6-12 mo<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x6253">
									<item>
										<label>•</label>
										<para> 6-8 mcg/kg/day as single dose in <emphasis style="smallcaps">am</emphasis></para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6262">
							<label>•</label>
							<sec_title>Child to 6 mo<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x6262">
									<item>
										<label>•</label>
										<para> 8-10 mcg/kg/day as single dose in <emphasis style="smallcaps">am</emphasis></para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6268">
						<sec_title>Myxedema coma</sec_title>
						<section type="none" id="sidelem4x6276">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x6276">
									<item>
										<label>•</label>
										<para> 200-500 mcg, may increase by 100-300 mcg after 24 hr; give oral medication as soon as possible</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6280">
						<sec_title>Subclinical hypothyroidism</sec_title>
						<section type="none" id="sidelem4x6288">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x6288">
									<item>
										<label>•</label>
										<para> 1 mcg/kg/day may be sufficient</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6292">
						<sec_title>Available forms:</sec_title>
						<para> Powder for inj 100, 200, 500 mcg/vial; tabs 25, 50, 88, 100, 112, 125, 137, 150, 175, 200, 300 mcg; cap (liquid filled) 13, 25, 50, 75, 88, 100, 112, 125, 137, 150 mcg</para>
					</section>
					<section type="none" id="sidelem4x6297">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x6301">
								<item>
									<label>•</label>
									<para>Store in tight, light-resistant container; sol should be discarded if not used immediately</para>
								</item>
								<item>
									<label>•</label>
									<para>Withdrawal of medication 4 wk before RAIU test</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x6312">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x6316">
									<item>
										<label>•</label>
										<para>In <emphasis style="smallcaps">am</emphasis> if possible as single dose to decrease sleeplessness; at same time each day to maintain product level; take on empty stomach</para>
									</item>
									<item>
										<label>•</label>
										<para>Only for hormone imbalances; not to be used for obesity, male infertility, menstrual conditions, lethargy</para>
									</item>
									<item>
										<label>•</label>
										<para>Lowest dose that relieves symptoms; lower dose to geriatric patients and for those with cardiac diseases</para>
									</item>
									<item>
										<label>•</label>
										<para>Crush and mix with water; nonsoy formula or breast milk for infants, children</para>
									</item>
									<item>
										<label>•</label>
										<para>Separate antacids, iron, calcium products by 4 hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6345">
							<sec_title>Direct IV route</sec_title>
							<para>
								<list id="lidelem4x6349">
									<item>
										<label>•</label>
										<para>IV after diluting with provided diluent 500 mcg/5 ml, 200 mcg/2 ml; shake; give through <emphasis style="sans-serif">Y</emphasis>-tube or 3-way stopcock; give ≤100 mcg/1 min; do not add to IV infusion</para>
									</item>
									<item>
										<label>•</label>
										<para>Considered to be incompatible in syringe with all other products</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x6363">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x6366">
					<section type="none" id="sidelem4x6367">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Anxiety, insomnia, tremors,</emphasis> headache, <emphasis style="bold">thyroid storm,</emphasis> excitability</para>
					</section>
					<section type="none" id="sidelem4x6378">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="italic">Tachycardia, palpitations, angina, dysrhythmias,</emphasis> hypertension, <emphasis style="bold">cardiac arrest</emphasis></para>
					</section>
					<section type="none" id="sidelem4x6388">
						<sec_title>GI:</sec_title>
						<para> Nausea, diarrhea, increased or decreased appetite, cramps</para>
					</section>
					<section type="none" id="sidelem4x6393">
						<sec_title>MISC:</sec_title>
						<para> Menstrual irregularities, weight loss, sweating, heat intolerance, fever, alopecia, decreased bone mineral density</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x6398">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Half-life euthyroid 6-7 days, hypothyroid 9-10 days, hyperthyroid 3-4 days, distributed throughout body tissues</para>
				<section type="none" id="sidelem4x6403">
					<section type="none" id="sidelem4x6404">
						<sec_title>PO:</sec_title>
						<para> Onset 24 hr</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x6409">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> cardiac insufficiency risk—EPINEPHrine products</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> effects of anticoagulants, sympathomimetics, tricyclics</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> levothyroxine absorption—bile acid sequestrants, orlistat, ferrous sulfate</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> levothyroxine effect—estrogens, antacids, sucralfate, aluminum, magnesium, calcium, iron, rifampin, rifabutin</para>
				<section type="none" id="sidelem4x6428">
					<section type="none" id="sidelem4x6429">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> thyroid hormone effect—soy</para>
					</section>
					<section type="none" id="sidelem4x6437">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> CPK, LDH, AST, blood glucose</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> thyroid function tests</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x6448">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x6451">
					<section type="none" id="sidelem4x6452">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x6456">
								<item>
									<label>•</label>
									<para>B/P, pulse periodically during treatment</para>
								</item>
								<item>
									<label>•</label>
									<para>Weight daily in same clothing, using same scale, at same time of day</para>
								</item>
								<item>
									<label>•</label>
									<para>Height, growth rate of child</para>
								</item>
								<item>
									<label>•</label>
									<para>T<emphasis style="inf">3</emphasis>, T<emphasis style="inf">4</emphasis>, FTIs, which are decreased; radioimmunoassay of TSH, which is increased; radio uptake, which is increased if patient receiving too low a dose of medication</para>
								</item>
								<item>
									<label>•</label>
									<para>Patient may require decreased anticoagulant; check for bleeding, bruising</para>
								</item>
								<item>
									<label>•</label>
									<para>Increased nervousness, excitability, irritability, which may indicate too high a dose of medication, usually after 1-3 wk of treatment</para>
								</item>
								<item>
									<label>•</label>
									<para>Cardiac status: angina, palpitation, chest pain, change in VS</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x6498">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x6502">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of depression; increased weight loss, diuresis, pulse, appetite; absence of constipation, peripheral edema, cold intolerance; pale, cool, dry skin; brittle nails, alopecia, coarse hair, menorrhagia, night blindness, paresthesias, syncope, stupor, coma, rosy cheeks</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x6508">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x6512">
								<item>
									<label>•</label>
									<para>That hair loss will occur in child, is temporary; that hypothyroid child will show almost immediate behavior/personality change</para>
								</item>
								<item>
									<label>•</label>
									<para>To report excitability, irritability, anxiety, which indicate overdose</para>
								</item>
								<item>
									<label>•</label>
									<para>Not to switch brands unless approved by prescriber</para>
								</item>
								<item>
									<label>•</label>
									<para>That product may be discontinued after giving birth; that thyroid panel should be evaluated after 1-2 mo</para>
								</item>
								<item>
									<label>•</label>
									<para>That product is not to be taken to reduce weight</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid OTC preparations with iodine; to read labels; to separate antacids, iron, calcium products by 4 hr</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid iodine-rich food, iodized salt, soybeans, tofu, turnips, high-iodine seafood, some bread</para>
								</item>
								<item>
									<label>•</label>
									<para>That product is not a cure but controls symptoms; that treatment is lifelong, full effect may take up to 6 wk</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="26" status="active" ha="yes">
			<mono_name> lidocaine (parenteral) (Rx)</mono_name>
			<info>
				<pronunciation>(lye′doe-kane)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x65602">LidoPen Auto-Injector</tradename>
					<tradename id="tnidelem4x65601">Xylocaine</tradename>
					<tradename id="tnidelem4x65600">
						<country code="CAN">Xylocard </country>
					</tradename>
				</tradenames>
				<class type="func"> Antidysrhythmic (Class Ib)</class>
				<class type="chem"> Aminoacyl amide</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="actions" id="sidelem4x6572">
				<sec_title>Action:</sec_title>
				<para>Increases electrical stimulation threshold of ventricle, His-Purkinje system, which stabilizes cardiac membrane, decreases automaticity</para>
			</section>
			<section type="uses" id="sidelem4x6577">
				<sec_title>Uses:</sec_title>
				<para>Ventricular tachycardia, ventricular dysrhythmias during cardiac surgery, digoxin toxicity, cardiac catheterization</para>
				<section type="none" id="sidelem4x6582">
					<section type="none" id="sidelem4x6583">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Attenuation of intracranial pressure increased during intubation/endotracheal tube suctioning</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x6588">
				<sec_title>Contraindications:</sec_title>
				<para>Hyper-sensitivity to amides, severe heart block, supraventricular dysrhythmias, Adams-Stokes syndrome, Wolff-Parkinson-White syndrome</para>
				<section type="none" id="sidelem4x6593">
					<section type="none" id="sidelem4x6594">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, children, geriatric patients, renal/hepatic disease, CHF, respiratory depression, malignant hyperthermia, myasthenia gravis, weight &lt;50 kg</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x6599">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x6607">
					<label>•</label>
					<sec_title>Adult<route> IV BOL</route></sec_title>
					<para>
						<list id="lidelem4x6607">
							<item>
								<label>•</label>
								<para> 50-100 mg (1-1.5 mg/kg) 25-50 mg/min, repeat q3-5min, max 300 mg in 1 hr; begin  1-4 mg/min (20-50 mcg/kg/min)</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x6614">
					<section type="none" id="sidelem4x6615">
						<sec_title>Available forms:</sec_title>
						<para> <emphasis style="bold">IV INFUSION</emphasis> 0.2% (2 mg/ml), 0.4% (4 mg/ml), 0.8% (8 mg/ml); IV 4% (40 mg/ml), 10% (100 mg/ml), 20% (200 mg/ml); <emphasis style="bold">IV dir</emphasis> 1% (10 mg/ml), 2% (20 mg/ml); <emphasis style="bold">Inj</emphasis> (to IV admix) 20% (200 mg/ml)</para>
					</section>
					<section type="none" id="sidelem4x6630">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x6634">
								<item>
									<label>•</label>
									<para>IM inj in deltoid; aspirate to avoid intravascular administration; check IV site daily for infiltration or extravasation</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x6640">
							<sec_title>IV route</sec_title>
							<para>
								<list id="lidelem4x6644">
									<item>
										<label>•</label>
										<para>Bolus undiluted (1%, 2% only), give ≤50 mg/1 min or dilute 1 g/250-500 ml D<emphasis style="inf">5</emphasis>W; titrate to patient response; use infusion pump; pediatric infusion 120 mg lidocaine/100 ml D<emphasis style="inf">5</emphasis>W; 1-2.5 ml/kg/hr = 20-50 mcg/kg/min; use only 1%, 2% sol for IV bol</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Acetaminophen, alemtuzumab, alfentanil, alteplase, amikacin, aminocaproic acid, aminophylline, amiodarone, amphotericin B lipid/liposome, anidulafungin, argatroban, ascorbic acid injection, atenolol, atropine, atracurium, azithromycin, aztreonam, benztropine, bivalirudin, bleomycin, bumetanide, buprenorphine, butorphanol, calcium chloride/gluconate, CARBOplatin, carmustine, ceFAZolin, cefotaxime, cefoTEtan, cefOXitin, ceftaroline, cefTAZidime, ceftizoxime, cefTRIAXone, cefuroxime, chloramphenicol, chlorproMAZINE, cimetidine, ciprofloxacin, cisatracurium, CISplatin, clarithromycin, clindamycin, cyanocobalamin, cyclophosphamide, cycloSPORINE, cytarabine, DACTINomycin, DAPTOmycin, DAUNOrubicin, dexamethasone, dexmedetomidine, dexrazoxane, digoxin, diltiazem, diphenhydrAMINE, DOBUTamine, DOCEtaxel, dolasetron, DOPamine, doxacurium, DOXOrubicin, DOXOrubicin lipsomal, doxycycline, enalaprilat, EPINEPHrine, epirubicin, epoetin alfa, eptifibatide, ertapenem, erythromycin, esmolol, etomidate, etoposide, etoposide phosphate, famotidine, fenoldopam, fentaNYL, fluconazole, fludarabine, fluorouracil, folic acid, furosemide, gentamicin, granisetron, haloperidol, heparin, hydrocortisone, imipenem/cilastatin, inamrinone, insulin, isoproterenol, ketorolac, labetalol, levofloxacin, linezolid, LORazepam, magnesium sulfate, meperidine, methylPREDNISolone sodium succinate, metoclopramide, metoprolol, metroNIDAZOLE, micafungin, midazolam, morphine, nafcillin, niCARdipine, nitroglycerin, nitroprusside, norepinephrine, ondansetron, palonosetron, penicillin G potassium, phenylephrine, phytonadione, piperacillin/tazobactam, potassium chloride, procainamide, prochlorperazine, promethazine, propofol, propranolol, protamine, quinupristin/dalfopristin, ranitidine, remifentanil, sodium bicarbonate, streptokinase, tacrolimus, theophylline, ticarcillin/clavulanate, tigecycline, tirofiban, tobramycin, vancomycin, vasopressin, verapamil, vitamin B complex with C, voriconazole, warfarin</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x6660">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x6663">
					<section type="none" id="sidelem4x6664">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache, dizziness,</emphasis> involuntary movement, confusion, tremor, drowsiness, euphoria, <emphasis style="bold">seizures,</emphasis> shivering</para>
					</section>
					<section type="none" id="sidelem4x6675">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="italic">Hypotension, bradycardia,</emphasis><emphasis style="bold">heart block, CV collapse, arrest</emphasis></para>
					</section>
					<section type="none" id="sidelem4x6684">
						<sec_title>EENT:</sec_title>
						<para> Tinnitus, blurred vision</para>
					</section>
					<section type="none" id="sidelem4x6689">
						<sec_title>GI:</sec_title>
						<para> Nausea, vomiting, anorexia</para>
					</section>
					<section type="none" id="sidelem4x6694">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Methemoglobinemia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x6701">
						<sec_title>INTEG:</sec_title>
						<para> Rash, urticaria, edema, swelling, petechiae, pruritus</para>
					</section>
					<section type="none" id="sidelem4x6706">
						<sec_title>MISC:</sec_title>
						<para> Febrile response, phlebitis at inj site</para>
					</section>
					<section type="none" id="sidelem4x6711">
						<sec_title>RESP:</sec_title>
						<para> Dyspnea, <emphasis style="bold">respiratory depression</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x6718">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Half-life 8 min, 1-2 hr (terminal); metabolized in liver; excreted in urine; crosses placenta</para>
				<section type="none" id="sidelem4x6723">
					<section type="none" id="sidelem4x6724">
						<sec_title>IM:</sec_title>
						<para> Onset 5-15 min, duration 1<emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> hr</para>
					</section>
					<section type="none" id="sidelem4x6735">
						<sec_title>IV:</sec_title>
						<para> Onset 2 min, duration 20 min</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x6740">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="lifethreat">Increase: cardiac depression, toxicity—amiodarone, phenytoin, procainamide, propranolol</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypotensive effects—MAOIs, antihypertensives</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> neuromuscular blockade—neuromuscular blockers, tubocurarine</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> lidocaine effects, toxicity—cimetidine, β-blockers, protease inhibitors, ritonavir</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> lidocaine effects—barbiturates, ciprofloxacin, voriconazole</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect of—cycloSPORINE</para>
				<section type="none" id="sidelem4x6767">
					<section type="none" id="sidelem4x6768">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> CPK</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x6775">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x6778">
					<section type="none" id="sidelem4x6779">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x6785">
								<item>
									<para>
										<emphasis alert="nurse">ECG continuously to determine increased PR or QRS segments; if these develop, discontinue or reduce rate; watch for increased ventricular ectopic beats, may have to rebolus; B/P</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x6793">
							<label>•</label>
							<sec_title>Blood levels</sec_title>
							<para>
								<list id="lidelem4x6793">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Blood levels:</emphasis> therapeutic level, 1.5-5 mcg/ml</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x6797">
								<item>
									<label>•</label>
									<para>I&amp;O ratio, electrolytes (potassium, sodium, chlorine)</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6803">
								<item>
									<para>
										<emphasis alert="nurse">Malignant hyperthermia: tachypnea, tachycardia, changes in B/P, increased temperature</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x6811">
							<label>•</label>
							<sec_title>Respiratory status</sec_title>
							<para>
								<list id="lidelem4x6811">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Respiratory status:</emphasis> rate, rhythm, lung fields for crackles, watch for respiratory depression; lung fields, bilateral crackles may occur with CHF; increased respiration, pulse; product should be discontinued</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6818">
							<label>•</label>
							<sec_title>CNS effects</sec_title>
							<para>
								<list id="lidelem4x6818">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">CNS effects:</emphasis> dizziness, confusion, psychosis, paresthesias, convulsions; product should be discontinued</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6822">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x6826">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased dysrhythmias</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x6832">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x6836">
								<item>
									<label>•</label>
									<para>About the use of automatic lidocaine injection device if ordered for personal use</para>
								</item>
								<item>
									<label>•</label>
									<para>To report signs of toxicity</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="none" id="sidelem4x6847">
				<sec_title>Treatment of overdose:</sec_title>
				<para>O<emphasis style="inf">2</emphasis>, artificial ventilation, ECG; administer DOPamine for circulatory depression, diazepam or thiopental for seizures; decrease product if needed</para>
			</section>
		</monograph>
<monograph id="27" status="active">
			<mono_name>lidocaine ophthalmic</mono_name>
			<section type="none" id="sidelem4x6858">
				<para>
					<see refid="tra">See Appendix B</see>
				</para>
			</section>
		</monograph>
<monograph id="28" status="active">
			<mono_name>lidocaine topical</mono_name>
			<section type="none" id="sidelem4x6864">
				<para>
					<see refid="tra">See Appendix B</see>
				</para>
			</section>
		</monograph>
<monograph id="29" status="active" ru="yes">
			<mono_name> linaclotide</mono_name>
			<info>
				<pronunciation>(lin′a-kloe′tide)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x68740">Linzess</tradename>
				</tradenames>
				<class type="func"> Functional GI disorder agent</class>
				<class type="chem"> Selective guanylate cyclase C agonist</class>
			</info>
			<section type="uses" id="sidelem4x6884">
				<sec_title>Uses:</sec_title>
				<para>Irritable bowel syndrome (IBS) with constipation, chronic constipation not associated with IBS</para>
			</section>
			<section type="contra" id="sidelem4x6889">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, urticaria, infection, sinusitis, GI obstruction</para>
				<para>
					<bbw>Children &lt;6 yr, infants, neonates</bbw>
				</para>
			</section>
			<section type="doses" id="sidelem4x6904">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x6907">
					<section type="none" id="sidelem4x6908">
						<sec_title>Constipation</sec_title>
						<section type="none" id="sidelem4x6916">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x6916">
									<item>
										<label>•</label>
										<para> 145 mcg/day on empty stomach, <emphasis style="smallcaps">am</emphasis></para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6922">
						<sec_title>Irritable bowel syndrome</sec_title>
						<section type="none" id="sidelem4x6930">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x6930">
									<item>
										<label>•</label>
										<para> 290 mcg/day on empty stomach, <emphasis style="smallcaps">am</emphasis></para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="30" status="active" ha="yes">
			<mono_name> linagliptin</mono_name>
			<info>
				<pronunciation>(lin′a-glip′tin)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x69440">Tradjenta</tradename>
				</tradenames>
				<class type="func"> Antidiabetic</class>
				<class type="chem"> Didipeptidyl peptidase-4 inhibitor</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="actions" id="sidelem4x6954">
				<sec_title>Action:</sec_title>
				<para>Slows the inactivation of incretin hormones; concentrations of the active, intact hormones are increased, thereby increasing and prolonging the action of these hormones; incretin hormones are released by the intestine throughout the day, and levels are increased in response to a meal</para>
			</section>
			<section type="uses" id="sidelem4x6959">
				<sec_title>Uses:</sec_title>
				<para>Type 2 diabetes mellitus</para>
			</section>
			<section type="contra" id="sidelem4x6964">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to linagliptin, type 1 diabetes mellitus, diabetic ketoacidosis (DKA)</para>
				<section type="none" id="sidelem4x6969">
					<section type="none" id="sidelem4x6970">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (category <preg cat="B">B</preg>), breastfeeding, adolescents or children &lt;18 yr, debilitated physical condition, malnutrition, uncontrolled adrenal insufficiency, pituitary insufficiency, hypo/hyperthyroidism, diarrhea, gastroparesis, GI obstruction, ileus, female hormonal changes, high fever, severe psychological stress, uncontrolled hypercortisolism</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x6975">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x6983">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x6983">
							<item>
								<label>•</label>
								<para> 5 mg daily; when used with a sulfonylurea or insulin; a lower dose of the sulfonylurea may be necessary to minimize the risk of hypoglycemia</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x6987">
					<section type="none" id="sidelem4x6988">
						<sec_title>Available forms:</sec_title>
						<para> Tab 5 mg</para>
					</section>
					<section type="none" id="sidelem4x6993">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x6997">
								<item>
									<label>•</label>
									<para>Once daily; may give without regard to food</para>
								</item>
								<item>
									<label>•</label>
									<para>Store at room temperature</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x7008">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x7011">
					<section type="none" id="sidelem4x7012">
						<sec_title>CNS:</sec_title>
						<para> Headache</para>
					</section>
					<section type="none" id="sidelem4x7017">
						<sec_title>EENT:</sec_title>
						<para> Nasopharyngitis</para>
					</section>
					<section type="none" id="sidelem4x7022">
						<sec_title>ENDO:</sec_title>
						<para> Hypoglycemia, hyperuricemia</para>
					</section>
					<section type="none" id="sidelem4x7027">
						<sec_title>GI:</sec_title>
						<para> Body weight loss, <emphasis style="bold">pancreatitis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x7034">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="bold">Serious hypersensitivity reactions,</emphasis> urticaria, <emphasis style="bold">angioedema, exfoliative dermatitis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x7044">
						<sec_title>MISC:</sec_title>
						<para> Arthralgia, back pain</para>
					</section>
					<section type="none" id="sidelem4x7049">
						<sec_title>RESP:</sec_title>
						<para> Bronchial hyperreactivity (with <emphasis style="bold">bronchospasm</emphasis>), nasopharyngitis, cough</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x7057">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Extensively distributed in the tissues, protein binding is concentration-dependent, a weak to moderate inhibitor of CYP3A4, plasma terminal half life of &gt;100 hr; effective half-life 12 hr, 90% excreted unchanged, 85% excreted via the enterohepatic system (80%) or in urine (5%) within 4 days of dosing, rapidly absorbed, peak in 1.5 hr; bioavailability 30%</para>
			</section>
			<section type="interactions" id="sidelem4x7062">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypoglycemia: sulfonylureas, β-blockers, ACE inhibitors, angiotensin II receptor antagonists, disopyramide, guanethidine, cloNIDine, octreotide, fenfluramine, dexfenfluramine, fibric acid derivatives, monoamine oxidase inhibitors (MAOIs), FLUoxetine, salicylates</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> masking of the signs and symptoms of hypoglycemia: reserpine, β-blockers</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> need for dosing change: cisapride, metoclopramide, tegaserod, androgens, alcohol, lithium, quinolones</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> hypoglycemic effect—dextrothyroxine, bumetanide, furosemide, ethacrynic acid, torsemide, estrogens, progestins, oral contraceptives, thyroid hormones, glucocorticoids, glucagon, carbonic anhydrase inhibitors, phenytoin, fosphenytoin, or ethotoin; atypical antipsychotics (ARIPiprazole, cloZAPine, OLANZapine, QUEtiapine, risperiDONE, and ziprasidone), phenothiazine, niacin (nicotinic acid), triamterene, thiazide diuretics</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect of linagliptin—CYP3A4 inducers (topiramate, rifabutin, pioglitazone, OXcarbazepine, carBAMazepine, nevirapine, modafinil, metyrapone, etravirine, efavirenz, bosentan, barbiturates, aprepitant, fosaprepitant)</para>
				<section type="none" id="sidelem4x7085">
					<section type="none" id="sidelem4x7086">
						<sec_title>Drug/Herb:</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> linagliptin effect—St. John’s wort</para>
					</section>
					<section type="none" id="sidelem4x7094">
						<sec_title>Drug/Lab Test:</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> uric acid</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x7101">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x7104">
					<section type="none" id="sidelem4x7105">
						<sec_title>Assess</sec_title>
						<para>
							<list id="lidelem4x7109">
								<item>
									<label>•</label>
									<para>Monitor blood glucose, A1c, during treatment to determine diabetes control</para>
								</item>
								<item>
									<label>•</label>
									<para>CBC baseline and periodically during treatment, report decreased blood counts</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x7120">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x7124">
								<item>
									<label>•</label>
									<para>Improving blood glucose level, A1c; decreasing polydipsia, polyphagia, polyuria, clear sensorium, absence of dizziness</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x7130">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x7135">
								<item>
									<label>•</label>
									<para>About the symptoms of hypo/hyperglycemia and what to do about each; to have glucagon emergency kit available, to carry sugar packets</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7140">
								<item>
									<label>•</label>
									<para>That product must be continued on a daily basis, about the consequences of discontinuing product abruptly; to take only as directed</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7145">
								<item>
									<label>•</label>
									<para>To avoid OTC products unless approved by prescriber</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7150">
								<item>
									<label>•</label>
									<para>That diabetes is a life-long illness, that product will not cure diabetes</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7155">
								<item>
									<label>•</label>
									<para>To carry emergency ID with prescriber, condition and medications taken</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x7163">
							<label>•</label>
							<sec_title>
								<route>To immediately report skin disorders, swelling, difficulty breathing, or severe abdominal pain</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="31" status="active">
			<mono_name>lindane (Rx)</mono_name>
			<info>
				<pronunciation>(lin′dane)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x71710">
						<country code="CAN">Hexit </country>
					</tradename>
				</tradenames>
				<class type="func"> Scabicide, pediculicide</class>
				<class type="chem"> Chlorinated hydrocarbon (synthetic)</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x7183">
				<sec_title>Action:</sec_title>
				<para>Stimulates nervous system of arthropods, resulting in seizures, death</para>
			</section>
			<section type="uses" id="sidelem4x7188">
				<sec_title>Uses:</sec_title>
				<para>Scabies, lice (head/pubic/body), nits in those intolerant to or who do not respond to other agents</para>
			</section>
			<section type="contra" id="sidelem4x7193">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, patients with known seizure disorders, Norwegian (crusted) scabies</para>
				<para>
					<bbw>Premature neonate; inflammation of skin, abrasions, skin breaks; seizure disorder</bbw>
				</para>
				<section type="none" id="sidelem4x7208">
					<section type="none" id="sidelem4x7209">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, infants, children &lt;10 yr, avoid contact with eyes</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x7214">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x7217">
					<section type="none" id="sidelem4x7218">
						<sec_title>Lice</sec_title>
						<section type="none" id="sidelem4x7226">
							<label>•</label>
							<sec_title>Adult and child<route> CREAM/LOTION</route></sec_title>
							<para>
								<list id="lidelem4x7226">
									<item>
										<label>•</label>
										<para> shampoo using 30 ml: work into lather, rub for 5 min, rinse, dry with towel; comb with fine-toothed comb to remove nits; most require 1 oz, max 2 oz</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x7230">
						<sec_title>Scabies</sec_title>
						<section type="none" id="sidelem4x7238">
							<label>•</label>
							<sec_title>Adult and child<route> TOP</route></sec_title>
							<para>
								<list id="lidelem4x7238">
									<item>
										<label>•</label>
										<para> apply 1% cream/lotion to skin, from neck to bottom of feet, toes; wash area with soap, water; remove visible crusts; apply to skin surfaces; remove with soap, water in 8-12 hr; repeat after 1 wk prn; most require 1 oz, max 2 oz</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x7242">
						<sec_title>Available forms:</sec_title>
						<para> Lotion, shampoo, cream (1%)</para>
					</section>
					<section type="none" id="sidelem4x7247">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x7252">
								<item>
									<label>•</label>
									<para>Caregivers should wear gloves less permeable to lindane, thoroughly clean hands after application; avoid natural latex gloves</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x7260">
							<label>•</label>
							<sec_title>Cream/ointment/lotion</sec_title>
							<para>
								<list id="lidelem4x7260">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Cream/ointment/lotion:</emphasis> use for scabies only; skin should be clean without other products on it, wait 1 hr after bathing or showering before application, shake well, apply under fingernails after trimming; toothbrush can be used to apply; after application, wrap toothbrush in paper and throw away; use only a single application, apply as thin layer over all skin from neck down, close bottle containing leftover lotion, throw away</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x7264">
								<item>
									<label>•</label>
									<para>Do not cover, wash off after 8-12 hr</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7269">
								<item>
									<label>•</label>
									<para>Use warm, not hot, water; do not leave on &gt;12hr</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x7277">
							<label>•</label>
							<sec_title>Shampoo</sec_title>
							<para>
								<list id="lidelem4x7277">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Shampoo:</emphasis> for lice only; do not use other hair products before use; shake well; hair should be completely dry; use only enough shampoo to lightly coat hair and scalp, work into hair, do not use water; allow to remain only 4 min, rinse, lather away, towel briskly</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x7283">
								<item>
									<label>•</label>
									<para>To scalp only; do not apply to face, lips, mouth, eyes, any mucous membrane, anus, or meatus</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7288">
								<item>
									<label>•</label>
									<para>Topical corticosteroids as ordered to decrease contact dermatitis; antihistamines</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7293">
								<item>
									<label>•</label>
									<para>Lotions of menthol or phenol to control itching</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7298">
								<item>
									<label>•</label>
									<para>Topical antibiotics for infection</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x7303">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x7306">
					<section type="none" id="sidelem4x7307">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="bold">Seizures, CNS toxicity,</emphasis> stimulation, dizziness</para>
					</section>
					<section type="none" id="sidelem4x7315">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Pruritus, rash, irritation, contact dermatitis</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x7322">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Onset 3 hr, half-life 18-22 hr</para>
			</section>
			<section type="interactions" id="sidelem4x7327">
				<sec_title>Interactions</sec_title>
				<para>
					<list id="lidelem4x7331">
						<item>
							<label>•</label>
							<para>Oils may increase absorption; if oil-based hair dressing used, shampoo, rinse, dry hair before applying lindane shampoo</para>
						</item>
					</list>
				</para>
			</section>
			<section type="considerations" id="sidelem4x7337">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x7340">
					<section type="none" id="sidelem4x7341">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>Skin for abrasions, breaks, inflammation; do not use on these areas</bbw>
						</para>
						<section type="none" id="sidelem4x7358">
							<label>•</label>
							<sec_title>Infestation</sec_title>
							<para>
								<list id="lidelem4x7358">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Infestation:</emphasis> head, hair for lice, nits before and after treatment; if scabies present, check all skin surfaces; identify source of infection: school, family, sexual contacts</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x7362">
								<item>
									<label>•</label>
									<para>Isolation until areas on skin, scalp have cleared, treatment completed</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7367">
								<item>
									<label>•</label>
									<para>Removal of nits with fine-toothed comb rinsed in vinegar after treatment; use gloves</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x7372">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x7376">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased crusts, nits, brownish trails on skin, itching papules in skin folds, decreased itching after several weeks</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x7382">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x7387">
								<item>
									<label>•</label>
									<para>To wash all inhabitants’ clothing using insecticide; that preventive treatment may be required of all persons living in same house using lotion or shampoo to decrease spread of infection; to use rubber gloves when applying product</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7392">
								<item>
									<label>•</label>
									<para>That itching may continue for 4-6 wk</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7397">
								<item>
									<label>•</label>
									<para>That product must be reapplied if accidently washed off or treatment will be ineffective</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x7405">
							<label>•</label>
							<sec_title>
								<route>Not to apply to face; if accidental contact with eyes occurs, flush with water</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x7411">
							<label>•</label>
							<sec_title>
								<route>To remove product after specified time to prevent toxicity</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x7414">
								<item>
									<label>•</label>
									<para>To treat sexual contacts simultaneously</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x7422">
							<label>•</label>
							<sec_title>To check for CNS toxicity<route> dizziness, cramps, anxiety, nausea, vomiting, seizures</route></sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="32" status="active">
			<mono_name>linezolid (Rx)</mono_name>
			<info>
				<pronunciation>(line-zoe′lide)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x74300">Zyvox</tradename>
				</tradenames>
				<class type="func"> Broad-spectrum antiinfective</class>
				<class type="chem"> Oxazolidinone</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x7440">
				<para>
					<confusion>
						<tradename id="tnidelem4x74400">Zyvox</tradename>
						<drug type="generic" refid="idelem4x74400">Ziox/Zosyn</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x7444">
				<sec_title>Action:</sec_title>
				<para>Inhibits protein synthesis by interfering with translation; binds to bacterial 23S ribosomal RNA of the 50S subunit, thus preventing formation of the bacterial translation process in primarily gram-positive organisms</para>
			</section>
			<section type="uses" id="sidelem4x7449">
				<sec_title>Uses:</sec_title>
				<para>Vancomycin-resistant <emphasis style="italic">Enterococcus faecium</emphasis> infections, nosocomial pneumonia caused by <emphasis style="italic">Staphylococcus aureus</emphasis> or <emphasis style="italic">Streptococcus</emphasis> pneumonia, uncomplicated or complicated skin and skin-structure infections, community-acquired pneumonia, <emphasis style="italic">Pasteurella multocida,</emphasis> viridans streptococci, <emphasis style="italic">E. faecium</emphasis> infections, <emphasis style="italic">S. aureus, S. pyogenes;</emphasis> can be used for MSSA/MRSA/MDRSP strains</para>
			</section>
			<section type="contra" id="sidelem4x7472">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<section type="none" id="sidelem4x7477">
					<section type="none" id="sidelem4x7478">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, thrombocytopenia, bone marrow suppression, hypertension, hyperthyroidism, pheochromocytoma, seizure disorder, ulcerative colitis, MI, PKU, renal/GI disease</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x7485">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x7488">
					<section type="none" id="sidelem4x7489">
						<sec_title>Vancomycin-resistant Enterococcus faecium infections</sec_title>
						<section type="none" id="sidelem4x7497">
							<label>•</label>
							<sec_title>Adult/adolescent/child ≥12 yr<route> IV/PO</route></sec_title>
							<para>
								<list id="lidelem4x7497">
									<item>
										<label>•</label>
										<para> 600 mg q12hr × 14-28 days; max 1200 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x7504">
							<label>•</label>
							<sec_title>Child &lt;12 yr/infant/term neonate<route> IV/PO</route></sec_title>
							<para>
								<list id="lidelem4x7504">
									<item>
										<label>•</label>
										<para> 10 mg/kg q8hr × 14-28 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x7508">
						<sec_title>Nosocomial pneumonia/complicated skin infections/community-acquired pneumonia/concurrent bacterial infection</sec_title>
						<section type="none" id="sidelem4x7516">
							<label>•</label>
							<sec_title>Adult<route> IV/PO</route></sec_title>
							<para>
								<list id="lidelem4x7516">
									<item>
										<label>•</label>
										<para> 600 mg q12hr × 10-14 days; max 1200 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x7523">
							<label>•</label>
							<sec_title>Child<route> birth-11 yr</route></sec_title>
							<para>
								<list id="lidelem4x7523">
									<item>
										<label>•</label>
										<para> 10 mg/kg q8hr × 10-14 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x7527">
						<sec_title>Uncomplicated skin infections</sec_title>
						<section type="none" id="sidelem4x7535">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x7535">
									<item>
										<label>•</label>
										<para> 400 mg q12hr × 10-14 days; max 1200 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x7542">
							<label>•</label>
							<sec_title>Adolescent<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x7542">
									<item>
										<label>•</label>
										<para> 600 mg q12hr × 10-14 days; max 1200 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x7549">
							<label>•</label>
							<sec_title>Infant preterm &lt;7 days old<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x7549">
									<item>
										<label>•</label>
										<para> 10 mg/kg q12hr × 10-14 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x7553">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 600 mg; oral susp 100 mg/5 ml; inj 2 mg/ml</para>
					</section>
					<section type="none" id="sidelem4x7558">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x7561">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x7565">
									<item>
										<label>•</label>
										<para>With/without food</para>
									</item>
									<item>
										<label>•</label>
										<para>Store reconstituted oral susp at room temperature, use within 3 wk</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x7576">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x7580">
									<item>
										<label>•</label>
										<para>Do not use if particulate is present, yellow color is normal</para>
									</item>
									<item>
										<label>•</label>
										<para>Premixed sol ready to use (2 mg/ml), give over 30-120 min; do not use IV infusion bag in series connections; do not use with additives in sol; do not use with another product, administer separately, flush line before and after use</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Acyclovir, alfen-tanil, amikacin, aminophylline, ampicillin, aztreonam, buprenorphine, butorphanol, calcium gluconate, CARBOplatin, ceFAZolin, cefoTEtan, cefOXitin, cefTAZidime, ceftizoxime, cefuroxime, cimetidine, ciprofloxacin, cisatracurium, CISplatin, clindamycin, cyclophosphamide, cycloSPORINE, cytarabine, digoxin, furosemide, ganciclovir, gemcitabine, gentamicin, heparin, HYDROmorphone, ifosfamide, labetalol, leucovorin, levofloxacin, lidocaine, LORazepam, magnesium sulfate, mannitol, meperidine, meropenem, mesna, methotrexate, methylPREDNISolone, metoclopramide, metroNIDAZOLE, midazolam, minocycline, mitoXANtrone, morphine, nalbuphine, naloxone, nitroglycerin, ofloxacin, ondansetron, PACLitaxel, PENTobarbital, PHENobarbital, piperacillin, potassium chloride, prochlorperazine, promethazine, propranolol, ranitidine, remifentanil, SUFentanil, theophylline, ticarcillin, tobramycin, vancomycin, vecuronium, verapamil, vinCRIStine, zidovudine</para>
							<para>
								<emphasis style="bold">Solution compatibilities:</emphasis> D<emphasis style="inf">5</emphasis>W, 0.9% NaCl, LR</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x7602">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x7605">
					<section type="none" id="sidelem4x7606">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache,</emphasis> dizziness, insomnia</para>
					</section>
					<section type="none" id="sidelem4x7614">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, diarrhea,</emphasis><emphasis style="bold">pseudomembranous colitis,</emphasis> increased ALT/AST, <emphasis style="italic">vomiting,</emphasis> taste change, tongue-color change</para>
					</section>
					<section type="none" id="sidelem4x7627">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Myelosuppression</emphasis></para>
					</section>
					<section type="none" id="sidelem4x7634">
						<sec_title>MISC:</sec_title>
						<para> Vaginal moniliasis, fungal infection, oral moniliasis, <emphasis style="bold">lactic acidosis, anaphylaxis, angioedema, Stevens-Johnson syndrome</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x7641">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Peak 1-2 hr, terminal half-life 4-5 hr, rapidly and extensively absorbed, protein binding 31%, metabolized by oxidation of the morpholine ring</para>
			</section>
			<section type="interactions" id="sidelem4x7646">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="nurse">Do not use with MAOIs (or within 2 wk) or with products that possess MAOI-like action (furazolidone, isoniazid, INH, procarbazine); hypertensive crisis may occur</emphasis>
				</para>
				<para>
					<emphasis alert="nurse">Increase: hypertensive crisis, seizures, coma—amoxapine, maprotiline, mirtazapine, traZODone, cyclobenzaprine, tricyclics, methyldopa</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> serotonin syndrome—SSRIs, SNRIs, serotonin receptor agonists</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> effects of adrenergic agents (DOPamine, EPINEPHrine, pseudoephedrine)</para>
				<section type="none" id="sidelem4x7668">
					<section type="none" id="sidelem4x7669">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<list id="lidelem4x7673">
								<item>
									<label>•</label>
									<para>Avoid use with green tea, valerian, ginseng, yohimbine, kava, guarana, St. John’s wort</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x7679">
						<sec_title>Drug/Food</sec_title>
						<para>
							<list id="lidelem4x7683">
								<item>
									<label>•</label>
									<para>Tyramine foods: avoid; increased pressor response</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x7689">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x7692">
					<section type="none" id="sidelem4x7693">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x7698">
								<item>
									<label>•</label>
									<para>CBC with differential weekly, assess for myelosuppression (anemias, leukopenia, pancytopenia, thrombocytopenia)</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x7706">
							<label>•</label>
							<sec_title>Serotonin syndrome<route> at least 2 wk should elapse between discontinuing linezolid and starting serotonergic agents; assess for increased heart rate, shivering, sweating, dilated pupils, tremor, high B/P, hyperthermia, headache, confusion; if these occur, stop linezolid, administer a serotonin antagonist if needed</route></sec_title>
						</section>
						<section type="none" id="sidelem4x7712">
							<label>•</label>
							<sec_title>Lactic acidosis<route> repeated nausea/vomiting, unexplained acidosis, low bicarbonate level; notify prescriber immediately</route></sec_title>
						</section>
						<section type="none" id="sidelem4x7718">
							<label>•</label>
							<sec_title>Anaphylaxis/angioedema/Stevens-Johnson syndrome<route> rash, pruritus, difficulty breathing, fever; have emergency equipment nearby</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x7721">
								<item>
									<label>•</label>
									<para>CNS symptoms: headache, dizziness</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7726">
								<item>
									<label>•</label>
									<para>Hepatic studies: AST, ALT</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x7734">
							<label>•</label>
							<sec_title>Diabetes mellitus</sec_title>
							<para>
								<list id="lidelem4x7734">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Diabetes mellitus:</emphasis> monitor those receiving insulin or oral antidiabetics for increased hypoglycemia</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x7739">
								<item>
									<para>
										<emphasis alert="nurse">Pseudomembranous colitis: diarrhea, abdominal pain, fever, fatigue, anorexia, possible anemia, elevated WBC, low serum albumin; stop product, usually either vancomycin or IV metroNIDAZOLE given</emphasis>
									</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x7744">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x7748">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased symptoms of infection, blood cultures negative</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x7754">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x7759">
								<item>
									<label>•</label>
									<para>If dizziness occurs, to ambulate, perform activities with assistance</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7764">
								<item>
									<label>•</label>
									<para>To complete full course of product therapy</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7769">
								<item>
									<label>•</label>
									<para>To contact prescriber if adverse reaction occurs</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x7777">
							<label>•</label>
							<sec_title>
								<route>To inform prescriber if SSRIs or cold products, decongestants being used</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x7780">
								<item>
									<label>•</label>
									<para>To inform prescriber of history of hypertension</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7785">
								<item>
									<label>•</label>
									<para>To avoid large amounts of high-tyramine foods, drinks; provide list</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="33" status="active" ru="yes">
			<mono_name> liothyronine (T3) (Rx)</mono_name>
			<info>
				<pronunciation>(lye-oh-thye′roe-neen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x78001">Cytomel</tradename>
					<tradename id="tnidelem4x78000">Triostat</tradename>
				</tradenames>
				<class type="func"> Thyroid hormone</class>
				<class type="chem"> Synthetic T</class>
			</info>
			<section type="uses" id="sidelem4x7812">
				<sec_title>Uses:</sec_title>
				<para>Hypothyroidism, myxedema coma, thyroid hormone replacement, congenital hypothyroidism, nontoxic goiter, T<emphasis style="inf">3</emphasis> suppression test</para>
			</section>
			<section type="contra" id="sidelem4x7820">
				<sec_title>Contraindications:</sec_title>
				<para>Adrenal insufficiency, MI, thyrotoxicosis, untreated hypertension</para>
				<para>
					<bbw>Obesity treatment</bbw>
				</para>
			</section>
			<section type="doses" id="sidelem4x7835">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x7843">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x7843">
							<item>
								<label>•</label>
								<para> 25 mcg/day, increase by 12.5-25 mcg q1-2wk until desired response, maintenance dose 25-75 mcg/day, max 100 mcg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x7850">
					<label>•</label>
					<sec_title>Geriatric<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x7850">
							<item>
								<label>•</label>
								<para> 5 mcg/day, increase by 5 mcg/day q1-2wk, maintenance 25-75 mcg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x7854">
					<section type="none" id="sidelem4x7855">
						<sec_title>Congenital hypothyroidism</sec_title>
						<section type="none" id="sidelem4x7863">
							<label>•</label>
							<sec_title>Child &gt;3 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x7863">
									<item>
										<label>•</label>
										<para> 50-100 mcg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x7870">
							<label>•</label>
							<sec_title>Child &lt;3 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x7870">
									<item>
										<label>•</label>
										<para> 5 mcg/day, increase by 5 mcg q3-4days titrated to response, infant maintenance 20 mcg/day; 1-3 yr 50 mcg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x7874">
						<sec_title>Myxedema, severe hypothyroidism</sec_title>
						<section type="none" id="sidelem4x7882">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x7882">
									<item>
										<label>•</label>
										<para> 25-50 mcg, then may increase by 5-10 mcg q1-2wk; maintenance dose 50-100 mcg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x7887">
						<sec_title>Myxedema coma/precoma</sec_title>
						<section type="none" id="sidelem4x7895">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x7895">
									<item>
										<label>•</label>
										<para> 25-50 mcg initially, 5 mcg in geriatric patients, 10-20 mcg with cardiac disease; give doses q4-12hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x7899">
						<sec_title>Nontoxic goiter</sec_title>
						<section type="none" id="sidelem4x7907">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x7907">
									<item>
										<label>•</label>
										<para> 5 mcg/day, increase by 12.5-25 mcg q1-2wk; maintenance dose 75 mcg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x7911">
						<sec_title>Suppression test</sec_title>
						<section type="none" id="sidelem4x7919">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x7919">
									<item>
										<label>•</label>
										<para> 75-100 mcg/day × 1 wk; radioactive <emphasis style="sup">131</emphasis>I given before and after 1-wk dose</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="34" status="active" ru="yes">
			<mono_name> liotrix (Rx)</mono_name>
			<info>
				<pronunciation>(lye′oh-trix)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x79331">Thyrolar</tradename>
					<tradename id="tnidelem4x79330">T3/T4</tradename>
				</tradenames>
				<class type="func"> Thyroid hormone</class>
				<class type="chem"> Levothyroxine/liothyronine (synthetic T, T)</class>
			</info>
			<section type="uses" id="sidelem4x7954">
				<sec_title>Uses:</sec_title>
				<para>Hypothyroidism, thyroid hormone replacement</para>
			</section>
			<section type="contra" id="sidelem4x7959">
				<sec_title>Contraindications:</sec_title>
				<para>Adrenal insufficiency, MI, thyrotoxicosis</para>
				<para>
					<bbw>Obesity treatment</bbw>
				</para>
			</section>
			<section type="doses" id="sidelem4x7974">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x7982">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x7982">
							<item>
								<label>•</label>
								<para> single dose of Thyrolar, <emphasis style="sup">1</emphasis>/<emphasis style="inf">4</emphasis> or <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> of adult dose, adjust as needed at 2-wk intervals</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x8001">
					<label>•</label>
					<sec_title>Geriatric<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x8001">
							<item>
								<label>•</label>
								<para>
									<emphasis style="sup">1</emphasis>/<emphasis style="inf">4</emphasis> tab initially, adjust q6-8wk</para>
							</item>
						</list>
					</para>
				</section>
			</section>
		</monograph>
<monograph id="35" status="active" ha="yes">
			<mono_name> liraglutide (Rx)</mono_name>
			<info>
				<pronunciation>(lir′a-gloo′tide)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x80171">Saxenda</tradename>
					<tradename id="tnidelem4x80170">Victoza</tradename>
				</tradenames>
				<class type="func"> Antidiabetic agent</class>
				<class type="chem"> Incretin mimetics</class>
			</info>
			<section type="actions" id="sidelem4x8027">
				<sec_title>Action:</sec_title>
				<para>Improved glycemic control and potential weight loss via activation of the glucagon-like peptide-1 (GLP-1) receptor</para>
			</section>
			<section type="uses" id="sidelem4x8032">
				<sec_title>Uses:</sec_title>
				<para>Type 2 diabetes mellitus in combination with diet/exercise, obesity</para>
			</section>
			<section type="contra" id="sidelem4x8037">
				<sec_title>Contraindications:</sec_title>
				<para>Hyper-sensitivity</para>
				<para>
					<bbw>Medullary thyroid carcinoma (MTC), multiple endocrine neoplasia syndrome type 2 (MEN 2), thyroid cancer</bbw>
				</para>
				<section type="none" id="sidelem4x8052">
					<section type="none" id="sidelem4x8053">
						<sec_title>Precautions:</sec_title>
						<para> Breastfeeding, children, geriatric patients, alcoholism, cholelithiasis, ketoacidosis, diarrhea, fever, gastroparesis, hepatic/renal disease, hypoglycemia, infection, surgery, thyroid disease, trauma, vomiting, pancreatitis</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x8058">
				<sec_title>Dosages and routes</sec_title>
				<section type="none" id="sidelem4x8066">
					<label>•</label>
					<sec_title>Adult<route> SUBCUT</route></sec_title>
					<para>
						<list id="lidelem4x8066">
							<item>
								<label>•</label>
								<para> 0.6 mg/day × 1 wk, then increase to 1.2 mg/day, max 1.8 mg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x8070">
					<section type="none" id="sidelem4x8071">
						<sec_title>Available forms:</sec_title>
						<para> Solution for injection 18 mg/3 ml pre-filled pen</para>
					</section>
					<section type="none" id="sidelem4x8076">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x8079">
							<sec_title>SUBCUT route</sec_title>
							<para>
								<list id="lidelem4x8083">
									<item>
										<label>•</label>
										<para>Give subcut only, inspect for particulate matter, discoloration; do not use if unusually viscous, cloudy, discolored, or if particles present; give daily anytime, without regard to meals; pen needles must be purchased separately, use Novo Nordisk needle; before first use, prime, see manual for directions; give in thigh, abdomen, or upper arm; lightly pinch fold of skin, insert needle at 90-degree angle (45-degree angle if thin), release skin; aspiration is not needed, give over 6 sec, rotate injection sites</para>
									</item>
									<item>
										<label>•</label>
										<para>If dose is missed, resume once-daily dosing at next scheduled dose; if &gt;3 days have elapsed since last dose, reinitiate at 0.6 mg, titrate</para>
									</item>
									<item>
										<label>•</label>
										<para>Storage: do not store pen with needle attached; avoid direct heat and sunlight; discard 30 days after first use; after first use may be stored at room temperature or refrigerated; do not freeze</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x8100">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x8103">
					<section type="none" id="sidelem4x8104">
						<sec_title>CNS:</sec_title>
						<para> Dizziness, headache</para>
					</section>
					<section type="none" id="sidelem4x8109">
						<sec_title>CV:</sec_title>
						<para> Hypertension</para>
					</section>
					<section type="none" id="sidelem4x8114">
						<sec_title>ENDO:</sec_title>
						<para> Hypoglycemia</para>
					</section>
					<section type="none" id="sidelem4x8119">
						<sec_title>EENT:</sec_title>
						<para> Sinusitis</para>
					</section>
					<section type="none" id="sidelem4x8124">
						<sec_title>GI:</sec_title>
						<para> Abdominal pain, anorexia, constipation, diarrhea, dyspepsia, nausea, vomiting, <emphasis style="bold">pancreatitis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x8131">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="bold">Angioedema,</emphasis> erythema, injection site reaction, urticaria</para>
					</section>
					<section type="none" id="sidelem4x8139">
						<sec_title>MS:</sec_title>
						<para> Back pain</para>
					</section>
					<section type="none" id="sidelem4x8144">
						<sec_title>SYST:</sec_title>
						<para> Antibody formation, infection, influenza, <emphasis style="bold">secondary thyroid malignancy, anaphylaxis, angioedema</emphasis></para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x8151">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypoglycemic reactions—angiotensin II receptor antagonists, ACE inhibitors, other antidiabetics, β-blockers, dexfenfluramine, fenfluramine, disopyramide, FLUoxetine, fibric acid derivatives, mecasermin, MAOIs, octreotide, pegvisomant, salicylates</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> liraglutide effect—protease inhibitors, phenothiazines, baclofen, atypical antipsychotics, corticosteroids, cycloSPORINE, tacrolimus, carbonic anhydrase inhibitors, dextrothyroxine, diazoxide, phenytoin, fosphenytoin, ethotoin, isoniazid, INH, niacin, nicotine, estrogens, progestins, oral contraceptives, growth hormones, sympathomimetics</para>
				<para>
					<emphasis style="bold">Increase or decrease:</emphasis> hypoglycemic reactions—androgens, bortezomib, quinolones, cloNIDine, alcohol, lithium, pentamidine</para>
				<para>
					<emphasis style="bold">Increase or decrease:</emphasis> effects of—atorvastatin, acetaminophen, griseofulvin</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> levels of digoxin</para>
			</section>
			<section type="kinetics" id="sidelem4x8174">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Protein binding (98%); half-life 12-13 hr; binds to albumin, then released into circulation; peak 8-12 hr; body weight significantly affects pharmacokinetics</para>
			</section>
			<section type="considerations" id="sidelem4x8179">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x8182">
					<section type="none" id="sidelem4x8183">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>Thyroid C-cell tumors; monitor during treatment</bbw>
						</para>
						<section type="none" id="sidelem4x8200">
							<label>•</label>
							<sec_title>
								<route>Hypoglycemic reactions</route>
							</sec_title>
							<para>
								<list id="lidelem4x8200">
									<item>
										<label>•</label>
										<para> that may occur soon after meals: hunger, sweating, weakness, dizziness, tremors, restlessness, tachycardia</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x8204">
								<item>
									<label>•</label>
									<para>Hypersensitivity to this product</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8209">
								<item>
									<label>•</label>
									<para>Serum glucose, A1c, CBC during treatment</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x8217">
							<label>•</label>
							<sec_title>Stress</sec_title>
							<para>
								<list id="lidelem4x8217">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Stress:</emphasis> those diabetic patients exposed to stress, surgery, fever, infections may require insulin administration temporarily</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<emphasis alert="nurse">Serious skin reactions: angioedema; also pancreatitis</emphasis>
						</para>
					</section>
					<section type="none" id="sidelem4x8226">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x8230">
								<item>
									<label>•</label>
									<para>Therapeutic response: stable and improved serum glucose, A1C, weight loss</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x8236">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x8241">
								<item>
									<label>•</label>
									<para>About symptoms of hypo/hyperglycemia, what to do for each; to have glucagon emergency kit available; to carry a carbohydrate source at all times</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8246">
								<item>
									<label>•</label>
									<para>About side effects associated with therapy, such as nausea and vomiting; that upward dose titration can be delayed or ignored, depending on tolerance</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8251">
								<item>
									<label>•</label>
									<para>That diabetes is a lifelong illness; that product does not cure disease and must be continued on a daily basis</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8256">
								<item>
									<label>•</label>
									<para>To carry emergency ID with prescriber’s phone number and medications taken</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8261">
								<item>
									<label>•</label>
									<para>To continue with other recommendations: diet, exercise, hygiene</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8266">
								<item>
									<label>•</label>
									<para>To test blood glucose using a blood glucose meter</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8271">
								<item>
									<label>•</label>
									<para>To avoid other medications, herbs, supplements unless approved by prescriber</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8277">
								<item>
									<para>
										<emphasis alert="nurse">To report serious skin effects, abdominal pain with nausea/vomiting</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8282">
								<item>
									<label>•</label>
									<para>Provide patient with written instructions if self-administration is ordered</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="36" status="active">
			<mono_name>lisdexamfetamine (Rx)</mono_name>
			<info>
				<pronunciation>(lis-dex′am-fet′a-meen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x82930">Vyvanse</tradename>
				</tradenames>
				<class type="func"> CNS stimulant</class>
				<class type="chem"> Amphetamine</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
				<class type="schedule">Controlled Substance Schedule <schedule num="2">II</schedule></class>
			</info>
			<section type="actions" id="sidelem4x8305">
				<sec_title>Action:</sec_title>
				<para>Increases release of norepinephrine, DOPamine in cerebral cortex to reticular activating system</para>
			</section>
			<section type="uses" id="sidelem4x8310">
				<sec_title>Uses:</sec_title>
				<para>Attention-deficit/hyperactivity disorder (ADHD), binge eating disorder</para>
			</section>
			<section type="contra" id="sidelem4x8315">
				<sec_title>Contraindications:</sec_title>
				<para>Breast-feeding, hyperthyroidism, hypertension, glaucoma, severe arteriosclerosis, hypersensitivity to sympathomimetic amines</para>
				<para>
					<bbw>Substance abuse</bbw>
				</para>
				<section type="none" id="sidelem4x8330">
					<section type="none" id="sidelem4x8331">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), children &lt;6 yr, Gilles de la Tourette’s disorder, depression, anorexia nervosa, psychosis, seizure disorder, suicidal ideation, MI, heart failure, alcoholism, aortic stenosis, bipolar disorder, CV disease</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x8336">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x8344">
					<label>•</label>
					<sec_title>Adult/Child 6-12 yr<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x8344">
							<item>
								<label>•</label>
								<para> 30 mg/day, may increase by 10-20 mg/day at weekly intervals, max 70 mg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x8348">
					<section type="none" id="sidelem4x8349">
						<sec_title>Available forms:</sec_title>
						<para> Caps 10, 20, 30, 40, 50, 60, 70 mg</para>
					</section>
					<section type="none" id="sidelem4x8354">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x8358">
								<item>
									<label>•</label>
									<para>Give daily in <emphasis style="smallcaps">am</emphasis></para>
								</item>
								<item>
									<label>•</label>
									<para>Without regard to meals</para>
								</item>
								<item>
									<label>•</label>
									<para>Caps: may take whole or opened and contents dissolved in water</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x8376">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x8379">
					<section type="none" id="sidelem4x8380">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Hyperactivity, insomnia, restlessness, talkativeness,</emphasis> dizziness, headache, dysphoria, irritability, CNS tumor, dependence, addiction, mild euphoria, somnolence, lability, psychosis, mania, hallucinations, aggression; movement disorders, psychiatric events (child)</para>
					</section>
					<section type="none" id="sidelem4x8388">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="italic">Palpitations, tachycardia,</emphasis> hypertension, decrease in heart rate, <emphasis style="bold">dysrhythmias,</emphasis> MI, <emphasis style="bold">cardiomyopathy</emphasis></para>
					</section>
					<section type="none" id="sidelem4x8401">
						<sec_title>EENT:</sec_title>
						<para> Blurred vision, mydriasis, dyplopia</para>
					</section>
					<section type="none" id="sidelem4x8406">
						<sec_title>ENDO:</sec_title>
						<para> Growth inhibition</para>
					</section>
					<section type="none" id="sidelem4x8411">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Anorexia,</emphasis> dry mouth, diarrhea, weight loss</para>
					</section>
					<section type="none" id="sidelem4x8419">
						<sec_title>GU:</sec_title>
						<para> Impotence, change in libido</para>
					</section>
					<section type="none" id="sidelem4x8424">
						<sec_title>INTEG:</sec_title>
						<para> Urticaria, <emphasis style="bold">angioedema, Stevens-Johnson syndrome, toxic epidermal necrolysis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x8431">
						<sec_title>MISC:</sec_title>
						<para>
							<emphasis alert="lifethreat">Rhabdomyolysis</emphasis>
						</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x8437">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Metabolized by liver; urine excretion pH dependent; crosses placenta, breast milk; half-life &lt;1 hr</para>
			</section>
			<section type="interactions" id="sidelem4x8442">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="nurse">Hypertensive crisis: MAOIs or within 14 days of MAOIs</emphasis>
				</para>
				<para>
					<emphasis alert="lifethreat">Increase: serotonin syndrome, neuroleptic malignant syndrome—SSRIs, SNRIs, serotonin-receptor agonists</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> lisdexamfetamine effect—acetaZOLAMIDE, antacids, sodium bicarbonate, urinary alkalinizers</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> CNS effect—haloperidol, tricyclics, phenothiazines, modafinil, meperidine, PHENobarbital, phenytoin</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> CNS stimulation—melatonin</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> absorption of phenytoin</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> lisdexamfetamine effect—ascorbic acid, ammonium chloride, urinary acidifiers</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect of—adrenergic blockers, antidiabetics</para>
				<section type="none" id="sidelem4x8477">
					<section type="none" id="sidelem4x8478">
						<sec_title>Drug/Herb</sec_title>
						<section type="none" id="sidelem4x8486">
							<label>•</label>
							<sec_title>Serotonin syndrome<route> St. John’s wort</route></sec_title>
						</section>
						<para>
							<emphasis style="bold">Increase:</emphasis> stimulant effect—khat, melatonin, green tea, guarana</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> stimulant effect—eucalyptus</para>
					</section>
					<section type="none" id="sidelem4x8497">
						<sec_title>Drug/Food</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> amine effect—caffeine</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x8504">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x8507">
					<section type="none" id="sidelem4x8508">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x8513">
								<item>
									<label>•</label>
									<para>VS, B/P; product may reverse antihypertensives; check patients with cardiac disease often</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8519">
								<item>
									<label>•</label>
									<para>CBC, urinalysis; in diabetes: blood glucose; insulin changes may be required because eating may decrease</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8524">
								<item>
									<label>•</label>
									<para>Height, growth rate in children; growth rate may be decreased</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8529">
								<item>
									<label>•</label>
									<para>Mental status: mood, sensorium, affect, stimulation, insomnia, irritability</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8535">
								<item>
									<para>
										<emphasis alert="nurse">Serotonin syndrome, neuroleptic malignant syndrome: increased heart rate, shivering, sweating, dilated pupils, tremors, high B/P, hyperthermia, headache, confusion; if these occur, stop product, administer serotonin antagonist if needed; at least 2 wk should elapse between discontinuation of serotonergic agents and start of product</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x8543">
							<label>•</label>
							<sec_title>Tolerance or dependency</sec_title>
							<para>
								<list id="lidelem4x8543">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Tolerance or dependency:</emphasis> increased amount of product may be used to get same effect; will develop after long-term use</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x8547">
								<item>
									<label>•</label>
									<para>Overdose: pain, fever, dehydration, insomnia, hyperactivity
<bbw>Before giving this product, identify presence of substance abuse; high potential for abuse</bbw>
</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x8561">
						<sec_title>Perform/provide:</sec_title>
						<para>
							<list id="lidelem4x8565">
								<item>
									<label>•</label>
									<para>Gum, hard candy, frequent sips of water for dry mouth</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x8571">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x8575">
								<item>
									<label>•</label>
									<para>Therapeutic response: increased CNS stimulation, decreased drowsiness</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x8581">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x8589">
							<label>•</label>
							<sec_title>Seizures<route> product may decrease seizure threshold; those with a seizure disorder should notify prescriber if seizure occurs</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x8592">
								<item>
									<label>•</label>
									<para>To report CNS changes, blurred vision, dose may need decreasing</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8597">
								<item>
									<label>•</label>
									<para>To decrease caffeine consumption (coffee, tea, cola, chocolate); may increase irritability, stimulation</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8602">
								<item>
									<label>•</label>
									<para>To avoid OTC preparations unless approved by prescriber</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8607">
								<item>
									<label>•</label>
									<para>To taper product over several weeks; depression, increased sleeping, lethargy may occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8612">
								<item>
									<label>•</label>
									<para>To avoid alcohol ingestion</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8617">
								<item>
									<label>•</label>
									<para>To avoid breastfeeding</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8622">
								<item>
									<label>•</label>
									<para>To avoid hazardous activities until stabilized on medication</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8627">
								<item>
									<label>•</label>
									<para>To get needed rest; patient will feel more tired at end of day</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8632">
								<item>
									<label>•</label>
									<para>To use as part of a comprehensive treatment program
<bbw>Serious CV effects may occur from increasing dose</bbw>
</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="none" id="sidelem4x8646">
				<sec_title>Treatment of overdose:</sec_title>
				<para>Administer fluids, antihypertensive for increased B/P, ammonium chloride for increased excretion, chlorproMAZINE for antagonizing CNS effects</para>
			</section>
		</monograph>
<monograph id="37" status="active">
			<mono_name>lisinopril (Rx)</mono_name>
			<info>
				<pronunciation>(lyse-in′oh-pril)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x86561">Prinivil</tradename>
					<tradename id="tnidelem4x86560">Zestril</tradename>
				</tradenames>
				<class type="func"> Antihypertensive, angiotensin-converting enzyme 1 (ACE) inhibitor</class>
				<class type="chem"> Enalaprilat lysine analog</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="confusion" id="sidelem4x8666">
				<para>
					<confusion>
						<tradename id="tnidelem4x86660">lisinopril</tradename>
						<drug type="generic" refid="idelem4x86660">RisperDAL/Lipitor</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x8676">
				<sec_title>Action:</sec_title>
				<para>Selectively suppresses renin-angiotensin-aldosterone system; inhibits ACE, thereby preventing conversion of angiotensin I to angiotensin II</para>
			</section>
			<section type="uses" id="sidelem4x8681">
				<sec_title>Uses:</sec_title>
				<para>Mild to moderate hypertension, adjunctive therapy of systolic CHF, acute MI</para>
				<section type="none" id="sidelem4x8686">
					<section type="none" id="sidelem4x8687">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Diabetic nephropathy/retinopathy, proteinuria, post MI</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x8692">
				<sec_title>Contraindications:</sec_title>
				<para>Hyper-sensitivity, angioedema</para>
				<para>
					<bbw>Pregnancy (D), 2nd/3rd trimesters</bbw>
				</para>
				<section type="none" id="sidelem4x8707">
					<section type="none" id="sidelem4x8708">
						<sec_title>Precautions:</sec_title>
						<para> Breastfeeding, renal disease, hyperkalemia, renal artery stenosis, CHF, pregnancy (C) 1st trimester, aortic stenosis</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x8714">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x8717">
					<section type="none" id="sidelem4x8718">
						<sec_title>Hypertension</sec_title>
						<section type="none" id="sidelem4x8726">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x8726">
									<item>
										<label>•</label>
										<para> initially 10 mg, 10-40 mg/day; max 80 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x8733">
							<label>•</label>
							<sec_title>Child ≥6 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x8733">
									<item>
										<label>•</label>
										<para> 0.07 mg/kg/day up to 5 mg/day; titrate q1-2wk up to 0.6 mg/kg/day or 40 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x8740">
							<label>•</label>
							<sec_title>Geriatric<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x8740">
									<item>
										<label>•</label>
										<para> 2.5-5 mg/day, increase q7days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8744">
						<sec_title>CHF</sec_title>
						<section type="none" id="sidelem4x8752">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x8752">
									<item>
										<label>•</label>
										<para> 5 mg initially with diuretics, range 5-40 mg</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x8759">
							<label>•</label>
							<sec_title>Acute myocardial infarction in adults who are hemodynamically stable<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x8759">
									<item>
										<label>•</label>
										<para> give 5 mg within 24 hr of onset of symptoms, then 5 mg after 24 hr, 10 mg after 48 hr, then 10 mg daily</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8763">
						<sec_title>
							<emphasis style="bold">Renal dose</emphasis>
						</sec_title>
						<section type="none" id="sidelem4x8772">
							<label>•</label>
							<sec_title>Adult<route> PO CCr &lt;30 ml/min, reduce dose by 50%, initially 5 mg/day, max 40 mg/day; CCr &lt;10 ml/min, 2.5 mg/day, max 40 mg/day</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x8775">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 2.5, 5, 10, 20, 30, 40 mg</para>
					</section>
					<section type="none" id="sidelem4x8780">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x8784">
								<item>
									<label>•</label>
									<para>Severe hypotension may occur after 1st dose of product; may be prevented by reducing or discontinuing diuretic therapy 3 days before beginning lisinopril therapy</para>
								</item>
								<item>
									<label>•</label>
									<para>Without regard to food</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x8795">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x8798">
					<section type="none" id="sidelem4x8799">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Vertigo,</emphasis> depression, <emphasis style="bold">stroke,</emphasis> insomnia, paresthesias, <emphasis style="italic">headache, fatigue,</emphasis> asthenia, <emphasis style="italic">dizziness</emphasis></para>
					</section>
					<section type="none" id="sidelem4x8815">
						<sec_title>CV:</sec_title>
						<para> Chest pain, <emphasis style="italic">hypotension,</emphasis> sinus tachycardia</para>
					</section>
					<section type="none" id="sidelem4x8823">
						<sec_title>EENT:</sec_title>
						<para> Blurred vision, nasal congestion</para>
					</section>
					<section type="none" id="sidelem4x8828">
						<sec_title>GI:</sec_title>
						<para> Nausea, vomiting, anorexia, constipation, flatulence, GI irritation, diarrhea, <emphasis style="bold">hepatic failure, hepatic necrosis, pancreatitis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x8835">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="bold">Proteinuria, renal insufficiency,</emphasis> sexual dysfunction, impotence</para>
					</section>
					<section type="none" id="sidelem4x8843">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Neutropenia, agranulocytosis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x8850">
						<sec_title>INTEG:</sec_title>
						<para> Rash, pruritus</para>
					</section>
					<section type="none" id="sidelem4x8855">
						<sec_title>MISC:</sec_title>
						<para> Muscle cramps, <emphasis style="italic">hyperkalemia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x8862">
						<sec_title>RESP:</sec_title>
						<para> Dry cough, dyspnea</para>
					</section>
					<section type="none" id="sidelem4x8867">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Angioedema, anaphylaxis, toxic epidermal necrolysis</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x8874">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Onset 1 hr, peak 6-8 hr, duration 24 hr, excreted unchanged in urine, half-life 12 hr</para>
			</section>
			<section type="interactions" id="sidelem4x8879">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> hyperkalemia—potassium salt substitutes, potassium-sparing diuretics, potassium supplements, cycloSPORINE</para>
				<para>
					<emphasis alert="lifethreat">Increase: possible toxicity—lithium</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypotensive effect—diuretics, other antihypertensives, probenecid, phenothiazines, nitrates, acute alcohol ingestion</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypersensitivity—allopurinol</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> lisinopril effects—aspirin, indomethacin, NSAIDs</para>
				<section type="none" id="sidelem4x8901">
					<section type="none" id="sidelem4x8902">
						<sec_title>Drug/Food</sec_title>
						<para>
							<list id="lidelem4x8906">
								<item>
									<label>•</label>
									<para>High-potassium diet (bananas, orange juice, avocados, nuts, spinach) should be avoided; hyperkalemia may occur</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x8912">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Interference:</emphasis> glucose/insulin tolerance tests, ANA titer</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x8919">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x8922">
					<section type="none" id="sidelem4x8923">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x8929">
								<item>
									<para>
										<emphasis alert="nurse">Blood studies, platelets; WBC with differential at baseline, periodically q3mo; if neutrophils &lt;1000/mm<emphasis style="sup">3</emphasis>, discontinue treatment (recommended with collagen-vascular disease)</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8937">
								<item>
									<label>•</label>
									<para>Baselines of renal, hepatic studies before therapy begins, periodically; LFTs, uric acid, glucose may be increased</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x8945">
							<label>•</label>
							<sec_title>Angioedema<route> anaphylaxis, toxic epidermal necrolysis, facial swelling, dyspnea, tongue swelling (rare)</route></sec_title>
						</section>
						<para>
							<bbw>Pregnancy before starting treatment; pregnancy (D)</bbw>
						</para>
						<section type="none" id="sidelem4x8962">
							<label>•</label>
							<sec_title>Hypertension</sec_title>
							<para>
								<list id="lidelem4x8962">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hypertension:</emphasis> B/P, pulse q4hr during beginning treatment and periodically thereafter; note rate, rhythm, quality; apical/pedal pulse before administration; notify prescriber of any significant changes</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x8966">
								<item>
									<label>•</label>
									<para>Electrolytes: potassium, sodium, chlorine</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x8975">
							<label>•</label>
							<sec_title>CHF</sec_title>
							<para>
								<list id="lidelem4x8975">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">CHF:</emphasis> edema in feet, legs daily; weight daily; dyspnea, wet crackles</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x8979">
								<item>
									<label>•</label>
									<para>Skin turgor, dryness of mucous membranes for hydration status</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x8984">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x8988">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased B/P, CHF symptoms</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x8994">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x8998">
								<item>
									<label>•</label>
									<para>Not to discontinue product abruptly; to taper</para>
								</item>
								<item>
									<label>•</label>
									<para>To rise slowly to sitting or standing position to minimize orthostatic hypotension</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid increasing potassium in the diet</para>
								</item>
								<item>
									<label>•</label>
									<para>To report dry cough
<bbw>To report if pregnancy is planned or suspected; pregnancy (D) 2nd/3rd trimesters</bbw>
</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="none" id="sidelem4x9028">
				<sec_title>Treatment of overdose:</sec_title>
				<para>Lavage, IV atropine for bradycardia, IV theophylline for bronchospasm, digoxin, O<emphasis style="inf">2</emphasis>, diuretic for cardiac failure</para>
			</section>
		</monograph>
<monograph id="38" status="active">
			<mono_name>lithium (Rx)</mono_name>
			<info>
				<pronunciation>(li′thee-um)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x90412">
						<country code="CAN">Carbolith </country>
					</tradename>
					<tradename id="tnidelem4x90411">
						<country code="CAN">Lithane </country>
					</tradename>
					<tradename id="tnidelem4x90410">
						<country code="CAN">Lithobid </country>
					</tradename>
				</tradenames>
				<class type="func"> Psychotropic agent—antimanic</class>
				<class type="chem"> Alkali metal ion salt</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="actions" id="sidelem4x9059">
				<sec_title>Action:</sec_title>
				<para>May alter sodium, potassium ion transport across cell membrane in nerve, muscle cells; may balance biogenic amines of norepinephrine, serotonin in CNS areas involved in emotional responses</para>
			</section>
			<section type="uses" id="sidelem4x9064">
				<sec_title>Uses:</sec_title>
				<para>Bipolar disorders (manic phase), prevention of bipolar manic-depressive psychosis</para>
				<section type="none" id="sidelem4x9069">
					<section type="none" id="sidelem4x9070">
						<sec_title>Unlabeled Uses:</sec_title>
						<para> Borderline personality disorder</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x9075">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>), breastfeeding, children &lt;12 yr, hepatic disease, brain trauma, organic brain syndrome, schizophrenia, severe cardiac/renal disease, severe dehydration</para>
				<section type="none" id="sidelem4x9080">
					<section type="none" id="sidelem4x9081">
						<sec_title>Precautions:</sec_title>
						<para> Geriatric patients, thyroid disease, seizure disorders, diabetes mellitus, systemic infection, urinary retention, QT prolongation</para>
						<para>
							<bbw>Lithium level &gt;1.5 mmol/L</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x9096">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x9099">
					<section type="none" id="sidelem4x9100">
						<sec_title>Bipolar Disorder (mania)</sec_title>
						<section type="none" id="sidelem4x9108">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x9108">
									<item>
										<label>•</label>
										<para> 300-600 mg tid, maintenance 300 mg tid or qid;  900 mg q12hr; dose should be individualized to maintain blood levels at 1-1.5 mEq/L or 0.6-1.2 mEq/L (maintenance)</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9118">
							<label>•</label>
							<sec_title>Geriatric<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x9118">
									<item>
										<label>•</label>
										<para> 300 mg bid, increase q7days by 300 mg to desired dose</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9125">
							<label>•</label>
							<sec_title>Child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x9125">
									<item>
										<label>•</label>
										<para> 15-20 mg/kg/day in 3-4 divided doses; increase as needed; do not exceed adult doses; maintain blood levels at 0.4-0.5 mEq/L</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9129">
						<sec_title>Borderline Personality Disorder (unlabeled)</sec_title>
						<section type="none" id="sidelem4x9137">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x9137">
									<item>
										<label>•</label>
										<para> 900-2400 mg in 3-4 divided doses or  900-1800 mg in 2 divided doses, maintain levels 0.8-1 mEq/L</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9144">
						<sec_title>Available forms:</sec_title>
						<para> Caps 150, 300, 600 mg; tabs 300 mg; ext rel tabs 300, 450 mg; syr 300 mg/5 ml (8 mEq/5 ml)</para>
					</section>
					<section type="none" id="sidelem4x9149">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x9153">
								<item>
									<label>•</label>
									<para>Do not break, crush, chew caps, ext rel tabs</para>
								</item>
								<item>
									<label>•</label>
									<para>Reduced dose to geriatric patients</para>
								</item>
								<item>
									<label>•</label>
									<para>With meals to avoid GI upset</para>
								</item>
								<item>
									<label>•</label>
									<para>Adequate fluids (2-3 L/day) to prevent dehydration during initial treatment, 1-2 L/day during maintenance</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x9174">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x9177">
					<section type="none" id="sidelem4x9178">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache, drowsiness, dizziness,</emphasis> tremors, twitching, ataxia, <emphasis style="bold">seizure,</emphasis> slurred speech, restlessness, confusion, stupor, memory loss, clonic movements, fatigue</para>
					</section>
					<section type="none" id="sidelem4x9189">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="italic">Hypotension,</emphasis> ECG changes, <emphasis style="bold">dysrhythmias, circulatory collapse,</emphasis> edema, Brugada syndrome, <emphasis style="bold">QT prolongation</emphasis></para>
					</section>
					<section type="none" id="sidelem4x9203">
						<sec_title>EENT:</sec_title>
						<para> Tinnitus, blurred vision</para>
					</section>
					<section type="none" id="sidelem4x9208">
						<sec_title>ENDO:</sec_title>
						<para> Hyponatremia, goiter, hyperglycemia, hypo/hyperthyroidism</para>
					</section>
					<section type="none" id="sidelem4x9213">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Dry mouth, anorexia, nausea, vomiting, diarrhea,</emphasis> incontinence, abdominal pain, metallic taste</para>
					</section>
					<section type="none" id="sidelem4x9221">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="bold">Polyuria, glycosuria, proteinuria, albuminuria,</emphasis> urinary incontinence, polydipsia</para>
					</section>
					<section type="none" id="sidelem4x9229">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Leukocytosis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x9236">
						<sec_title>INTEG:</sec_title>
						<para> Drying of hair, alopecia, rash, pruritus, hyperkeratosis, acneiform lesions, folliculitis</para>
					</section>
					<section type="none" id="sidelem4x9241">
						<sec_title>MS:</sec_title>
						<para> Muscle weakness</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x9246">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x9249">
					<section type="none" id="sidelem4x9250">
						<sec_title>PO:</sec_title>
						<para> Onset rapid, peak <emphasis style="sup">1</emphasis>⁄<emphasis style="inf">2</emphasis>-3 hr, half-life 18-36 hr depending on age, crosses blood-brain barrier, 80% of filtered lithium reabsorbed by renal tubules, excreted in urine, crosses placenta, enters breast milk, well absorbed by oral method</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x9261">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x9269">
					<label>•</label>
					<sec_title>Neurotoxicity<route> haloperidol, thioridazine</route></sec_title>
				</section>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypothyroid effects—antithyroid agents, calcium iodide, potassium iodide, iodinated glycerol</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> effects of neuromuscular blocking agents, phenothiazines</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> renal clearance—sodium bicarbonate, acetaZOLAMIDE, mannitol, aminophylline</para>
				<para>
					<emphasis alert="lifethreat">Increase: masking of lithium toxicity—β-blockers used for lithium tremor</emphasis>
				</para>
				<para>
					<emphasis alert="lifethreat">Increase: toxicity—indomethacin, diuretics, NSAIDs, losartan</emphasis>
				</para>
				<para>
					<emphasis alert="lifethreat">Increase: lithium effect/toxicity—carBAMazepine, FLUoxetine, methyldopa, thiazide diuretics, probenecid</emphasis>
				</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> lithium effects—theophyllines, urea, urinary alkalinizers</para>
				<section type="none" id="sidelem4x9297">
					<section type="none" id="sidelem4x9298">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<list id="lidelem4x9302">
								<item>
									<label>•</label>
									<para>Avoid use with kava, St. John’s wort, valerian</para>
								</item>
							</list>
						</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> lithium levels—black/green tea, guarana</para>
					</section>
					<section type="none" id="sidelem4x9312">
						<sec_title>Drug/Food</sec_title>
						<para>
							<list id="lidelem4x9316">
								<item>
									<label>•</label>
									<para>Significant changes in sodium intake alter lithium excretion</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x9322">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> potassium excretion, urine glucose, blood glucose, protein, BUN</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> VMA, T<emphasis style="inf">3</emphasis>, T<emphasis style="inf">4</emphasis>, <emphasis style="sup">131</emphasis>I</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x9342">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x9345">
					<section type="none" id="sidelem4x9346">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x9354">
							<label>•</label>
							<sec_title>Mental status</sec_title>
							<para>
								<list id="lidelem4x9354">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Mental status:</emphasis> manic symptoms, mood, behavior before, during treatment
<bbw>
												<emphasis alert="lifethreat">Lithium toxicity:</emphasis> diarrhea, vomiting, tremor, twitching; serum lithium levels 2×/wk initially, then q2mo (therapeutic level: 0.5-1.5 mEq/L); toxic level &gt;1.5 mcg/L</bbw>
</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x9369">
								<item>
									<label>•</label>
									<para>Weight daily; check for, report edema in legs, ankles, wrists</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x9377">
							<label>•</label>
							<sec_title>
								<route>Sodium intake; decreased sodium intake with decreased fluid intake may lead to lithium retention; increased sodium, fluids may decrease lithium retention</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x9380">
								<item>
									<label>•</label>
									<para>Skin turgor at least daily</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9385">
								<item>
									<label>•</label>
									<para>Urine for albuminuria, glycosuria, uric acid during beginning treatment, q2mo thereafter</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9390">
								<item>
									<label>•</label>
									<para>Neurologic status: LOC, gait, motor reflexes, hand tremors</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x9398">
							<label>•</label>
							<sec_title>
								<route>ECG in those &gt;50 yr with CV disease, cardiology consult is recommended in those with risk factor, QT prolongation may occur</route>
							</sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x9401">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x9405">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in excitement, manic phase</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x9411">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x9419">
							<label>•</label>
							<sec_title>About the symptoms of minor toxicity<route> vomiting, diarrhea, poor coordination, fine motor tremors, weakness, lassitude; major toxicity</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x9422">
								<item>
									<label>•</label>
									<para>To monitor urine specific gravity, emphasize need for follow-up care to determine lithium levels; to monitor lithium levels to ensure effective levels and treatment</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x9430">
							<label>•</label>
							<sec_title>
								<route>That contraception is necessary because lithium may harm fetus (pregnancy [D]); not to breastfeed</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x9433">
								<item>
									<label>•</label>
									<para>Not to operate machinery until lithium levels stable</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9439">
								<item>
									<label>•</label>
									<para>That beneficial effects may take 1-3 wk</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9444">
								<item>
									<label>•</label>
									<para>About products that interact with lithium (provide list); about need for adequate, stable intake of salt and fluids; not to use OTC products unless approved by prescriber</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="none" id="sidelem4x9449">
				<sec_title>Treatment of overdose:</sec_title>
				<para>Induce emesis or lavage, maintain airway, respiratory function; dialysis for severe intoxication</para>
			</section>
		</monograph>
<monograph id="39" status="active">
			<mono_name>lodoxamide ophthalmic</mono_name>
			<section type="none" id="sidelem4x9457">
				<para>
					<see refid="tra">See Appendix B</see>
				</para>
			</section>
		</monograph>
<monograph id="40" status="active">
			<mono_name>loperamide (<emphasis style="smallcaps">otc</emphasis>, Rx)</mono_name>
			<info>
				<pronunciation>(loe-per′a-mide)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x94682">Diamode</tradename>
					<tradename id="tnidelem4x94681">
						<country code="CAN">Imodium </country>
					</tradename>
					<tradename id="tnidelem4x94680">Imodium A-D</tradename>
				</tradenames>
				<class type="func"> Antidiarrheal</class>
				<class type="chem"> Piperidine derivative</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x9481">
				<para>
					<confusion>
						<tradename id="tnidelem4x94810">Imodium</tradename>
						<drug type="generic" refid="idelem4x94810">Indocin</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x9488">
				<sec_title>Action:</sec_title>
				<para>Direct action on intestinal muscles to decrease GI peristalsis; reduces volume, increases bulk; electrolytes not lost</para>
			</section>
			<section type="uses" id="sidelem4x9493">
				<sec_title>Uses:</sec_title>
				<para>Diarrhea (cause undetermined), travelers’ diarrhea, chronic diarrhea, to decrease amount of ileostomy discharge</para>
				<section type="none" id="sidelem4x9498">
					<section type="none" id="sidelem4x9499">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Irritable bowel syndrome, traveler’s diarrhea</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x9504">
				<sec_title>Contraindications:</sec_title>
				<para>Hyper-sensitivity, pseudomembranous colitis, constipation, dysentery, GI bleeding/obstruction/perforation, ileus, vomiting</para>
				<section type="none" id="sidelem4x9509">
					<section type="none" id="sidelem4x9510">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children &lt;2 yr, hepatic disease, dehydration, gastroenteritis, toxic megacolon, geriatric patients, severe ulcerative colitis</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x9515">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x9523">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x9523">
							<item>
								<label>•</label>
								<para> 4 mg, then 2 mg after each loose stool, max 16 mg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x9530">
					<label>•</label>
					<sec_title>Child 9-11 yr<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x9530">
							<item>
								<label>•</label>
								<para> 2 mg, then 1 mg after each loose stool, max 6 mg/24 hr</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x9537">
					<label>•</label>
					<sec_title>Child 6-8 yr<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x9537">
							<item>
								<label>•</label>
								<para> 2 mg, then 0.1 mg/kg after each loose stool, max 4 mg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x9544">
					<label>•</label>
					<sec_title>Child 2-5 yr<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x9544">
							<item>
								<label>•</label>
								<para> 1 mg, then 0.1 mg/kg after each loose stool, max 4 mg/24 hr</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x9548">
					<section type="none" id="sidelem4x9549">
						<sec_title>Traveler’s diarrhea (unlabeled)</sec_title>
						<section type="none" id="sidelem4x9557">
							<label>•</label>
							<sec_title>
								<route>Adult PO</route>
							</sec_title>
							<para>
								<list id="lidelem4x9557">
									<item>
										<label>•</label>
										<para> 4 mg, then 2 mg after each diarrhea stool, max 16 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9561">
						<sec_title>Available forms:</sec_title>
						<para> Caps 2 mg; liq 1 mg/5 ml; tabs 2 mg, chew tabs 2 mg</para>
					</section>
					<section type="none" id="sidelem4x9566">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x9570">
								<item>
									<label>•</label>
									<para>Do not break, crush, or chew caps</para>
								</item>
								<item>
									<label>•</label>
									<para>For 48 hr only</para>
								</item>
								<item>
									<label>•</label>
									<para>Do not mix oral sol with other sol</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x9586">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x9589">
					<section type="none" id="sidelem4x9590">
						<sec_title>CNS:</sec_title>
						<para> Dizziness, drowsiness, fatigue</para>
					</section>
					<section type="none" id="sidelem4x9595">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, dry mouth, vomiting, constipation,</emphasis> abdominal pain, anorexia, <emphasis style="bold">toxic megacolon,</emphasis> bacterial enterocolitis, flatulence</para>
					</section>
					<section type="none" id="sidelem4x9606">
						<sec_title>INTEG:</sec_title>
						<para> Rash</para>
					</section>
					<section type="none" id="sidelem4x9611">
						<sec_title>MISC:</sec_title>
						<para> Hyperglycemia</para>
					</section>
					<section type="none" id="sidelem4x9616">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Anaphylaxis, angioedema, toxic epidermal necrolysis</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x9623">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x9626">
					<section type="none" id="sidelem4x9627">
						<sec_title>PO:</sec_title>
						<para> Duration 24 hr, half-life 9-14 hr, metabolized in liver, excreted in feces as unchanged product, small amount in urine</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x9632">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> CNS depression—alcohol, antihistamines, analgesics, opioids, sedative/hypnotics</para>
				<section type="none" id="sidelem4x9639">
					<section type="none" id="sidelem4x9640">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> CNS depression—chamomile, hops, kava, valerian</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x9647">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x9650">
					<section type="none" id="sidelem4x9651">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x9659">
							<label>•</label>
							<sec_title>Stools</sec_title>
							<para>
								<list id="lidelem4x9659">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Stools:</emphasis> volume, color, characteristics, frequency; bowel pattern before product; rebound constipation</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x9663">
								<item>
									<label>•</label>
									<para>Electrolytes (potassium, sodium, chlorine) if receiving long-term therapy</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9669">
								<item>
									<label>•</label>
									<para>Skin turgor q8hr if dehydration is suspected; fluid replacement</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9674">
								<item>
									<label>•</label>
									<para>Response after 48 hr; if no response, product should be discontinued</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x9682">
							<label>•</label>
							<sec_title>
								<route>Dehydration, CNS problems in children, those with hepatic disease</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x9688">
							<label>•</label>
							<sec_title>
								<route>Abdominal distention, toxic megacolon; may occur with ulcerative colitis</route>
							</sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x9691">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x9695">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased diarrhea (48 hr); decreased chronic diarrhea (10 days)</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x9701">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x9705">
								<item>
									<label>•</label>
									<para>To avoid OTC products unless directed by prescriber</para>
								</item>
								<item>
									<label>•</label>
									<para>That ileostomy patient may take product for extended time</para>
								</item>
								<item>
									<label>•</label>
									<para>If drowsiness occurs, not to operate machinery</para>
								</item>
								<item>
									<label>•</label>
									<para>To use hard candy, sips of water for dry mouth</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="41" status="active">
			<mono_name>lopinavir/ritonavir</mono_name>
			<info>
				<pronunciation>(low-pin′ah-ver/ri-toe′na-veer)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x97310">Kaletra</tradename>
				</tradenames>
				<class type="func"> Antiretroviral</class>
				<class type="chem"> Protease inhibitor</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x9741">
				<sec_title>Action:</sec_title>
				<para>Inhibits human immunodeficiency virus (HIV-1) protease and prevents maturation of the infectious virus</para>
			</section>
			<section type="uses" id="sidelem4x9746">
				<sec_title>Uses:</sec_title>
				<para>HIV-1 in combination with or without other antiretrovirals</para>
			</section>
			<section type="contra" id="sidelem4x9751">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product or polyoxyethylated castor oil (oral solution), CYP3A4 metabolized products</para>
				<section type="none" id="sidelem4x9756">
					<section type="none" id="sidelem4x9757">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, hepatic disease, pancreatitis, diabetes, hemophilia, AV block, hypercholesterolemia, immune reconstitution syndrome, neonates, cardiomyopathy, congenital long-QT prolongation, hypokalemia, elderly patients, Graves’ disease, polymyositis, Guillain-Barr(c) syndrome, children, HBV/HCV coinfection</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x9762">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x9765">
					<section type="none" id="sidelem4x9766">
						<sec_title>HIV infection in combination with other antiretroviral agents</sec_title>
						<section type="none" id="sidelem4x9774">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x9774">
									<item>
										<label>•</label>
										<para> 400 mg lopinavir/100 mg ritonavir bid or 800 mg lopinavir/200 mg ritonavir per day may be administered to patients with &lt;3 lopinavir resistance–associated substitutions (L10F/I/R/V, K20M/N/R, L24I, L33F, M36I, I47V, G48V, 154L/T/V, V82A/C/F/S/T, and I84V); do not give once-daily dosing with concomitant carBAMazepine, PHENobarbital, or phenytoin; do not give as once-daily dosing with efavirenz, nevirapine, (fos)amprenavir, nelfinavir</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9781">
							<label>•</label>
							<sec_title>Pregnant adults<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x9781">
									<item>
										<label>•</label>
										<para> 400 mg lopinavir/100 mg ritonavir bid, may need 600 mg lopinavir/150 mg ritonavir bid in the 2nd/3rd trimesters; once-daily dosing is not recommended; a preferred PI-based regimen for pregnant patients combines twice-daily lopinavir; ritonavir with zidovudine and either lamiVUDine or emtricitabine</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9788">
							<label>•</label>
							<sec_title>Adult receiving concomitant efavirenz, nelfinavir, or nevirapine<route> PO TABS,</route></sec_title>
							<para>
								<list id="lidelem4x9788">
									<item>
										<label>•</label>
										<para> 500 mg lopinavir/125 mg ritonavir bid; , 533 mg lopinavir/133 mg ritonavir bid</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9798">
							<label>•</label>
							<sec_title>Adolescent/child/infant &gt;6 mo</sec_title>
							<para>
								<list id="lidelem4x9798">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Adolescent/child/infant &gt;6 mo:</emphasis> 300 mg lopinavir/75 mg ritonavir/m<emphasis style="sup">2</emphasis>/dose bid. The once-daily regimen is not recommended in pediatric patients; capsules are not recommended for use in patients ≤40 kg; a preferred PI-based regimen for all children combines lopinavir/ritonavir with a dual NRTI; a lopinavir/ritonavir plus dual NRTI regimen is an alternative option in adolescents</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9805">
						<sec_title>Available forms:</sec_title>
						<para> Oral solution 400 mg lopinavir/100 mg ritonavir/5 ml; tablets 100 mg lopinavir/25 mg ritonavir, 200 mg lopinavir/50 mg ritonavir</para>
					</section>
					<section type="none" id="sidelem4x9810">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x9813">
							<sec_title>PO route</sec_title>
							<section type="none" id="sidelem4x9821">
								<label>•</label>
								<sec_title>TAB</sec_title>
								<para>
									<list id="lidelem4x9821">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">TAB:</emphasis> take without regard to food; swallow whole, do not crush, break, chew</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x9828">
								<label>•</label>
								<sec_title>ORAL SOL</sec_title>
								<para>
									<list id="lidelem4x9828">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">ORAL SOL:</emphasis> shake well, use calibrated measuring device</para>
										</item>
									</list>
								</para>
							</section>
							<para>
								<list id="lidelem4x9832">
									<item>
										<label>•</label>
										<para>Drug resistance testing should be done before beginning therapy in antiretroviral-naive patients and before changing therapy for treatment failure</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x9838">
									<item>
										<label>•</label>
										<para>For adults and adolescents, therapy is recommended in those with a CD4 ≤500/mm<emphasis style="sup">3</emphasis>, who is pregnant, who has HIV-associated nephropathy, or who is being treated for hepatitis B (HBV) infection; therapy should be offered to patients at risk of transmitting HIV to sexual partners; treatment in those with a CD4 count &gt;500/mm<emphasis style="sup">3</emphasis> may be considered</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x9849">
									<item>
										<label>•</label>
										<para>For children, use is recommended in any symptomatic patient; for asymptomatic or mildly symptomatic children ≥5 years, therapy is recommended for those with HIV RNA ≥100,000 copies/ml or CD4 &lt;500/mm<emphasis style="sup">3</emphasis>; for asymptomatic or mildly symptomatic children 1-4 yr, therapy is recommended for patients with HIV RNA ≥100,000 copies/ml or CD4 &lt;25%</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x9857">
									<item>
										<label>•</label>
										<para>For infants &lt;12 mo, therapy is recommended regardless of clinical status, CD4 percentage, or viral load</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x9862">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x9865">
					<section type="none" id="sidelem4x9866">
						<sec_title>CNS:</sec_title>
						<para> Paresthesia, headache, <emphasis style="bold">seizures,</emphasis> fever, dizziness, insomnia, asthenia, <emphasis style="bold">intracranial bleeding, encephalopathy</emphasis></para>
					</section>
					<section type="none" id="sidelem4x9876">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">QT, PR interval prolongation, deep vein thrombosis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x9883">
						<sec_title>EENT:</sec_title>
						<para> Blurred vision, otitis media, tinnitus</para>
					</section>
					<section type="none" id="sidelem4x9888">
						<sec_title>GI:</sec_title>
						<para> Diarrhea, buccal mucosa ulceration, abdominal pain, nausea, taste perversion, dry mouth, vomiting, anorexia</para>
					</section>
					<section type="none" id="sidelem4x9893">
						<sec_title>INTEG:</sec_title>
						<para> Rash</para>
					</section>
					<section type="none" id="sidelem4x9898">
						<sec_title>MISC:</sec_title>
						<para> Asthenia, <emphasis style="bold">angioedema, anaphylaxis, Stevens-Johnson syndrome,</emphasis> increase lipids, lipodystrophy</para>
					</section>
					<section type="none" id="sidelem4x9906">
						<sec_title>MS:</sec_title>
						<para> Pain, <emphasis style="bold">rhabdomyolysis,</emphasis> myalgias</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x9914">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Well absorbed, 98% protein binding, hepatic metabolism, peak 4 hr, terminal half-life 6 hr</para>
			</section>
			<section type="interactions" id="sidelem4x9919">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="lifethreat">Increase: Toxicity—amiodarone, avanafil, azole antifungals, benzodiazepines, buPROPion, cloZAPine, desipramine, dihydroergotamine, encainide, ergotamine, flecainide, HMG-CoA reductase inhibitors, interleukins, meperidine, midazolam, pimozide, piroxicam, propafenone, quiNIDine, ranolazine, rivaroxaban, saquinavir, triazolam, zolpidem</emphasis>
				</para>
				<para>
					<emphasis alert="lifethreat">Increase: QT prolongation—class 1A/III antidysrhythmics, some phenothiazines, β-agonists, local anesthetics, tricyclics, haloperidol, chloroquine, droperidol, pentamidine, CYP3A4 inhibitors (amiodarone, clarithromycin, erythromycin, telithromycin, troleandomycin), arsenic trioxide, levomethadyl, CYP3A4 substrates (methadone, pimozide, QUEtiapine, quiNIDine, risperiDONE, ziprasidone)</emphasis>
				</para>
				<para>
					<emphasis alert="lifethreat">Increase: Ritonavir levels—fluconazole</emphasis>
				</para>
				<para>
					<emphasis alert="lifethreat">Increase: Level of both products—clarithromycin, ddI</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> Levels of bosentan</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> Ritonavir levels—rifamycins, nevirapine, barbiturates, phenytoin, budesonide, predniSONE</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> Levels of anticoagulants, atovaquone, divalproex, ethinyl estradiol, lamoTRIgine, phenytoin, sulfamethoxazole, theophylline, voriconazole, zidovudine</para>
				<section type="none" id="sidelem4x9946">
					<section type="none" id="sidelem4x9947">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> AST, ALT, CPK, cholesterol, GGT, triglycerides, uric acid, glucose</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> Hct, Hgb, RBC, neutrophils, WBC</para>
					</section>
					<section type="none" id="sidelem4x9958">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> Ritonavir levels—St. John’s wort; avoid concurrent use</para>
						<para>Avoid use with red yeast rice, evening primrose oil</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x9967">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x9970">
					<section type="none" id="sidelem4x9971">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x9976">
								<item>
									<label>•</label>
									<para>HIV: viral load, CD4 at baseline, throughout therapy; blood glucose, plasma HIV RNA, serum cholesterol/lipid profile; resistance testing before starting therapy and after treatment failure</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9981">
								<item>
									<label>•</label>
									<para>Signs of infection, anemia</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9986">
								<item>
									<label>•</label>
									<para>Hepatic studies: ALT, AST</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9991">
								<item>
									<label>•</label>
									<para>Bowel pattern before, during treatment; if severe abdominal pain with bleeding occurs, discontinue product; monitor hydration</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9996">
								<item>
									<label>•</label>
									<para>Skin eruptions; rash</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10002">
								<item>
									<para>
										<emphasis alert="nurse">Rhabdomyolysis: Muscle pain, increased CPK, weakness, swelling of affected muscles; if these occur and if confirmed by CPK, product should be discontinued</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10009">
								<item>
									<para>
										<emphasis alert="nurse">QT prolongation: ECG for QT prolongation, ejection fraction; assess for chest pain, palpitations, dyspnea</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10015">
								<item>
									<para>
										<emphasis alert="nurse">Serious skin disorders: Stevens–Johnson syndrome, angioedema, anaphylaxis</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x10020">
							<sec_title>Evaluate:</sec_title>
							<para>
								<list id="lidelem4x10024">
									<item>
										<label>•</label>
										<para>Therapeutic response: improvement in HIV symptoms; improving viral load, CD4+ T cells</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x10030">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x10034">
								<item>
									<label>•</label>
									<para>To take as prescribed; if dose is missed, to take as soon as remembered up to 1 hr before next dose; not to double dose</para>
								</item>
								<item>
									<label>•</label>
									<para>That product is not a cure for HIV; that opportunistic infections can continue to be acquired</para>
								</item>
								<item>
									<label>•</label>
									<para>That redistribution of body fat or accumulation of body fat may occur</para>
								</item>
								<item>
									<label>•</label>
									<para>That others can continue to contract HIV from patient</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid OTC, prescription medications, herbs, supplements unless approved by prescriber; not to use St. John’s wort because it decreases product’s effect</para>
								</item>
								<item>
									<label>•</label>
									<para>That regular follow-up exams and blood work will be required</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="42" status="active">
			<mono_name>loratadine (<emphasis style="smallcaps">otc</emphasis>, Rx)</mono_name>
			<info>
				<pronunciation>(lor-a′ti-deen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x100736">Alavert</tradename>
					<tradename id="tnidelem4x100735">Claritin</tradename>
					<tradename id="tnidelem4x100734">Claritin Children’s</tradename>
					<tradename id="tnidelem4x100733">Claritin RediTabs</tradename>
					<tradename id="tnidelem4x100732">Clear-Atadine</tradename>
					<tradename id="tnidelem4x100731">Dimetapp</tradename>
					<tradename id="tnidelem4x100730">Triaminic AllerChews</tradename>
				</tradenames>
				<class type="func"> Antihistamine, 2nd generation</class>
				<class type="chem"> Selective histamine (H)-receptor antagonist</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="confusion" id="sidelem4x10086">
				<para>
					<confusion>
						<tradename id="tnidelem4x100860">loratadine</tradename>
						<drug type="generic" refid="idelem4x100860">lovastatin/LORazepam/losartan</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x10090">
				<sec_title>Action:</sec_title>
				<para>Binds to peripheral histamine receptors, thereby providing antihistamine action without sedation</para>
			</section>
			<section type="uses" id="sidelem4x10095">
				<sec_title>Uses:</sec_title>
				<para>Seasonal rhinitis, chronic idiopathic urticaria for those ≥2 yr</para>
			</section>
			<section type="contra" id="sidelem4x10100">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, acute asthma attacks, lower respiratory tract disease</para>
				<section type="none" id="sidelem4x10105">
					<section type="none" id="sidelem4x10106">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, increased intraocular pressure, bronchial asthma, hepatic/renal disease</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x10111">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x10119">
					<label>•</label>
					<sec_title>Adult and child ≥6 yr<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x10119">
							<item>
								<label>•</label>
								<para> 10 mg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x10126">
					<label>•</label>
					<sec_title>Child 2-5 yr<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x10126">
							<item>
								<label>•</label>
								<para> 5 mg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x10130">
					<section type="none" id="sidelem4x10131">
						<sec_title>Renal/hepatic dose</sec_title>
						<section type="none" id="sidelem4x10139">
							<label>•</label>
							<sec_title>Adult<route> PO CCr &lt;30 ml/min or hepatic disease, 10 mg every other day</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x10142">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 10 mg; rapid-disintegrating tabs 10 mg; orally disintegrating tabs 10 mg; syr 1 mg/ml; susp 5 mg/ml, ext rel tab 10 mg</para>
					</section>
					<section type="none" id="sidelem4x10147">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x10155">
							<label>•</label>
							<sec_title>
								<route>Rapid-disintegrating tabs</route>
							</sec_title>
							<para>
								<list id="lidelem4x10155">
									<item>
										<label>•</label>
										<para> by placing on tongue, to be swallowed after disintegrated with/without water</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x10159">
								<item>
									<label>•</label>
									<para>Use within 6 mo of opening pouch and immediately after opening blister pack</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10164">
								<item>
									<label>•</label>
									<para>On empty stomach daily</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x10169">
							<sec_title>Ext Rel Tab</sec_title>
							<para>
								<list id="lidelem4x10173">
									<item>
										<label>•</label>
										<para>Do not break, crush, or chew</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x10179">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x10182">
					<section type="none" id="sidelem4x10183">
						<sec_title>CNS:</sec_title>
						<para> Sedation (more common with increased doses), headache, fatigue, restlessness</para>
					</section>
					<section type="none" id="sidelem4x10188">
						<sec_title>EENT:</sec_title>
						<para> Dry mouth</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x10193">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Peak 1.3-2.5 hr, duration 24 hr, metabolized in liver to active metabolites, excreted in urine, active metabolite desloratadine half-life 20 hr</para>
			</section>
			<section type="interactions" id="sidelem4x10198">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> CNS depressant effects—alcohol, antidepressants, other antihistamines, sedative/hypnotics</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> loratadine level—cimetidine, ketoconazole, macrolides (clarithromycin, erythromycin)</para>
				<section type="none" id="sidelem4x10211">
					<section type="none" id="sidelem4x10212">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">False negative:</emphasis> skin allergy tests (discontinue antihistamine 3 days before testing)</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x10219">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x10222">
					<section type="none" id="sidelem4x10223">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x10231">
							<label>•</label>
							<sec_title>Allergy</sec_title>
							<para>
								<list id="lidelem4x10231">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Allergy:</emphasis> hives, rash, rhinitis; monitor respiratory status</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x10235">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x10239">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of running or congested nose, other allergy symptoms</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x10245">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x10249">
								<item>
									<label>•</label>
									<para>To avoid driving, other hazardous activities if drowsiness occurs</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid use of other CNS depressants</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="43" status="active" ha="yes">
			<mono_name> LORazepam (Rx)</mono_name>
			<info>
				<pronunciation>(lor-a′ze-pam)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x102670">Ativan</tradename>
				</tradenames>
				<class type="func"> Sedative, hypnotic; antianxiety</class>
				<class type="chem"> Benzodiazepine, short acting</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
				<class type="schedule">Controlled Substance Schedule <schedule num="4">IV</schedule></class>
			</info>
			<section type="confusion" id="sidelem4x10279">
				<para>
					<confusion>
						<tradename id="tnidelem4x102790">LORazepam</tradename>
						<drug type="generic" refid="idelem4x102790">ALPRAZolam/clonazePAM</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x10283">
				<sec_title>Action:</sec_title>
				<para>Potentiates the actions of GABA, especially in the limbic system and the reticular formation</para>
			</section>
			<section type="uses" id="sidelem4x10288">
				<sec_title>Uses:</sec_title>
				<para>Anxiety, irritability with psychiatric or organic disorders, preoperatively; insomnia; adjunct for endoscopic procedures, status epilepticus</para>
				<section type="none" id="sidelem4x10293">
					<section type="none" id="sidelem4x10294">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Antiemetic before chemotherapy, rectal use, alcohol withdrawal, seizure prophylaxis, agitation, insomnia, sedation maintenance</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x10299">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>), breastfeeding, hypersensitivity to benzodiazepines, benzyl alcohol; closed-angle glaucoma, psychosis, history of drug abuse, COPD, sleep apnea</para>
				<section type="none" id="sidelem4x10304">
					<section type="none" id="sidelem4x10305">
						<sec_title>Precautions:</sec_title>
						<para> Children &lt;12 yr, geriatric patients, debilitated, renal/hepatic disease, addiction, suicidal ideation, abrupt discontinuation</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x10310">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x10313">
					<section type="none" id="sidelem4x10314">
						<sec_title>Anxiety</sec_title>
						<section type="none" id="sidelem4x10322">
							<label>•</label>
							<sec_title>Adult/adolescent<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x10322">
									<item>
										<label>•</label>
										<para> 2-3 mg/day in divided doses, max 10 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x10329">
							<label>•</label>
							<sec_title>Geriatric<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x10329">
									<item>
										<label>•</label>
										<para> 1-2 mg/day in divided doses or 0.5-1 mg at bedtime</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x10333">
						<sec_title>Preoperatively</sec_title>
						<section type="none" id="sidelem4x10341">
							<label>•</label>
							<sec_title>Adult<route> IM</route></sec_title>
							<para>
								<list id="lidelem4x10341">
									<item>
										<label>•</label>
										<para> 50 mcg/kg 2 hr before surgery;  44 mcg/kg 15-20 min before surgery, max 2 mg 15-20 min before surgery</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x10351">
							<label>•</label>
							<sec_title>Child ≥12 yr<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x10351">
									<item>
										<label>•</label>
										<para> 0.05 mg/kg, max 4 mg</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x10355">
						<sec_title>Status epilepticus</sec_title>
						<section type="none" id="sidelem4x10363">
							<label>•</label>
							<sec_title>Neonate<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x10363">
									<item>
										<label>•</label>
										<para> 0.05 mg/kg</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x10370">
							<label>•</label>
							<sec_title>Child<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x10370">
									<item>
										<label>•</label>
										<para> 0.1 mg/kg up to 4 mg/dose;  (unlabeled) 0.05-0.1 mg × 2; wait 7 min before giving 2nd dose</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x10377">
						<sec_title>Sedation in mechanically ventilated patients (unlabeled)</sec_title>
						<section type="none" id="sidelem4x10385">
							<label>•</label>
							<sec_title>Adult/Adolescent<route> Intermittent IV</route></sec_title>
							<para>
								<list id="lidelem4x10385">
									<item>
										<label>•</label>
										<para> 0.044 mg/kg q2-4hr, prn, max 4 mg single dose;</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x10392">
							<label>•</label>
							<sec_title>Adult/Adolescent<route> IV infusion</route></sec_title>
							<para>
								<list id="lidelem4x10392">
									<item>
										<label>•</label>
										<para> 0.5-8 mg/hr titrate, use loading dose of 2-4 mg</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x10396">
						<sec_title>Alcohol withdrawal (unlabeled)</sec_title>
						<section type="none" id="sidelem4x10404">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x10404">
									<item>
										<label>•</label>
										<para> 2 mg q6hr × 4 doses, then 1 mg q6hr for 8 doses</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x10408">
						<sec_title>Insomnia (unlabeled)</sec_title>
						<section type="none" id="sidelem4x10416">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x10416">
									<item>
										<label>•</label>
										<para> 2-4 mg at bedtime; only minimally effective after 2 wk continuous therapy</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x10423">
							<label>•</label>
							<sec_title>Geriatric<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x10423">
									<item>
										<label>•</label>
										<para> 0.5-1 mg initially</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x10427">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 0.5, 1, 2 mg; inj 2, 4 mg/ml; concentration oral sol 2 mg/ml</para>
					</section>
					<section type="none" id="sidelem4x10432">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x10435">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x10440">
									<item>
										<label>•</label>
										<para>With food or milk for GI symptoms; crushed if patient is unable to swallow medication whole</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x10445">
									<item>
										<label>•</label>
										<para>Sugarless gum, hard candy, frequent sips of water for dry mouth</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x10450">
									<item>
										<label>•</label>
										<para>Give largest dose before bedtime if giving in divided doses</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x10459">
								<label>•</label>
								<sec_title>Concentrate</sec_title>
								<para>
									<list id="lidelem4x10459">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Concentrate:</emphasis> use calibrated dropper; add to food/drink; consume immediately</para>
										</item>
									</list>
								</para>
							</section>
						</section>
						<section type="none" id="sidelem4x10463">
							<sec_title>IM route</sec_title>
							<para>
								<list id="lidelem4x10467">
									<item>
										<label>•</label>
										<para>Deep into large muscle mass</para>
									</item>
									<item>
										<label>•</label>
										<para>Use this route when IV is not feasible</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x10478">
							<sec_title>Direct IV route</sec_title>
							<para>
								<list id="lidelem4x10483">
									<item>
										<label>•</label>
										<para>Prepare immediately before use; short stability time</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x10488">
									<item>
										<label>•</label>
										<para>IV after diluting in equal vol sterile water, 5% dextrose, or 0.9% NaCl for inj; give through <emphasis style="sans-serif">Y</emphasis>-tube or 3-way stopcock; give at ≤2 mg/1 min; do not give rapidly</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x10499">
								<label>•</label>
								<sec_title>
									<route>Do not use in neonates (benzyl alcohol)</route>
								</sec_title>
							</section>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Acetaminophen, acyclovir, albumin, allopurinol, amifostine, amikacin, amoxicillin, amoxicillin/clavulanate, amphotericin B cholesteryl, amsacrine, atenolol, atracurium, bivalirudin, bleomycin, bumetanide, butorphanol, calcium chloride/gluconate, CARBOplatin, ceFAZolin, cefepime, cefotaxime, cefoTEtan, cefOXitin, cefTAZidime, ceftizoxime, ceftobiprole, cefTRIAXone, cefuroxime, chloramphenicol, chlorproMAZINE, cimetidine, ciprofloxacin, cisatracurium, CISplatin, cladribine, clindamycin, cloNIDine, cyclophosphamide, cycloSPORINE, cytarabine, DACTINomycin, DAPTOmycin, dexamethasone, dexmedetomidine, diltiazem, DOBUTamine, DOCEtaxel, DOPamine, doripenem, DOXOrubicin, DOXOrubicin liposomal, droperidol, enalaprilat, ePHEDrine, EPINEPHrine, epirubicin, eptifibatide, erythromycin, esmolol, etomidate, famotidine, fenoldopam, fentaNYL, filgrastim, fluconazole, fludarabine, fosphenytoin, furosemide, ganciclovir, gatifloxacin, gemcitabine, gentamicin, glycopyrrolate, granisetron, haloperidol, heparin, hydrocortisone, HYDROmorphone, hydrOXYzine, ifosfamide, inamrinone, insulin (regular), irinotecan, isoproterenol, ketorolac, labetalol, lidocaine, linezolid, magnesium sulfate, mannitol, mechlorethamine, melphalan, meropenem, metaraminol, methadone, methotrexate, methyldopate, methylPREDNISolone, metoclopramide, metoprolol, metroNIDAZOLE, micafungin, midazolam, milrinone, minocycline, mitoXANtrone, morphine, mycophenolate, nafcillin, nalbuphine, naloxone, nesiritide, niCARdipine, nitroglycerin, nitroprusside, norepinephrine, octreotide, oxaliplatin, oxytocin, PACLitaxel, palonosetron, pamidronate, pancuronium, PEMEtrexed, pentamidine, PENTobarbital, PHENobarbital, piperacillin, piperacillin-tazobactam, polymyxin B, potassium chloride, propofol, ranitidine, remifentanil, tacrolimus, teniposide, theophylline, thiotepa, ticarcillin, ticarcillin-clavulanate, tigecycline, tirofiban, tobramycin, TPN, trastuzumab, trimethobenzamide, trimethoprim-sulfamethoxazole, vancomycin, vasopressin, vecuronium, verapamil, vinCRIStine, vinorelbine, voriconazole, zidovudine</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x10506">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x10509">
					<section type="none" id="sidelem4x10510">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Dizziness, drowsiness,</emphasis> confusion, headache, anxiety, tremors, stimulation, fatigue, depression, insomnia, hallucinations, weakness, unsteadiness</para>
					</section>
					<section type="none" id="sidelem4x10518">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="italic">Orthostatic hypotension,</emphasis><emphasis style="bold">ECG changes, tachycardia,</emphasis> hypotension; <emphasis style="bold">apnea, cardiac arrest (IV, rapid)</emphasis></para>
					</section>
					<section type="none" id="sidelem4x10530">
						<sec_title>EENT:</sec_title>
						<para> <emphasis style="italic">Blurred vision,</emphasis> tinnitus, mydriasis</para>
					</section>
					<section type="none" id="sidelem4x10538">
						<sec_title>GI:</sec_title>
						<para> Constipation, dry mouth, nausea, vomiting, anorexia, diarrhea</para>
					</section>
					<section type="none" id="sidelem4x10543">
						<sec_title>INTEG:</sec_title>
						<para> Rash, dermatitis, itching</para>
					</section>
					<section type="none" id="sidelem4x10548">
						<sec_title>MISC:</sec_title>
						<para> Acidosis</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x10553">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Metabolized by liver; excreted by kidneys; crosses placenta, excreted in breast milk; half-life 42 hr (neonates), 10.5 hr (older child), 12 hr (adult), 91% protein bound</para>
				<section type="none" id="sidelem4x10558">
					<section type="none" id="sidelem4x10559">
						<sec_title>PO:</sec_title>
						<para> Onset 1 hr, peak 2 hr, duration 12-24 hr</para>
					</section>
					<section type="none" id="sidelem4x10564">
						<sec_title>IM:</sec_title>
						<para> Onset 15-30 min, peak 1-1<emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> hr, duration 6-8 hr</para>
					</section>
					<section type="none" id="sidelem4x10575">
						<sec_title>IV:</sec_title>
						<para> Onset 5 min, peak 1-1<emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> hr, duration 6-8 hr</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x10586">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> LORazepam effects—CNS depressants, alcohol, disulfiram</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> LORazepam effects—valproic acid, oral contraceptives</para>
				<section type="none" id="sidelem4x10599">
					<section type="none" id="sidelem4x10600">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> CNS depression—chamomile, kava, valerian</para>
					</section>
					<section type="none" id="sidelem4x10607">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> AST, ALT</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x10614">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x10617">
					<section type="none" id="sidelem4x10618">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x10624">
								<item>
									<para>
										<emphasis alert="nurse">Anxiety: decrease in anxiety; mental status: mood, sensorium, affect, sleeping pattern, drowsiness, dizziness, suicidal tendencies</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10629">
								<item>
									<label>•</label>
									<para>Renal/hepatic/blood status if receiving high-dose therapy</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x10637">
							<label>•</label>
							<sec_title>Physical dependency, withdrawal symptoms<route> headache, nausea, vomiting, muscle pain, weakness, tremors, seizures, after long-term, excessive use</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x10640">
						<sec_title>Perform/provide:</sec_title>
						<para>
							<list id="lidelem4x10644">
								<item>
									<label>•</label>
									<para>Assistance with ambulation during beginning therapy, since drowsiness, dizziness occurs</para>
								</item>
								<item>
									<label>•</label>
									<para>Check to confirm that PO medication has been swallowed</para>
								</item>
								<item>
									<label>•</label>
									<para>Refrigerate parenteral form</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x10660">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x10664">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased anxiety, restlessness, insomnia</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x10670">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x10675">
								<item>
									<label>•</label>
									<para>That product may be taken with food</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10680">
								<item>
									<label>•</label>
									<para>Not to use product for everyday stress or for &gt;4 mo unless directed by prescriber</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x10688">
							<label>•</label>
							<sec_title>
								<route>Not to take more than prescribed amount; may be habit forming</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x10691">
								<item>
									<label>•</label>
									<para>To avoid OTC preparations (cough, cold, hay fever) unless approved by prescriber</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10696">
								<item>
									<label>•</label>
									<para>To avoid driving, activities that require alertness, since drowsiness may occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10701">
								<item>
									<label>•</label>
									<para>To avoid alcohol, other psychotropic medications unless directed by prescriber</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x10709">
							<label>•</label>
							<sec_title>
								<route>Not to discontinue medication abruptly after long-term use</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x10712">
								<item>
									<label>•</label>
									<para>To rise slowly because fainting may occur, especially among geriatric patients</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10717">
								<item>
									<label>•</label>
									<para>That drowsiness may worsen at beginning of treatment</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x10725">
							<label>•</label>
							<sec_title>
								<route>To notify prescriber if pregnancy is planned or suspected, pregnancy (D), do not breastfeed</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x10729">
							<sec_title>
								<route>To report suicidal ideation</route>
							</sec_title>
							<para>
								<list id="lidelem4x10729">
									<item>
										<para>•	</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="none" id="sidelem4x10733">
				<sec_title>Treatment of overdose:</sec_title>
				<para>Lavage, VS, supportive care, flumazenil</para>
			</section>
		</monograph>
<monograph id="44" status="active">
			<mono_name>lorcaserin</mono_name>
			<info>
				<pronunciation>(lor-ca-ser′in)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x107430">Belviq</tradename>
				</tradenames>
				<class type="func"> Weight-control agent (anorexiant)</class>
				<class type="chem"> Serotonin 2C (5-HT) receptor agonist</class>
				<class type="preg">Pregnancy category <preg cat="X">X</preg></class>
				<class type="schedule">Controlled Substance Schedule <schedule num="4">IV</schedule></class>
			</info>
			<section type="actions" id="sidelem4x10759">
				<sec_title>Action:</sec_title>
				<para>Decreases food consumption and decreases hunger by selectively activating 5-HT<emphasis style="inf">2C</emphasis> receptors</para>
			</section>
			<section type="uses" id="sidelem4x10767">
				<sec_title>Uses:</sec_title>
				<para>Obesity management</para>
			</section>
			<section type="contra" id="sidelem4x10772">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="X">X</preg>), breastfeeding, hypersensitivity, severe renal impairment</para>
				<section type="none" id="sidelem4x10777">
					<section type="none" id="sidelem4x10778">
						<sec_title>Precautions:</sec_title>
						<para> Children, other organic causes of obesity, anemia, AV block, bradycardia, bundle branch block, depression, dialysis, liver/kidney disease, multiple myeloma, neutropenia, suicidal ideation, Peyronie’s disease, pulmonary hypertension, sick sinus syndrome</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x10783">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x10786">
					<section type="none" id="sidelem4x10787">
						<section type="none" id="sidelem4x10788">
							<sec_title>Adult:</sec_title>
							<section type="none" id="sidelem4x10796">
								<label>•</label>
								<sec_title>
									<route>PO</route>
								</sec_title>
								<para>
									<list id="lidelem4x10796">
										<item>
											<label>•</label>
											<para> 10 mg bid; do not exceed recommended dosage</para>
										</item>
									</list>
								</para>
							</section>
						</section>
					</section>
					<section type="none" id="sidelem4x10800">
						<sec_title>Available forms:</sec_title>
						<para> Tabs, film-coated 10 mg</para>
					</section>
					<section type="none" id="sidelem4x10805">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x10809">
								<item>
									<label>•</label>
									<para>For obesity if patient is on weight reduction program that includes dietary changes, exercise</para>
								</item>
								<item>
									<label>•</label>
									<para>May give without regard to food</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x10820">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x10823">
					<section type="none" id="sidelem4x10824">
						<sec_title>CNS:</sec_title>
						<para> Insomnia, depression, serotonin syndrome, anxiety, <emphasis style="bold">suicidal ideation,</emphasis> dizziness, headache, fatigue</para>
					</section>
					<section type="none" id="sidelem4x10832">
						<sec_title>CV:</sec_title>
						<para> Bradycardia, hypertension</para>
					</section>
					<section type="none" id="sidelem4x10838">
						<sec_title>GI:</sec_title>
						<para> Diarrhea, constipation, nausea</para>
					</section>
					<section type="none" id="sidelem4x10843">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Neutropenia, leukopenia, lymphopenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x10850">
						<sec_title>INTEG:</sec_title>
						<para> Rash</para>
					</section>
					<section type="none" id="sidelem4x10855">
						<sec_title>MS:</sec_title>
						<para> Back pain</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x10860">
				<sec_title>Pharmacokinetics</sec_title>
				<para>70% protein binding, half-life 11 hr</para>
			</section>
			<section type="interactions" id="sidelem4x10865">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="lifethreat">Increase: life-threatening serotonin syndrome or NMS—SSRIs, SNRIs, serotonin-receptor agonists, sibutramine, MAOIs, linezolid, tricyclic antidepressants, buPROPion, lithium, DOPamine antagonist, traMADol</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> risk of hypoglycemia with sulfonylureas and insulin</para>
				<section type="none" id="sidelem4x10875">
					<section type="none" id="sidelem4x10876">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> Serotonin syndrome—St. John’s wort</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x10883">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x10886">
					<section type="none" id="sidelem4x10887">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x10892">
								<item>
									<label>•</label>
									<para>Weight weekly; oral hypoglycemic dosage might need to be reduced in diabetic patients</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10897">
								<item>
									<label>•</label>
									<para>Monitor blood glucose, CBC with differential, Hct/Hgb, serum prolactin</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10903">
								<item>
									<para>
										<emphasis alert="nurse">Pregnancy (X): do not use in pregnancy</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x10908">
							<sec_title>Suicidal Ideation:</sec_title>
							<para>
								<emphasis alert="nurse">Use caution in psychiatric disorders with emotional lability; assess for depression, suicidal thoughts/behaviors</emphasis>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x10916">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x10920">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in weight</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x10926">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x10931">
								<item>
									<label>•</label>
									<para>To avoid hazardous activities until stabilized on medication</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10936">
								<item>
									<label>•</label>
									<para>To discuss unpleasant side effects</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10942">
								<item>
									<para>
										<emphasis alert="nurse">To notify prescriber if pregnancy is planned or suspected, pregnancy X</emphasis>
									</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="45" status="active">
			<mono_name>losartan</mono_name>
			<info>
				<pronunciation>(lo-zar′tan)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x109520">Cozaar</tradename>
				</tradenames>
				<class type="func"> Antihypertensive</class>
				<class type="chem"> Angiotensin II receptor (type AT) antagonist</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg> <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x10965">
				<para>
					<confusion>
						<tradename id="tnidelem4x109650">losartan</tradename>
						<drug type="generic" refid="idelem4x109650">valsartan</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x10972">
				<sec_title>Action:</sec_title>
				<para>Blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II; selectively blocks the binding of angiotensin II to the AT<emphasis style="inf">1</emphasis> receptor found in tissues</para>
			</section>
			<section type="uses" id="sidelem4x10980">
				<sec_title>Uses:</sec_title>
				<para>Hypertension, alone or in combination; nephropathy in type 2 diabetes; proteinuria; stroke prophylaxis for hypertensive patients with left ventricular hypertrophy</para>
				<section type="none" id="sidelem4x10985">
					<section type="none" id="sidelem4x10986">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Heart failure</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x10991">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<para>
					<bbw>Pregnancy (D) 2nd/3rd trimesters</bbw>
				</para>
				<section type="none" id="sidelem4x11006">
					<section type="none" id="sidelem4x11007">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>) 1st trimester, breastfeeding, children, geriatric patients; hypersensitivity to ACE inhibitors; hepatic disease, angioedema, renal artery stenosis, African descent, hyperkalemia, hypotension</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x11012">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x11015">
					<section type="none" id="sidelem4x11016">
						<sec_title>Hypertension</sec_title>
						<section type="none" id="sidelem4x11024">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x11024">
									<item>
										<label>•</label>
										<para> 50 mg/day alone or 25 mg/day in combination with diuretic; maintenance 25-100 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x11031">
							<label>•</label>
							<sec_title>Child ≥6 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x11031">
									<item>
										<label>•</label>
										<para> 0.7 mg/kg/day, max 50 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x11035">
						<sec_title>Hypertension with left ventricular hypertrophy (benefit does not apply to those of African American descent)</sec_title>
						<section type="none" id="sidelem4x11043">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x11043">
									<item>
										<label>•</label>
										<para> 50 mg/day; add hydrochlorothiazide 12.5 mg/day and/or increase losartan to 100 mg/day, then increase hydrochlorothiazide to 25 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x11049">
						<sec_title>Nephropathy in type 2 diabetic patients/proteinuria</sec_title>
						<section type="none" id="sidelem4x11057">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x11057">
									<item>
										<label>•</label>
										<para> 50 mg/day, may increase to 100 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x11061">
						<sec_title>Hepatic dose/volume/depletion</sec_title>
						<section type="none" id="sidelem4x11069">
							<label>•</label>
							<sec_title>Adult<route> PO 25 mg/day as starting dose</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x11072">
						<sec_title>
							<emphasis style="bold">Available forms:</emphasis>
						</sec_title>
						<para>
							<emphasis alert="lifethreat"> Tabs 25, 50, 100 mg</emphasis>
						</para>
					</section>
					<section type="none" id="sidelem4x11079">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x11083">
								<item>
									<label>•</label>
									<para>Without regard to meals</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x11089">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x11092">
					<section type="none" id="sidelem4x11093">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Dizziness, insomnia,</emphasis> anxiety, confusion, abnormal dreams, migraine, tremor, vertigo, headache, malaise, depression, fatigue</para>
					</section>
					<section type="none" id="sidelem4x11101">
						<sec_title>CV:</sec_title>
						<para> Angina pectoris, 2nd-degree AV block, <emphasis style="bold">cerebrovascular accident,</emphasis><emphasis style="italic">hypotension,</emphasis><emphasis style="bold">MI, dysrhythmias</emphasis></para>
					</section>
					<section type="none" id="sidelem4x11112">
						<sec_title>EENT:</sec_title>
						<para> Blurred vision, burning eyes, conjunctivitis</para>
					</section>
					<section type="none" id="sidelem4x11117">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Diarrhea, dyspepsia,</emphasis> anorexia, constipation, dry mouth, flatulence, gastritis, vomiting</para>
					</section>
					<section type="none" id="sidelem4x11125">
						<sec_title>GU:</sec_title>
						<para> Impotence, nocturia, urinary frequency, UTI, <emphasis style="bold">renal failure</emphasis></para>
					</section>
					<section type="none" id="sidelem4x11132">
						<sec_title>HEMA:</sec_title>
						<para> Anemia, <emphasis style="bold">thrombocytopenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x11139">
						<sec_title>INTEG:</sec_title>
						<para> Alopecia, dermatitis, dry skin, flushing, photosensitivity, rash, pruritus, sweating, <emphasis style="bold">angioedema</emphasis></para>
					</section>
					<section type="none" id="sidelem4x11146">
						<sec_title>META:</sec_title>
						<para> Gout, hyperkalemia, hypoglycemia</para>
					</section>
					<section type="none" id="sidelem4x11151">
						<sec_title>MS:</sec_title>
						<para> Cramps, myalgia, pain, stiffness</para>
					</section>
					<section type="none" id="sidelem4x11156">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="italic">Cough, upper respiratory infection,</emphasis> congestion, dyspnea, bronchitis</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x11164">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Peak 1 hr, extensively metabolized, half-life 2 hr, metabolite 6-9 hr, excreted in urine/feces, protein binding 98.7%</para>
			</section>
			<section type="interactions" id="sidelem4x11169">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> lithium toxicity—lithium</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> antihypertensive effect—fluconazole</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hyperkalemia—potassium-sparing diuretics, potassium supplements, ACE inhibitors</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> antihypertensive effect—NSAIDs, PHENobarbital, rifamycin, salicylates</para>
			</section>
			<section type="considerations" id="sidelem4x11188">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x11191">
					<section type="none" id="sidelem4x11192">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x11197">
								<item>
									<label>•</label>
									<para>B/P with position changes, pulse before and periodically during treatment; note rate, rhythm, quality</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11202">
								<item>
									<label>•</label>
									<para>Baselines of renal, hepatic, electrolyte studies before therapy begins and periodically thereafter</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11207">
								<item>
									<label>•</label>
									<para>Skin turgor, dryness of mucous membranes for hydration status</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11213">
								<item>
									<para>
										<emphasis alert="nurse">Angioedema: facial swelling, dyspnea, wheezing; may occur rapidly; tongue swelling (rare)</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x11221">
							<label>•</label>
							<sec_title>CHF</sec_title>
							<para>
								<list id="lidelem4x11221">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">CHF:</emphasis> jugular venous distention; edema in feet/legs, weight daily</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x11228">
							<label>•</label>
							<sec_title>Blood dyscrasias<route> thrombocytopenia, anemia (rare)</route></sec_title>
						</section>
						<para>
							<bbw>Pregnancy before starting treatment; pregnancy (D) 2nd/3rd trimester</bbw>
						</para>
					</section>
					<section type="none" id="sidelem4x11241">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x11245">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased B/P, slowing diabetic neuropathy</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x11251">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x11255">
								<item>
									<label>•</label>
									<para>To avoid sunlight or to wear sunscreen if in sunlight; that photosensitivity may occur</para>
								</item>
								<item>
									<label>•</label>
									<para>To comply with dosage schedule, even if feeling better; not to discontinue abruptly</para>
								</item>
								<item>
									<label>•</label>
									<para>To notify prescriber of mouth sores, fever, swelling of hands or feet, irregular heartbeat, chest pain</para>
								</item>
								<item>
									<label>•</label>
									<para>That excessive perspiration, dehydration, vomiting, diarrhea may lead to fall in B/P; to consult prescriber if these occur</para>
								</item>
								<item>
									<label>•</label>
									<para>That product may cause dizziness, fainting, light-headedness; to avoid hazardous activities until reaction is known</para>
								</item>
								<item>
									<label>•</label>
									<para>To rise slowly to sitting or standing position to minimize orthostatic hypotension</para>
								</item>
							</list>
						</para>
						<para>
							<bbw>To use contraception while taking this product; pregnancy (D) 2nd/3rd trimesters</bbw>
						</para>
						<para>
							<list id="lidelem4x11297">
								<item>
									<label>•</label>
									<para>To avoid salt substitutes, alcohol, grapefruit juice, OTC products unless approved by prescriber</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="46" status="active">
			<mono_name>loteprednol ophthalmic</mono_name>
			<section type="none" id="sidelem4x11306">
				<para>
					<see refid="tra">See Appendix B</see>
				</para>
			</section>
		</monograph>
<monograph id="47" status="active">
			<mono_name>lovastatin (Rx)</mono_name>
			<info>
				<pronunciation>(loh-vah-stat′in)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x113141">Altoprev</tradename>
					<tradename id="tnidelem4x113140">Mevacor</tradename>
				</tradenames>
				<class type="func"> Antilipemic</class>
				<class type="chem"> HMG-CoA reductase inhibitor</class>
				<class type="preg">Pregnancy category <preg cat="X">X</preg></class>
			</info>
			<section type="confusion" id="sidelem4x11324">
				<para>
					<confusion>
						<tradename id="tnidelem4x113240">lovastatin</tradename>
						<drug type="generic" refid="idelem4x113240">Lotensin/Leustatin</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x11331">
				<sec_title>Action:</sec_title>
				<para>Inhibits HMG-CoA reductase enzyme, which reduces cholesterol synthesis</para>
			</section>
			<section type="uses" id="sidelem4x11336">
				<sec_title>Uses:</sec_title>
				<para>As an adjunct for primary hypercholesterolemia (types IIa, IIb), atherosclerosis; heterozygous familial hypercholesterolemia (adolescents)</para>
			</section>
			<section type="contra" id="sidelem4x11341">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="X">X</preg>), breastfeeding, hypersensitivity, active hepatic disease</para>
				<section type="none" id="sidelem4x11346">
					<section type="none" id="sidelem4x11347">
						<sec_title>Precautions:</sec_title>
						<para> Children, past hepatic disease, alcoholism, severe acute infections, trauma, hypotension, uncontrolled seizure disorders, severe metabolic disorders, electrolyte imbalances, visual disorder</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x11352">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x11360">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x11360">
							<item>
								<label>•</label>
								<para> 20 mg/day with evening meal; may increase to 20-80 mg/day in single or divided doses, max 80 mg/day;  20-60 mg/day at bedtime, max 60 mg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x11367">
					<section type="none" id="sidelem4x11368">
						<sec_title>Heterozygous familial hypercholesterolemia</sec_title>
						<section type="none" id="sidelem4x11376">
							<label>•</label>
							<sec_title>Adolescent 10-17 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x11376">
									<item>
										<label>•</label>
										<para> 10-40 mg with evening meal</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x11380">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x11388">
							<label>•</label>
							<sec_title>Adult<route> PO CCr &lt;30 mg/min, max 20 mg/day unless titrated</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x11391">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 10, 20, 40 mg; ext rel tab 20, 40, 60 mg</para>
					</section>
					<section type="none" id="sidelem4x11396">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x11400">
								<item>
									<label>•</label>
									<para>In evening with meal; if dose is increased, take with breakfast and evening meal</para>
								</item>
								<item>
									<label>•</label>
									<para>Altroprev not equivalent to Mevacor</para>
								</item>
								<item>
									<label>•</label>
									<para>Do not crush, chew ext rel tab</para>
								</item>
								<item>
									<label>•</label>
									<para>Store in cool environment in airtight, light-resistant container</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x11421">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x11424">
					<section type="none" id="sidelem4x11425">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Dizziness, headache, tremor,</emphasis> insomnia, paresthesia</para>
					</section>
					<section type="none" id="sidelem4x11433">
						<sec_title>EENT:</sec_title>
						<para> <emphasis style="italic">Blurred vision,</emphasis> lens opacities</para>
					</section>
					<section type="none" id="sidelem4x11441">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="bold">Flatus, nausea, constipation, diarrhea, dyspepsia, abdominal pain, heartburn, hepatic dysfunction,</emphasis> vomiting, acid regurgitation, dry mouth, dysgeusia</para>
					</section>
					<section type="none" id="sidelem4x11449">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Thrombocytopenia, hemolytic anemia, leukopenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x11456">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash, pruritus,</emphasis> photosensitivity</para>
					</section>
					<section type="none" id="sidelem4x11464">
						<sec_title>MS:</sec_title>
						<para> <emphasis style="italic">Muscle cramps, myalgia,</emphasis><emphasis style="bold">myositis, rhabdomyolysis;</emphasis> leg, shoulder, or localized pain</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x11474">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x11477">
					<section type="none" id="sidelem4x11478">
						<sec_title>PO:</sec_title>
						<para> Peak 2 hr; peak response 4-6 wk, ext rel peak 14 hr; metabolized in liver (metabolites); highly protein bound; excreted in urine 10%, feces 83%; crosses blood-brain barrier, placenta; excreted in breast milk; half-life 1 hr</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x11483">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="lifethreat">Increase: myalgia, myositis, rhabdomyolysis—azole antifungals, clarithromycin, clofibrate, cycloSPORINE, danazol, diltiazem, erythromycin, gemfibrozil, niacin, protease inhibitors, quinupristin-dalfopristin, telithromycin, verapamil, avoid concurrent use</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> bleeding—warfarin</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> lovastatin effects—diltiazem</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effects of lovastatin—bile acid sequestrants, exonatide, bosentan</para>
				<section type="none" id="sidelem4x11503">
					<section type="none" id="sidelem4x11504">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> effect—pectin, St. John’s wort</para>
						<para>
							<emphasis style="bold">Increase:</emphasis> adverse reactions—red yeast rice</para>
					</section>
					<section type="none" id="sidelem4x11515">
						<sec_title>Drug/Food</sec_title>
						<para>
							<list id="lidelem4x11519">
								<item>
									<label>•</label>
									<para>Possible toxicity: grapefruit juice</para>
								</item>
							</list>
						</para>
						<para>
							<emphasis style="bold">Increase:</emphasis> levels of lovastatin with food; must be taken with food</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> absorption—oat bran</para>
					</section>
					<section type="none" id="sidelem4x11533">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> CK, LFTs</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x11540">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x11543">
					<section type="none" id="sidelem4x11544">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x11552">
							<label>•</label>
							<sec_title>
								<route>Diet;</route>
							</sec_title>
							<para>
								<list id="lidelem4x11552">
									<item>
										<label>•</label>
										<para> obtain diet history including fat, cholesterol in diet</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x11556">
								<item>
									<label>•</label>
									<para>Fasting cholesterol, LDL, HDL, triglycerides periodically during treatment</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11561">
								<item>
									<label>•</label>
									<para>Hepatic studies at initiation, 6 wk, 12 wk after initiation or change in dose, periodically thereafter; AST, ALT, LFTs may increase</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11566">
								<item>
									<label>•</label>
									<para>Renal function in patients with compromised renal system: BUN, creatinine, I&amp;O ratio</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x11571">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x11575">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased triglycerides, sLDL, total cholesterol; increased HDL; slowing CAD</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x11581">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x11589">
							<label>•</label>
							<sec_title>
								<route>To report suspected pregnancy (pregnancy [X]); not to breastfeed</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x11592">
								<item>
									<label>•</label>
									<para>That blood work, ophthalmic exam will be necessary during treatment</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11597">
								<item>
									<label>•</label>
									<para>To report blurred vision, severe GI symptoms, dizziness, headache, muscle pain, weakness</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11602">
								<item>
									<label>•</label>
									<para>To use sunscreen or to stay out of the sun to prevent photosensitivity</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11607">
								<item>
									<label>•</label>
									<para>That previously prescribed regimen will continue: low-cholesterol diet, exercise program, smoking cessation</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11612">
								<item>
									<label>•</label>
									<para>That product should be taken with food, not to crush, chew ext rel product</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="48" status="active" ru="yes">
			<mono_name> loxapine (Rx)</mono_name>
			<info>
				<pronunciation>(lox′a-peen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x116241">Adasuve</tradename>
					<tradename id="tnidelem4x116240">
						<country code="CAN">Loxapac </country>
					</tradename>
				</tradenames>
				<class type="func"> Antipsychotic, neuroleptic</class>
				<class type="chem"> Dibenzoxazepine</class>
			</info>
			<section type="uses" id="sidelem4x11636">
				<sec_title>Uses:</sec_title>
				<para>Schizophrenia, bipolar disorder</para>
				<section type="none" id="sidelem4x11641">
					<section type="none" id="sidelem4x11642">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Anxiety</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x11647">
				<sec_title>Contraindications:</sec_title>
				<para>
					<emphasis style="italic">Hypersensitivity, coma</emphasis>
				</para>
				<para>
					<bbw>Acute bronchospasm, asthma, COPD, emphysema</bbw>
				</para>
			</section>
			<section type="doses" id="sidelem4x11663">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x11671">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x11671">
							<item>
								<label>•</label>
								<para> 10 mg bid-qid initially, may be rapidly increased depending on severity of condition, maintenance 60-100 mg/day; inhalation powder 10 mg as a single dose in 24 hr</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x11678">
					<label>•</label>
					<sec_title>Geriatric<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x11678">
							<item>
								<label>•</label>
								<para> 5-10 mg daily-bid, increase q4-7days by 5-10 mg, max 250 mg/day</para>
							</item>
						</list>
					</para>
				</section>
			</section>
		</monograph>
<monograph id="49" status="active" ru="yes">
			<mono_name> lubiprostone (Rx)</mono_name>
			<info>
				<pronunciation>(loo-bee-pros′tone)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x116890">Amitiza</tradename>
				</tradenames>
				<class type="func"> Gastrointestinal agent —miscellaneous</class>
			</info>
			<section type="uses" id="sidelem4x11695">
				<sec_title>Uses:</sec_title>
				<para>Chronic idiopathic constipation, constipation-predominant irritable bowel syndrome in women &gt;18 yr, opiate agonist–induced constipation with chronic non-cancer pain</para>
			</section>
			<section type="contra" id="sidelem4x11700">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, GI obstruction</para>
			</section>
			<section type="doses" id="sidelem4x11705">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x11708">
					<section type="none" id="sidelem4x11709">
						<sec_title>Chronic idiopathic constipation/opiate agonist–induced constipation</sec_title>
						<section type="none" id="sidelem4x11717">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x11717">
									<item>
										<label>•</label>
										<para> 24 mcg bid with food, water</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x11722">
						<sec_title>IBS with constipation (females)</sec_title>
						<section type="none" id="sidelem4x11730">
							<label>•</label>
							<sec_title>Adult and adolescent ≥18 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x11730">
									<item>
										<label>•</label>
										<para> 8 mcg bid with food, water</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x11734">
						<sec_title>Hepatic dose</sec_title>
						<section type="none" id="sidelem4x11742">
							<label>•</label>
							<sec_title>Adult<route> PO For chronic constipation</route></sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="50" status="active">
			<mono_name>lucinactant</mono_name>
			<info>
				<pronunciation>(loo′sin-ak′tant)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x117500">Surfaxin</tradename>
				</tradenames>
				<class type="func"> Synthetic lung surfactant</class>
			</info>
			<section type="uses" id="sidelem4x11756">
				<sec_title>Uses:</sec_title>
				<para>Prevention of respiratory distress syndrome in premature neonates (RDS)</para>
			</section>
			<section type="doses" id="sidelem4x11761">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x11764">
					<section type="none" id="sidelem4x11765">
						<sec_title>Premature neonate</sec_title>
						<para>
							<emphasis style="bold">Intratracheal</emphasis> 5.8 ml/kg birth weight divided in 4 doses; give each dose with neonate in a different position; provide positive pressure ventilation when stable; dosage may be repeated 4 times in first 48 hr</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="51" status="active">
			<mono_name>luliconazole topical</mono_name>
			<section type="none" id="sidelem4x11775">
				<para>See <see refid="tra">Appendix B</see></para>
			</section>
		</monograph>
<monograph id="52" status="active">
			<mono_name>lurasidone (Rx)</mono_name>
			<info>
				<pronunciation>(loo-ras′i-done)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x117840">Latuda</tradename>
				</tradenames>
				<class type="func"> Atypical antipsychotic</class>
				<class type="chem"> Benzoisothiazol derivative</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="actions" id="sidelem4x11794">
				<sec_title>Action:</sec_title>
				<para>May modulate central DOPaminergic and serotonergic activity; high affinity for DOPamine-D2 receptors, serotonin 5-HT2A receptors; partial agonist at serotonin 5-HT1A receptor</para>
			</section>
			<section type="uses" id="sidelem4x11799">
				<sec_title>Uses:</sec_title>
				<para>Schizophrenia, depression associated with bipolar disorder I</para>
			</section>
			<section type="contra" id="sidelem4x11804">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<section type="none" id="sidelem4x11809">
					<section type="none" id="sidelem4x11810">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, children, geriatric patients, abrupt discontinuation, ambient temperature increase, breast cancer, cardiac disease, dehydration, diabetes, ketoacidosis, driving, operating machinery, dysphagia, heart failure, hematologic/hepatic/renal disease, hypotension, hypovolemia, MI, infertility, obesity, Parkinson’s disease, seizures, strenuous exercise, stroke, substance abuse, suicidal ideation, syncope, tardive dyskinesia</para>
						<para>
							<bbw>Dementia: antipsychotics (e.g., as lurasidone) not approved for treatment of dementia-related psychosis in geriatric patients; may increase risk of death in this population</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x11825">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x11828">
					<section type="none" id="sidelem4x11829">
						<sec_title>Schizophrenia</sec_title>
						<section type="none" id="sidelem4x11837">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x11837">
									<item>
										<label>•</label>
										<para> 40 mg/day, range 40-160 mg/day; for those receiving CYP3A4 inhibitors (max 80 mg/day), do not use with strong CYP3A4 inducers/inhibitors</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x11841">
						<sec_title>Bipolar Disorder I</sec_title>
						<section type="none" id="sidelem4x11849">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x11849">
									<item>
										<label>•</label>
										<para> 20 mg daily, max 120 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x11853">
						<sec_title>Hepatic/renal dose</sec_title>
						<section type="none" id="sidelem4x11861">
							<label>•</label>
							<sec_title>Adult<route> PO Child-Pugh class B/C; CCr ≥10 ml/min, ≤50 ml/min, max 40 mg/day</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x11864">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 20, 40, 80, 120 mg</para>
					</section>
					<section type="none" id="sidelem4x11869">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x11873">
								<item>
									<label>•</label>
									<para>Give with meal of ≥350 calories</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x11879">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x11882">
					<section type="none" id="sidelem4x11883">
						<sec_title>CNS:</sec_title>
						<para> Agitation, akathisia, anxiety, dizziness, drowsiness, fatigue, hyperthermia, insomnia, dystonic reactions; <emphasis style="bold">neuroleptic malignant syndrome (rare),</emphasis> pseudoparkinsonism, restlessness, <emphasis style="bold">seizures, suicidal ideation,</emphasis> syncope, tardive dyskinesia, vertigo</para>
					</section>
					<section type="none" id="sidelem4x11896">
						<sec_title>CV:</sec_title>
						<para> Angina, <emphasis style="bold">AV block, bradycardia,</emphasis> hypertension, orthostatic hypotension, <emphasis style="bold">sinus tachycardia, stroke</emphasis></para>
					</section>
					<section type="none" id="sidelem4x11906">
						<sec_title>EENT:</sec_title>
						<para> Blurred vision</para>
					</section>
					<section type="none" id="sidelem4x11911">
						<sec_title>ENDO:</sec_title>
						<para> Diabetes mellitus, ketoacidosis, hyperglycemia, hyperprolactinemia</para>
					</section>
					<section type="none" id="sidelem4x11916">
						<sec_title>GI:</sec_title>
						<para> Abdominal pain, diarrhea, dyspepsia, nausea, vomiting, gastritis, weight gain/loss</para>
					</section>
					<section type="none" id="sidelem4x11921">
						<sec_title>GU:</sec_title>
						<para> Amenorrhea, breast enlargement, dysmenorrhea, impotence, dysuria, renal failure</para>
					</section>
					<section type="none" id="sidelem4x11926">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Agranulocytosis, anemia, leucopenia, neutropenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x11933">
						<sec_title>INTEG:</sec_title>
						<para> Pruritus, rash</para>
					</section>
					<section type="none" id="sidelem4x11938">
						<sec_title>MS:</sec_title>
						<para> Back pain, dysarthria; <emphasis style="bold">rhabdomyolysis (rare)</emphasis></para>
					</section>
					<section type="none" id="sidelem4x11945">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Angioedema</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x11952">
				<sec_title>Pharmacokinetics</sec_title>
				<para>99% protein binding; excreted 80% in feces, 9% in urine; elimination half-life 18 hr; 9%-19% absorbed; peak 1-3 hr, steady-state 7 days</para>
			</section>
			<section type="interactions" id="sidelem4x11957">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x11965">
					<label>•</label>
					<sec_title>
						<route>Do not use with metoclopramide</route>
					</sec_title>
				</section>
				<para>
					<emphasis alert="lifethreat">Increase: lurasidone effect—strong CYP3A4 inhibitors; do not use concurrently</emphasis>
				</para>
				<para>
					<emphasis alert="lifethreat">Increase: serotonin syndrome, neuroleptic malignant syndrome—SSRIs, SNRIs</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> sedation—other CNS depressants, alcohol</para>
				<para>
					<emphasis alert="lifethreat">Decrease: lurasidone effect—CYP3A4 inducers; do not use concurrently</emphasis>
				</para>
			</section>
			<section type="considerations" id="sidelem4x11981">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x11984">
					<section type="none" id="sidelem4x11985">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x11993">
							<label>•</label>
							<sec_title>Schizophrenia</sec_title>
							<para>
								<list id="lidelem4x11993">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Schizophrenia:</emphasis> hallucinations, delusions, agitation, social withdrawal; monitor orientation, behavior, mood before and periodically during therapy</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x12000">
							<label>•</label>
							<sec_title>Neuroleptic malignant syndrome (rare)<route> fever, dyspnea, tachycardia, seizures, sweating, hypo/hypertension, muscle stiffness, pallor; report immediately</route></sec_title>
						</section>
						<section type="none" id="sidelem4x12006">
							<label>•</label>
							<sec_title>Blood dyscrasias<route> CBC periodically; blood dyscrasias may occur</route></sec_title>
						</section>
						<section type="none" id="sidelem4x12012">
							<label>•</label>
							<sec_title>Serious cardiac symptoms<route> AV block, stroke, bradycardia may occur</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x12015">
								<item>
									<label>•</label>
									<para>AIMS assessment, thyroid function tests, LFTs, lipid panel, electrolytes</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x12023">
							<label>•</label>
							<sec_title>EPS</sec_title>
							<para>
								<list id="lidelem4x12023">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">EPS:</emphasis> restlessness, difficulty speaking, loss of balance, pill rolling, masklike face, shuffling gait, rigidity, tremors, muscle spasms; monitor before and periodically during therapy; report tardive dyskinesia immediately
<bbw>
												<emphasis alert="lifethreat">Dementia:</emphasis> this product is not approved for geriatric patients with dementia-related psychosis</bbw>
</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x12038">
								<item>
									<label>•</label>
									<para>Weight gain, hyperglycemia, metabolic changes in diabetes</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x12043">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x12047">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreasing hallucinations, delusions, agitation, social withdrawal</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x12053">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x12058">
								<item>
									<label>•</label>
									<para>About reason for treatment, expected results</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x12063">
								<item>
									<label>•</label>
									<para>That lab work will be needed regularly</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x12068">
								<item>
									<label>•</label>
									<para>To avoid hazardous activities until response is known</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x12073">
								<item>
									<label>•</label>
									<para>To avoid OTC products unless approved by prescriber</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x12081">
							<label>•</label>
							<sec_title>
								<route>To report fast heartbeat, extra beats</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x12087">
							<label>•</label>
							<sec_title>To report EPS symptoms, blood dyscrasias<route> sore throat, fever, unusual bleeding/bruising</route></sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="53" status="active">
			<mono_name>lymphocyte immune globulin (anti-thymocyte, equine) (Rx)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x120930">Atgam</tradename>
				</tradenames>
				<class type="func"> Immune globulins—immunosuppressant</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x12099">
				<sec_title>Action:</sec_title>
				<para>Produces immunosuppression by inhibiting the function of lymphocytes (T)</para>
			</section>
			<section type="uses" id="sidelem4x12104">
				<sec_title>Uses:</sec_title>
				<para>Renal organ transplants to prevent rejection, aplastic anemia</para>
				<section type="none" id="sidelem4x12109">
					<section type="none" id="sidelem4x12110">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Immunosuppressant in liver, bone marrow, heart, and other organ transplants; stem-cell transplant preparations</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x12116">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product or equine/leporine protein; acute illness</para>
				<section type="none" id="sidelem4x12121">
					<section type="none" id="sidelem4x12122">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, severe renal/hepatic disease, leukopenia, thrombocytopenia</para>
						<para>
							<bbw>Infection, neoplastic disease</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x12137">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x12140">
					<section type="none" id="sidelem4x12141">
						<sec_title>Renal allograft rejection</sec_title>
						<section type="none" id="sidelem4x12149">
							<label>•</label>
							<sec_title>Adult/child<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x12149">
									<item>
										<label>•</label>
										<para> 10-15 mg/kg/day × 14 days, then every other day for 14 days if needed up to 21 total</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x12153">
						<sec_title>Prevent renal allograft rejection</sec_title>
						<section type="none" id="sidelem4x12161">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x12161">
									<item>
										<label>•</label>
										<para> 15 mg/kg/day × 7-14 days, then every other day × 14 days for total of 21 doses in 28 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x12165">
						<sec_title>Aplastic anemia</sec_title>
						<section type="none" id="sidelem4x12173">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x12173">
									<item>
										<label>•</label>
										<para> 10-20 mg/kg/day × 8-14 days, then every other day for ≤21 total doses</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x12177">
						<sec_title>Available forms:</sec_title>
						<para> Inj 50 mg equine gamma globulin/ml</para>
					</section>
					<section type="none" id="sidelem4x12182">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x12190">
							<label>•</label>
							<sec_title>
								<route>Do not infuse &lt;4 hr; usually given over 4-8 hr</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x12193">
								<item>
									<label>•</label>
									<para>Use 0.2-1 micron in-line filter</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x12198">
								<item>
									<label>•</label>
									<para>Skin testing must be completed before treatment; use intradermal inj of 0.1 ml of a 1:1000 dilution (5 mcg horse IgG) in 0.9% NaCl; if wheal or rash &gt;10 mm or both, use caution during infusion</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x12203">
								<item>
									<label>•</label>
									<para>Dilute in saline sol before infusion; invert IV bag so undiluted product does not contact air inside; concentration should not be &gt;4 mg/ml; do not shake</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x12211">
							<label>•</label>
							<sec_title>
								<route>Keep emergency equipment nearby for severe allergic reaction</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x12214">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x12217">
					<sec_title>Renal transplant</sec_title>
					<section type="none" id="sidelem4x12220">
						<sec_title>CNS:</sec_title>
						<para> Fever, chills, headache, dizziness, weakness, faintness, <emphasis style="bold">seizures</emphasis></para>
					</section>
					<section type="none" id="sidelem4x12227">
						<sec_title>CV:</sec_title>
						<para> Chest pain, hypo/hypertension, tachycardia</para>
					</section>
					<section type="none" id="sidelem4x12232">
						<sec_title>GI:</sec_title>
						<para> Diarrhea, nausea, vomiting, epigastric pain, <emphasis style="bold">GI bleeding</emphasis></para>
					</section>
					<section type="none" id="sidelem4x12239">
						<sec_title>INTEG:</sec_title>
						<para> Rash, pruritus, urticaria, wheal, injection-site reactions</para>
					</section>
					<section type="none" id="sidelem4x12244">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Anaphylaxis</emphasis></para>
					</section>
				</section>
				<section type="none" id="sidelem4x12251">
					<sec_title>Aplastic anemia</sec_title>
					<section type="none" id="sidelem4x12254">
						<sec_title>CNS:</sec_title>
						<para> Fever, chills, headache, <emphasis style="bold">seizures,</emphasis> light-headedness, encephalitis, postviral encephalopathy</para>
					</section>
					<section type="none" id="sidelem4x12262">
						<sec_title>CV:</sec_title>
						<para> Bradycardia, myocarditis, irregularity</para>
					</section>
					<section type="none" id="sidelem4x12267">
						<sec_title>GI:</sec_title>
						<para> Nausea, LFTs abnormality</para>
					</section>
					<section type="none" id="sidelem4x12272">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Thrombocytopenia, leukopenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x12279">
						<sec_title>MS:</sec_title>
						<para> <emphasis style="bold">Backache</emphasis></para>
					</section>
					<section type="none" id="sidelem4x12286">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="bold">Dyspnea, pulmonary edema</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x12293">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Onset rapid, half-life 5-7 days</para>
			</section>
			<section type="considerations" id="sidelem4x12298">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x12301">
					<section type="none" id="sidelem4x12302">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x12310">
							<label>•</label>
							<sec_title>Infection</sec_title>
							<para>
								<list id="lidelem4x12310">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Infection:</emphasis> if infection occurs, evaluation will be needed to continue therapy</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x12314">
								<item>
									<label>•</label>
									<para>Renal studies: BUN, creatinine at least monthly during treatment, for 3 mo after treatment</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x12319">
								<item>
									<label>•</label>
									<para>Hepatic studies: alk phos, AST, ALT, bilirubin</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x12324">
								<item>
									<label>•</label>
									<para>CBC with differential</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x12329">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x12333">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of rejection; hematologic recovery (aplastic anemia)</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x12339">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x12344">
								<item>
									<label>•</label>
									<para>To report fever, chills, sore throat, fatigue, since serious infections may occur</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x12353">
							<label>•</label>
							<sec_title>
								<route>To use contraceptive measures during treatment, for 12 wk after therapy</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
</alpha>
</drug_guide>